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Chapter 1 
Introduction, Aim and Outline 
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Need for new therapies for severe neonatal morbidities 
Most of childhood deaths occur during the neonatal period, which extends from birth to 
the first 28 days of life (Pathirana et al., 2016). The 2.9 million annual neonatal deaths 
worldwide have been reported to be associated with prematurity complications, 
intrapartum related brain injury and infections (Lawn et al. 2014). As all these morbidities 
have high fatality rates, preventive measures are therefore needed either to reduce the 
development or to treat and prevent their progression into more severe forms (Lawn et 
al. 2014). 
Causes of preterm birth 
Preterm birth, defined by the World Health Organization as delivery before 37 weeks of 
gestation are completed (WHO, 1977), occurs in 1 of 10 pregnancies resulting in 
approximately 15 million premature deliveries worldwide (Blencowe et al., 2012). Two-
thirds of preterm birth occur after spontaneous onset of preterm labor. These cases have 
been mostly associated with several conditions such as preterm premature rupture of 
membranes (PPROM), intrauterine infection/inflammation, cervical insufficiency, uterine 
anomalies and distension (Romero et al., 2006). Morbidity and mortality after preterm 
birth are inversely associated with gestational age and birth weight. Preterm birth is not 
only associated with higher mortality rates, but also with increased morbidity severity, 
neurodevelopmental impairment, familial effects and significant costs (Frey et al., 2016). 
Preterm infants are also vulnerable to both short and long term complications including 
respiratory distress syndrome (RDS), chronic lung disease, injury to intestines, infections 
associated with compromised immune system, cardiovascular disorders, hearing and 
vision problems, and neurological impairment. All these preterm birth-related 
complications occur due to the immaturity of all organ systems; they are not yet prepared 
for extrauterine life (Bohlin, 2016). This thesis deals with three of the most common 
complications of preterm birth that will be introduced in the following sections. 
Complications of preterm birth 
Among the many complications after preterm birth that may have a long term impact on 
health, growth and development in preterm infants (Carter and Msell, 2017), 
bronchopulmonary dysplasia (BPD) is the most common complication/adverse outcome. 
BPD can be defined as a form of chronic lung disease as a result of impaired lung 
development. BPD was first described in 1967 (Northway et al., 1967). They reported this 
entity in babies of 32 weeks of gestation that had respiratory treatment for hyaline 
membrane disease. Because treatment options for preterm babies improved 
considerably in the past 50 years, BPD nowadays also occurs in extremely preterm infants 
(around 26 weeks of gestation) who are born during the late canalicular/early saccular 
stage of lung development. This form of BPD is associated with disrupted lung 
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development (Jobe and Bancalari, 2001). Currently, BPD is diagnosed as the need for 
assisted ventilation and/or supplemental oxygen at 36’ weeks postmenstrual age (Jobe 
and Bancalari, 2001). BPD has been diagnosed to develop in approximately 50% of 
extremely low birth weight (ELBW) preterm infants (Stoll et al., 2010). It is associated with 
higher mortality rates, and infants with BPD are prone to both respiratory and 
cardiovascular impairment with pulmonary hypertension, growth failure and 
neurodevelopmental delay (Carraro et al., 2013; Jensen et al., 2015; McEvoy et al., 2014; 
Stoll et al.,2010). As there is an improved survival for ELBW infants due to advances in 
perinatal and neonatal care, the incidence of BPD has not changed in recent years (Stoll 
et al, 2015). The etiology of BPD is multifactorial and includes mainly prematurity, 
antenatal/ postnatal infection and inflammation, exposure to mechanical ventilation and 
oxygen toxicity, all of which were suggested to contribute to impaired alveolar 
development and associated abnormal vascular growth (Bhandari and Bhandari, 2009). 
In recent years, both genetic and epigenetic mechanisms were reported to be associated 
with BPD development (Merritt et al., 2009). As BPD has a multifactorial pathogenesis, 
no definitive treatment strategy has been shown to be effective to reduce BPD incidence 
(Poets and Lorenz, 2018). Treatment modalities including antenatal steroids, surfactant, 
gentle ventilation strategies, targeted oxygen saturation goals, and optimization of 
nutrition just led to a modest improvement in BPD outcomes. Therefore, strategies 
aiming to prevent the development of BPD seems to be the key issue nowadays (Gien 
and Kinsella, 2011; McEvoy et al., 2014). In a recent review, postnatal steroids, caffeine, 
azithromycin and vitamin A were reported as the only pharmacological therapies for 
prevention of BPD in preterm infants (Jensen et al., 2015). The authors also suggested 
dexamethasone therapy as an effective option for prevention of BPD which bears 
however the risk to induce adverse neurodevelopmental outcome (Jensen et al., 2015). 
Therefore, new therapies are needed to prevent development of BPD. 
Necrotizing enterocolitis (NEC), defined as a multifactorial syndrome of acute intestinal 
ischemic necrosis, represents the most common neonatal gastrointestinal emergency, 
especially in preterm infants (Morgan et al., 2011). Prematurity is the most important risk 
factor and an inverse relationship was reported between gestational age and NEC 
development. It is less common in late preterm and term infants. Prematurity-associated 
intestinal immaturity, aggressive feeding strategies, and inflammatory response to 
interactions between intestinal epithelium and luminal microorganisms were suggested 
as the key contributors for NEC development (Sharma and Hudak, 2013). Intestinal and 
systemic perturbations commonly constitute the clinical presentation of NEC. Early 
systemic signs may be indistinguishable from neonatal sepsis (Cetinkaya et al., 2011). NEC 
may also progress to multiorgan system dysfunction and shock just within hours in a 
fulminant manner (Sharma and Hudak, 2013). Increased gastric residuals, abdominal 
distension, and emesis represent the most common initial clinical signs of NEC. Systemic 
signs usually include lethargy, hypotension, episodes of apnea/bradycardia, temperature 
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instability, tachycardia and worsening respiratory status (Neu and Walker, 2011). In 
addition to clinical and laboratory findings, radiographic features including pneumatosis 
intestinalis and portal venous gas constitute the mainstay tools for diagnosis of NEC 
(Kasivajjula and Maheshwari, 2014). As no single treatment option has been shown to be 
effective after NEC diagnosis, preventive strategies focusing on the pathogenesis of NEC 
have gained importance in recent years. Preventive strategies comprise antenatal 
steroids, breast milk, microbiome interventions and standardized feeding regimens 
(Kasivajjula and Maheshwari, 2014). 
Global hypoxia-ischemia is a birth-related complication that occurs in both preterm and 
term babies. Though global hypoxia-ischemia affects the whole body, organs like brain, 
kidney and the heart are most vulnerable. Brain injury inflicted by hypoxia-ischemia, 
called hypoxic- ischemic encephalopathy (HIE), is an important neonatal morbidity that, 
contrary to many other birth-related complications, mainly affects full term infants 
(Kurinczuk et al., 2011). The incidence of HIE ranges from 1 to 8 per 1000 live births in 
developed countries and is suggested to be higher in the developing countries (Douglas-
Escobar and Weiss, 2015). Hypoxic-ischemic insult during prenatal, intrapartum or 
postnatal period prevents adequate blood flow to the infant’s brain. This impaired 
cerebral blood flow and oxygen delivery to the brain results in primary and secondary 
energy failure that triggers several pathways as an evolving process leading to cell death 
(Davidson et al., 2015; Johnston et al., 2011; Kimberly and Brandon, 2011). Some 40-60% 
of affected infants die by 2 years of age or have severe disabilities such as cerebral palsy, 
mental retardation and epilepsy (Juul and Ferriero, 2014). Recent clinical evidence 
suggests that therapeutic hypothermia-induced reduced metabolic activity significantly 
improves survival and disability in term infants with mild to moderate HIE (Jacobs et al., 
2013). As the brain damage occurs via multiple pathways and repair occurs over a period 
of days, combination therapies acting on the different pathways at different time points 
including excitotoxicity, inflammation and apoptosis, thereby providing more long-lasting 
neuroprotection, were suggested to be more effective for treatment of HIE (Jacobs et al., 
2013; Juul and Ferriero, 2014). As therapeutic hypothermia is the standard effective 
treatment, this purpose can be achieved by adding a neuroprotective agent to 
hypothermia or by any combination of two different neuroprotective therapies. 
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Aim and outline of the thesis 
Before outlined approaches and ideas to improve the neonatal outcome can be applied 
in babies, solid supporting experimental data and understanding are needed. 
Translational models of neonatal morbidities should therefore be used to identify the 
possible underlying mechanisms and evaluate the effect of a therapy. Findings from these 
studies can also be used to establish a scientific interchange from experimental point to 
clinical usage in humans (Ward et al., 2006). The objective of this thesis was therefore to 
perform new experimental studies in rat models on a) hyperoxic lung injury, b) 
necrotizing enterocolitis, and c) hypoxic-ischemic brain injury in order to understand 
molecular and cellular mechanisms of these diseases and to investigate their therapeutic 
potentials. The therapeutic agents in these studies were selected in terms of their 
potential utility in neonates. Therefore, we evaluated the efficacy of several novel agents 
for prevention and treatment of important morbidities with multifactorial pathogenesis 
and limited definite treatment options. 
General Outline 
In Chapter 2, we tested the hypothesis that epigenetic mechanisms including histone 
acetylation-deacetylation process might play an important role in development of BPD. 
To this end, we used a neonatal rat model of hyperoxic lung injury in which we evaluated 
the efficacy of valproic acid, a histone-deacetylase inhibitor, for prevention of BPD. 
Since surfactant deficiency was suggested to play a role in evolving BPD in infants, we 
tested in Chapter 3 the hypothesis that exogenous administration of CDP-choline, an 
endogenous intermediate in the synthesis of the major surfactant component 
phosphatidylcholine, is protective against hyperoxic lung injury in a neonatal rat model. 
In addition to the replacement of major surfactant component, the anti-inflammatory 
effects of this intermediate was investigated for the first time in an experimental setting. 
In Chapter 4, we tested the hypothesis that major membrane phospholipid 
supplementation might ameliorate intestinal injury as the integrity of gut phospholipid 
barrier may confer benefit against intestinal tissue damage. Since intestinal membrane 
disruption, including the loss of membrane integrity and intestinal surfactant develops in 
the setting of NEC (Claud, 2009), we evaluated the effect of CDP-choline treatment in a 
neonatal NEC rat model. 
Since NEC has a multifactorial pathogenesis including inflammation and necrosis, we 
tested in Chapter 5 the hypothesis that a combination therapy of anti-inflammatory and 
cytoprotective agents leads to prevention of NEC in a neonatal rat model of NEC. 
Because epigenetic mechanisms are involved in the pathogenesis of HIE, we investigated 
in Chapter 6 the neuroprotective effect of exogenously-administered uridine, as well as 
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its possible mechanism of action with regard to modulating histone 
acetylation/deacetylation in a neonatal rat model of HIE. Uridine is the principal 
circulating pyrimidine nucleoside and a precursor for membrane phospholipid synthesis. 
In Chapters 7 and 8, we tested in a neonatal rat model of HIE the hypothesis that the 
combination of agents acting at different stages of HI brain damage might provide 
superior neuroprotection compared to single use of each agent. 
The thesis concludes with a General Discussion and Summary in Chapter 9. In this part, 
the results are put into broader perspective and the potential benefits of our studies in 
Neonatal Intensive Care Unit (NICU) practice and subsequent clinical studies are 
discussed. 
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Chapter 2
Protective effects of valproic acid, a histone 
deacetylase inhibitor, against hyperoxic lung 
injury in a neonatal rat model 
Published as: Cetinkaya M, Cansev M, Cekmez F, Tayman C, Canpolat FE, Kafa IM, 
Yaylagul EO, Kramer BW, Sarıcı SU. Protective effects of valproic acid, a histone 
deacetylase inhibitor, against hyperoxic lung injury in a neonatal rat model.  
PLoS One 2015; 10(5): e0126028. 
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Abstract 
Objective 
Histone acetylation and deacetylation may play a role in the pathogenesis of 
inflammatory lung diseases. We evaluated the preventive effect of valproic acid (VPA), a 
histone deacetylase (HDAC) inhibitor, on neonatal hyperoxic lung injury. 
Methods 
Forty newborn rat pups were randomized in normoxia, normoxia+VPA, hyperoxia and 
hyperoxia+VPA groups. Pups in the normoxia and normoxia+VPA groups were kept in 
room air and received daily saline and VPA (30 mg/kg) injections, respectively, while those 
in hyperoxia and hyperoxia+VPA groups were exposed to 95% O2 and received daily saline 
and VPA (30 mg/kg) injections for 10 days, respectively. Growth, histopathological, 
biochemical and molecular biological indicators of lung injury, apoptosis, inflammation, 
fibrosis and histone acetylation were evaluated. 
Results 
VPA treatment during hyperoxia significantly improved weight gain, histopathologic 
grade, radial alveolar count and lamellar body membrane protein expression, while it 
decreased number of TUNEL (+) cells and active Caspase-3 expression. Expressions of 
TGFβ3 and phospho-SMAD2 proteins and levels of tissue proinflammatory cytokines as 
well as lipid peroxidation biomarkers were reduced, while anti-oxidative enzyme activities 
were enhanced by VPA treatment. VPA administration also reduced HDAC activity while 
increasing acetylated H3 and H4 protein expressions. 
Conclusions 
The present study shows for the first time that VPA treatment ameliorates lung damage 
in a neonatal rat model of hyperoxic lung injury. The preventive effect of VPA involves 
HDAC inhibition. 
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Introduction 
Bronchopulmonary dysplasia (BPD) is a chronic lung disease developing especially in 
premature infants with significant morbidity and mortality [1]. The pathogenesis of BPD 
is multifactorial resulting in chronic inflammation of the airways that results in a simplified 
lung structure [2]. To date, despite antenatal steroids, vitamin A, and caffeine being 
suggested as beneficial agents for BPD prevention, BPD is still the most common adverse 
outcome after preterm birth and the use of postnatal steroids as potent anti-
inflammatory drugs is still under study [1,3,4]. Recent evidence suggests a net benefit of 
postnatal glucocorticoid therapy when administered shortly after the first week of life to 
premature infants with early and persistent pulmonary dysfunction [5]. Similarly, in a 
recent Cochrane review, late steroid therapy after 7 days of life for chronic lung disease 
was suggested to reduce neonatal mortality without significantly increasing the risk of 
adverse long-term neurodevelopmental outcomes [6]. Therefore, it is necessary to 
develop new strategies for the prevention of BPD. 
Chronic inflammation can be maintained by different triggers which promote 
transcription of pro-inflammatory cytokines. Transcription factors target gene 
transcription after activation and recruit transcriptional co-activators and chromatin-
remodeling enzymes that allows subsequent inflammatory gene expression [7]. The 
transcription of genes is mainly made possible by rearrangement of the chromatin 
structure by histone methylation and deacetylation, which are all epigenetic modification 
[8]. Epigenetic regulation of inflammation has therefore several components. Changes in 
histone acetylation are involved in induction of pro-inflammatory genes in human lung 
cells. Histone acetyltransferases (HATs) are expressed and activated in an abnormal 
fashion in inflammatory diseases and, histone deacetylase (HDAC) inhibitors show anti-
inflammatory effects [9]. Differentially-regulated chromatin remodeling pathways were 
reported in umbilical cord samples of infants who developed BPD by altering HDAC ratio, 
resulting in histone hypoacetylation. This suggests the use of HDAC inhibitors for the 
prevention of BPD development [10]. However, current therapies of BPD do not 
modulate the epigenetic compound of chronic inflammation. 
A candidate drug for this purpose is Valproic acid (VPA), an HDAC inhibitor that is 
clinically used as an anti-epileptic and mood-stabilizing agent. VPA is an HDAC inhibitor 
of class I, as well as class II histone deacetylases [11] which results in anti-inflammatory 
properties by reducing transcription of pro-inflammatory cytokines [12,13]. This effect 
was shown in a lipopolysaccharide (LPS)-induced septic shock model where VPA 
attenuated multiple organ dysfunctions by ameliorating histopathological lung injury, 
preventing pulmonary inflammation by reversing the reduction in histone H3 acetylation 
in lung tissue [14]. 
However, to the best of our knowledge, no experimental study has investigated VPA’s 
effectiveness in neonatal hyperoxic lung injury. Therefore, the aim of this study was to 
evaluate the possible preventive effect of VPA in a neonatal rat model of hyperoxic lung 
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injury and the involvement of HDAC inhibition in VPA’s effect. We used a rat model in 
which neonatal exposure to hyperoxia induced lung simplification resembling the lung 
structure of patients with BPD. 
Material and Methods 
Animals and experimental design 
The study was approved by Experimental Animal Ethics Committee of Gulhane Military 
Medical Academy (Ankara, Turkey, Permit number: 2011-6) and the experiments 
conformed to the National Institutes of Health Guide for the Care and Use of Laboratory 
Animals (NIH Publications No. 80-23) revised 1996 and EC Directive 86/609/EEC. 
Sprague-Dawley rats with dated pregnancies were housed in individual cages with 
free access to water and food. Pups born with spontaneous delivery to Sprague-Dawley 
pregnant rats were pooled, randomized, and delivered back to nursing dams. The 
offsprings from one dam were randomly introduced into all four study groups. A total of 
40 pups born to 4 dams were divided into 4 groups from each dam as follows: normoxia 
group (subjected to room air containing 21% O2 and received saline), normoxia+VPA 
group (subjected to room air containing 21% O2 and received VPA), hyperoxia group 
(subjected to 95% O2 and received saline), and hyperoxia+VPA group (subjected to 95% 
O2 and received VPA). 
Experiments began immediately after birth and continued throughout P10 as 
described previously [15]. Nursing dams were rotated between hyperoxia and room air-
exposed pups every 24h to prevent oxygen toxicity. In pups subjected to hyperoxia, 
continuous 95% O2 exposure was achieved in a Plexiglas chamber (70x60x30 cm) by a 
flow-through system. The oxygen level inside the Plexiglas chamber was monitored 
continuously with a Ceramatec (MAXO2) oxygen analyzer. Carbondioxide (CO2) 
concentration was kept below 0.5% using a gas monitor (Apex, BW Technologies, 
Lincolnshire, IL). Temperature and humidity were maintained at 22°C-25°C and 60%-70%, 
respectively.  
Intraperitoneal (i.p.) injections of saline (4 ml/kg) in normoxia and hyperoxia groups 
and those of VPA (30 mg/kg; Sigma-Aldrich, St. Louis, MO) in hyperoxia+VPA group were 
performed daily from the 1st day of life (P1) throughout P10. Pups in each group were 
weighed daily and weights were recorded. 
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Lung Tissue Preparation 
Pups were sacrificed at P10 under deep anesthesia and all efforts were performed to 
minimize suffering. Right lungs of rat pups were excised and snap frozen for analyzing 
tissue cytokines; HDAC activity; expressions of acetylated H3 and H4, TGFβ3, phospho-
SMAD2 and active Caspase-3; as well as oxidant/antioxidant enzyme activities and MDA 
content, while left lungs were perfused for histopathologic and immunohistochemical 
evaluation after ligation of the right main bronchus. 
Histopathologic and Immunohistochemical Evaluation of the Lungs 
Left lungs were fixed by perfusion with 0.1 M phosphate buffered saline (PBS; pH 7.4) 
containing 4% paraformaldehyde (PFA). Trachea was ligated with a surgical suture, and 
lungs were incubated in fresh 4% PFA-PBS solution on ice for 4-5 h. The lungs were 
paraffin-embedded for obtaining 5 μm sections which were then mounted onto poly-L-
lysine-coated slides (Paul Marienfeld GmbH&Co., Lauda-Konigshofen, Germany), stained 
with standard haematoxylin-eosin and Masson’s trichrome techniques for 
histopathologic evaluations and with ABC technique for lamellar body membrane protein 
(LBMP) expression as described previously [15-17]. 
Apoptosis was evaluated by Terminal Deoxynucleotidyl Transferase dUTP Nick End 
Labeling (TUNEL) technique using in situ cell death detection POD kit (Roche Molecular 
Biochemicals, Mannheim, Germany) as described previously [15]. 
Western Blot Analyses 
TGFβ isoforms (β1, β2, β3) play a role in normal tissue repair following lung injury [18]. 
The intracellular signaling pathway of TGFβ receptors is mediated by a family of 
transcription factors, called SMAD proteins. The receptor-regulated SMAD2 and/or 
SMAD3, in combination with SMAD4 positively regulate the effects of TGFβ [18]. 
Therefore, we also evaluated the effect of VPA treatment on TGFβ pathway and SMAD 
protein expression in this hyperoxic lung injury model. In addition, members of Bcl-2 gene 
family are known as the key regulators of cell survival, apoptosis and necrosis and bcl-2 
represents an anti-apoptotic protein [19]. Right lungs were homogenized in ice-cold PBS 
and aliquoted homogenates were used for total protein analysis by bicinchoninic acid 
(BCA) assay (Thermo Fisher Scientific, Rockford, IL). Aliquots of homogenates were used 
for determining specific proteins using antibodies against active Caspase-3 (Abcam, 
Cambridge, MA), bcl-2 (Cell Signaling Technology, Danvers, MA), TGFβ1 (Thermo 
Scientific, Rockford, IL), TGFβ3 (Thermo Scientific, Rockford, IL), phospho-SMAD2 
(pSer465/467; Thermo Scientific, Rockford, IL), acetyl-histone H3 (Cell Signaling 
Technology, Danvers, MA) and acetyl-histone H4 (Millipore, Billerica, MA) as described 
previously [15]. Equal protein loading was confirmed by incubating the stripped 
membranes with structural protein β-actin (Abcam, Cambridge, MA). 
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HDAC Activity 
HDAC activity was assayed using a colorimetric detection kit (Upstate, Temecula, CA) 
according to the manufacturer’s instructions. Absorbances were detected at 405 nm and 
results were expressed as the percentage of Normoxia group. 
Biochemical analyses 
Cell-free supernatants of lung tissue homogenates were used for determinig lung tissue 
pro-inflammatory cytokine (TNF-α, IL-6 and IL-1β) contents by specific enzyme-linked 
immunosorbent assay (ELISA) kits (R&D Systems, Minneapolis, MN) [17]. 
Activities of superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) and 
myeloperoxidase (MPO), as well as malondialdehyde (MDA) content of lung tissues were 
measured by spectrophotometric (UV-1700, Shimadzu, Japan) analyses [15]. 
Statistics 
Statistical analyses were performed using SPSS 16.0 software (IBM Corporation, Armonk, 
NY). Data were expressed as mean±standard error of means (SEM). Normal distributions 
of data were graphically examined with Shapiro-Wilk test. Categorical variables were 
compared with Chi square test. Immunohistochemical scores were assessed by Kruskal 
Wallis test. Treatment groups were compared using One-Way ANOVA and significance 
was determined using post-hoc Tukey test or Bonferroni’s correction for multiple 
comparisons where applicable. p<0.05 was considered statistically significant. 
Results 
We started the experiment with 10 rat pups in each group. No pups died in Normoxia or 
Normoxia+VPA groups throughout the study period. On the other hand, one pup in each 
Hyperoxia or Hyperoxia+VPA group died on the 2nd or the 3rd postnatal days, respectively. 
No significant difference was found in terms of survival rate among experimental groups 
(p>0.05) and our analyses were not affected by the number of surviving pups. A survival 
curve has been presented in Fig 1. 
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Fig 1. Number of surviving rat pups in experimental groups. 
doi:10.1371/journal.pone.0126028.g001 
The well-being of the rat pups was, in part, assessed with the weight gain during the 
experiment. Mean birth weights of pups in Normoxia, Normoxia+VPA, Hyperoxia and 
Hyperoxia+VPA groups (5.1±0.3 g vs. 5.1±0.2g vs. 5.0±0.4 g vs. 5.0±0.3 g, respectively) did 
not differ significantly. At the end of the experiment, the mean body weight of pups in 
Hyperoxia group (12.4±1.2 g) was significantly (p<0.05) lower than that of pups in 
Normoxia (17.1±1.5 g), Normoxia+VPA (16.8±1.4 g) and Hyperoxia+VPA (15.4±1.3 g) 
groups (Fig 2). The weight of the Hyperoxia+VPA group was not different to the Normoxia 
and Normoxia+VPA group. 
Fig 2. Bar graph depicting body weights of rat pups at birth and P10. *p<0.05 compared to Normoxia group; 
#p<0.05 compared to Normoxia+VPA group; and †p<0.05 compared to Hyperoxia group using One-Way ANOVA 
followed by post-hoc Tukey test. 
doi:10.1371/journal.pone.0126028.g002 
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The structure of the lung was assessed by histological examination. The mean 
histopathologic grade of lung injury in pups in Hyperoxia group was significantly (p<0.001) 
greater than that in Normoxia and Normoxia+VPA groups; VPA treatment significantly 
improved histological grading of lung injury compared with Hyperoxia group (Figs 3 & 4A). 
Thickening of the alveolar septi or cell infiltration was not observed in Normoxia, 
Normoxia+ VPA or Hyperoxia+VPA groups but in the Hyperoxia group (Fig 3). Masson’s 
trichrome-stained sections showed cell infiltration, edema and fibrosis in the Hyperoxia 
group but not in Normoxia, Normoxia+VPA and Hyperoxia+VPA groups (Fig 3). Mean 
radial alveolar count, reflecting the number of intact alveoli, was significantly (p<0.001) 
decreased in Hyperoxia group compared with Normoxia and Normoxia+VPA groups, 
while it was significantly greater in Hyperoxia+VPA group (p<0.05) compared to 
Hyperoxia group (Figs 3 & 4B). Similarly, the decrease in mean LBMP expression (p<0.001) 
in Hyperoxia group was significantly recovered by VPA treatment (p<0.001) (Figs 3 & 4C). 
The remodeling of the injured lung was assessed by evaluation of apoptosis including the 
number of apoptotic cells as well as expressions of active caspase-3 and bcl-2. When 
compared with the Normoxia and Normoxia+VPA groups, number of TUNEL (+) cells (Figs 
3 & 4D) and active Caspase-3 expression (Fig 5A) were significantly increased in Hyperoxia 
group (p<0.001 and p<0.001, respectively) while VPA treatment significantly decreased 
number of TUNEL (+) cells (p<0.001) (Figs 3 & 4D) and active Caspase-3 expression 
(p<0.05) (Fig 5A). In contrast to active Caspase-3, levels of bcl-2, an anti-apoptotic 
protein, were significantly decreased in Hyperoxia group (p<0.001) compared with the 
Normoxia and Normoxia+VPA groups, while bcl-2 was significantly increased in 
Hyperoxia+ VPA group in comparison with Hyperoxia group (p<0.05) (Fig 5B). 
Inflammation was assessed by levels of IL-1β, IL-6, TNF-α and by MPO activity as a 
marker of neutrophil invasion. Levels of IL-1β, IL-6 and TNF-α in the lung tissues were 
increased in Hyperoxia group compared with the Normoxia and Normoxia+VPA groups 
(p<0.05 for all), whereas VPA treatment significantly reduced hyperoxia-induced 
elevations of IL-1β, IL-6 and TNF-α (p<0.05 for all) (Table 1). MPO activity was found to 
be increased by hyperoxia, whereas VPA treatment decreased it in hyperoxia (Table 1). 
Expressions of TGFβ1 and TGFβ3 (Fig 6A & 6B) and phospho-SMAD2 (Fig 6C) in Hyperoxia 
group were significantly (p<0.05) greater compared with Normoxia and Normoxia+VPA 
groups, whereas expressions of both proteins were reduced by VPA treatment (p<0.05). 
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Fig 3. Histological examination of lung tissues by Haematoxylin-eosin (A-D, 100X magnification), Masson’s 
trichrome (E-H, 400X magnification), lamellar body membrane protein (LBMP) (I-L, 1000X magnification), and 
TUNEL-DAB stainings (M-P, 200X magnification) for Normoxia, Normoxia+VPA, Hyperoxia and Hyperoxia+VPA 
groups. Representative images show severe alveolar damage (panel C), cell infiltration and edema (panel G, 
arrow) in Hyperoxia group. Thickening of the alveolar septi or cell infiltration was not observed in Normoxia, 
Normoxia+VPA and Hyperoxia+VPA groups and panels A, B, D, E, F and H shows healthier and intact lung 
parenchymal appearance compared to hyperoxia group. Black arrows indicate positive immunoreactivity for 
LBMP and TUNEL (+) cells in panels I-P. 
Fig 4. Bar graphs depicting Histopathologic Grade (A), Radial Alveolar Count (B), LBMP per Unit Area 
(C) and TUNEL (+) Cells per Unit Area (D) in lung tissues of rat pups. *p<0.05 and **p<0.001 compared to
Normoxia group; #p<0.05 and ##p<0.001 compared to Normoxia+VPA group; and †p<0.05 and 
††p<0.001 compared to Hyperoxia group using One-Way ANOVA followed by post-hoc Tukey test. 
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Fig 5. Bar graphs depicting active Caspase-3 (A) and bcl2 (B) expressions in lung tissues of rat pups. Panel C 
depicts representative bands for each protein, including β-Actin, the protein which was used as a loading control 
for western blotting. *p<0.05 and **p<0.001 compared to Normoxia group; 
#p<0.05 and ##p<0.001 compared to Normoxia+VPA group; and †p<0.05 compared to Hyperoxia group using 
One-Way ANOVA followed by post-hoc Tukey test. 
Fig 6. Bar graphs depicting TGFβ1 (A), TGFβ3 (B) and phospho-SMAD2 (C) expressions in lung tissues of rat pups. 
Panel D depicts representative bands for each protein, including β-Actin, the protein which was used as a 
loading control for western blotting. *p<0.05 and **p<0.001 compared to Normoxia group; #p<0.05 and 
##p<0.001 compared to Normoxia+VPA group; and †p<0.05 and ††p<0.001 compared to Hyperoxia group using 
One-Way ANOVA followed by post-hoc Tukey test. 
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The maturity of the antioxidant enzyme systems was assessed by oxidant and 
antioxidant enzyme activities. The decreases in lung tissue GSH-Px and SOD activities in 
Hyperoxia group were prevented by VPA in the Hyperoxia+VPA group (Table 1). Similarly, 
the increases by hyperoxia of lung tissue MDA levels were significantly reduced in 
Hyperoxia+VPA group (Table 1). 
HDAC activity was analyzed in order to test our hypothesis that VPA administration 
affected epigenetic regulation of pulmonary inflammation in this hyperoxic lung injury 
model. HDAC activity in lung tissues was found to be significantly enhanced (p<0.05) in 
Hyperoxia group compared to Normoxia and Normoxia+VPA groups. VPA treatment 
reduced the increased HDAC activity significantly (p<0.05) (Fig 7A). Consistently, acetyl-
histone H3 and H4 protein expressions in Hyperoxia+VPA group were significantly 
(p<0.001) increased compared with Hyperoxia group (Fig 7B & 7C, respectively). 
Table 1. Comparison of lung tissue pro-inflammatory cytokine levels and superoxide dismutase (SOD), 
glutathione peroxidase (GSH-Px) and myeloperoxdase (MPO) activities and malonedialdehyde (MDA) content 
in all groups. 
Cytokine Levels 
(pg/ml) 
Normoxia  
Group 
Normoxia+VPA  
Group 
Hyperoxia 
Group 
Hyperoxia+VPA 
Group 
IL-1β 86.2 ± 6.4 89.4 ± 7.6 129.2 ± 10.1* 98.6 ± 7.5† 
IL-6 36.1 ± 5.7 37.3 ± 5.4 58.4 ± 5.1* 42.5 ± 4.7† 
TNF-α 101.6 ± 18.4 106.7 ± 12.6 242.5 ± 32.9* 141.7 ± 19.2† 
Biochemical Analyses 
GSH-Px (U/mg protein) 13.2 ± 1.4 12.4 ± 1.2 4.1 ± 1.4* 9.5 ± 1.3† 
SOD (U/mg protein) 115.8 ± 10.6 118.6 ± 9.1 60.5 ± 3.1** 90.8 ± 8.4‡ 
MPO (U/g protein) 25.7 ± 3.6 31.7 ± 4.4 82.7 ± 4.3** 56.5 ± 5.2‡ 
MDA (nmol/g protein)
    
24.6 ± 26.8 ± 4.1 80.4 ± 4.7** 47.6 ± 4.1† 
*p<0,05 and 
**p<0,01 compared to Normoxia group; and 
†p<0,05 and 
‡p<0,01 compared to Hyperoxia group using One-Way ANOVA followed by post-hoc Tukey test. 
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Fig 7. Bar graphs depicting histone deacetylase (HDAC) activity (A) as well as acetylated histone H3 
and acetylated histone H4 (C) protein expressions in lung tissues of rat pups. *p<0.05 and 
**p<0.001 compared to Normoxia group; #p<0.05 and ##p<0.001 compared to Normoxia+VPA group; and 
††p<0.001 compared to Hyperoxia group using One-Way ANOVA followed by post-hoc Tukey test. 
doi:10.1371/journal.pone.0126028.g007 
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Discussion 
The present data showed that systemic administration of VPA to rat pups under hyperoxic 
conditions provided significant protection against lung damage in a neonatal rat model 
of hyperoxic lung injury and preserved body growth. The effect of VPA was in part 
mediated by epigenetic modulation of inflammation. We conclude that VPA treatment 
exhibits anti-inflammatory, anti-apoptotic and anti-fibrotic effects in hyperoxic lung 
injury model in neonatal rats. 
Chronic inflammation is the hallmark of hyperoxic lung damage and BPD, which were 
shown to alter HAT/HDAC ratio, resulting in histone hypoacetylation [9]. Given the 
problems associated with the use of postnatal steroids for the prevention of BPD with 
respect to long term neurodevelopmental outcome, we successfully tested a different 
approach of epigenetic modulation for postnatal chronic pulmonary inflammation. 
Recent data established that VPA might lead to hyperacetylation of histones by directly 
inhibiting HDACs. Since histone acetylation and deacetylation might play an important 
role in the pathogenesis of inflammatory lung diseases [9,20], HDAC inhibitors were 
already suggested to provide protection against lung fibrosis to altered gene expression 
after hyperacetylation [7,21]. Therefore, we used VPA for this purpose and showed that 
VPA affected acetylation process in the lung, prevented apoptosis, and decreased 
inflammation. 
VPA attenuated hyperoxic lung injury by improving the histopathological score and 
preserving alveolarization in the present study. Our data are in accordance with a 
previous report which showed that VPA improved histopathological injury in lung, liver 
and kidney, and ameliorated multiple organ dysfunction caused by LPS induced septic 
shock [14]. In addition, we showed that VPA significantly increased lamellar membrane 
protein expression and mean radial alveolar count as an evidence for the preservation of 
alveolarization in hyperoxic lung injury. The structural changes were associated with 
elevated expressions of TGFβ3 and SMAD2 proteins in lung tissue samples of rat pups 
exposed to hyperoxia and these elevations were restored by VPA treatment which is in 
line with clinical data where increased levels of TGFβ isoforms in bronchoalveolar lavage 
fluid of preterm infants were associated with the severity of BPD [22]. In addition, our 
data showed that VPA decreased apoptosis by reducing both the number of TUNEL (+) 
cell count and active caspase-3 expression in lung tissue. Exposure of neonatal rat lung 
to hyperoxia resulted in apoptosis which was associated with the early rise in pro-
apoptotic proteins that overcome the anti-apoptotic activity of Bcl-2 [23]. Although the 
protective effects of HDAC inhibitors in experimental models of inflammation were found 
to be associated with increased expression of bcl-2 protein family, the precise mechanism 
of this up-regulation has not been defined [24]. We had similar findings in our study in 
which VPA administration increased bcl-2 expression in neonatal rats subjected to 
hyperoxia. To the best of our knowledge, this is the first study to present data on the 
effect of VPA on bcl-2 expression in a neonatal rat model of hyperoxia. The mechanism 
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by which VPA administration increased bcl-2 expression in neonatal rats under hyperoxic 
conditions is yet to be determined. On the other hand, the effect may involve a regulation 
by p53. It was shown in cancer cells that the tumor suppressor p53 induces apoptosis by 
inhibiting the anti-apoptotic bcl-2 [25] as well as the pro-apoptotic bax protein [26]. In 
addition, recent studies report a direct effect of HDAC inhibitors on p53, again in cancer 
cells [27-29]. Accordingly, HDAC inhibitors induce p53 expression, which in turn inhibits 
the expression of bcl-2 to promote apoptotic death in certain cancer types. However, we 
found in our study that VPA administration increased the expression of the anti-apoptotic 
bcl-2 while decreasing the expression of the pro-apoptotic Caspase-3 protein. Therefore, 
it is reasonable to speculate that the regulation of bcl-2 in hyperoxic lung may be different 
from that in cancer cells. Nevertheless, our study was not designed to unravel the 
mechanism of bcl-2 regulation by VPA which must be investigated by future studies. All 
these results suggest that protective effect of VPA on fibrotic tissue remodeling involves 
reduction of TGFβ/SMAD expression and also apoptosis. The positive impact of VPA on 
alveolar lung development and apoptotic mechanisms must be evaluated in future 
studies. 
The structural benefit was associated with preserved GSH-Px and SOD activities and 
reduced tissue MDA content, MPO activity and levels of pro-inflammatory cytokines 
suggesting that one of the mechanisms by which VPA prevents hyperoxic lung injury is 
enhancement of antioxidant activity and reduction of lipid peroxidation and 
inflammation. Similarly, VPA showed protection from lung inflammation by decreasing 
serum IL-6 and TNF-α levels, as well as MPO activity significantly in pulmonary tissue by 
amelioration of lung damage in a rat model of septic shock [14] or acute lung injury [30]. 
The systemic effects on pro-inflammatory cytokine concentrations may have resulted in 
one of the most interesting effects of VPA. VPA promoted growth in the rat pups that 
were exposed to hyperoxia. Since malnutrition is known to worsen BPD by compromising 
lung growth [31], we consider VPA as an interesting candidate for the prevention of BPD. 
However, it is difficult to translate experimental studies into clinical setting [32]. First of 
all, our study is limited with the lack of data on antenatal steroids, the effects of which 
on epigenetic regulation, lung growth, inflammation and TGF-β signaling have not been 
taken into account in our model. Although the effect of antenatal steroids on epigenetic 
mechanisms in the lung is not known, intrauterine inflammation induced TGF-β signaling 
was shown to be inhibited by antenatal steroids [33]. It was also reported that the order 
of exposure to inflammation or maternal steroids had large and different effects on fetal 
lung maturation [34]. Therefore, future studies are warranted that aim to investigate the 
role of antenatal steroids on epigenetic changes in lung development. Second of all, VPA 
is a potent drug which has been shown to induce cognitive deficits and the risk of autism 
after in utero exposure [32,35]. In addition, VPA in neonates may lead to progressive 
hyperammonemia, cerebral edema, and diminished level of consciousness and these 
potential adverse effects hamper the clinical usage of VPA in this high risk group [36]. 
However, on the other hand, VPA has been used in neonates with refractory convulsions 
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[37]. Therefore, experimental and clinical data regarding the safety of VPA usage in 
neonates are required before its clinical applicability. In addition, postnatal VPA usage in 
clinical care warrants long term neurodevelopmental outcome studies in neonates. 
In conclusion, VPA treatment improved alveolarization by preserving 
histopathological structure, radial alveolar count and lamellar body membrane protein 
expression in the alveoli as well as it reduced fibrosis, TUNEL (+) cell counts, active 
Caspase-3 expression and inflammation, and enhanced antioxidant activity while 
decreasing lipid peroxidation in the hyperoxic lung. In addition, VPA reduced HDAC 
activity and enhanced acetyl-histone H4 protein expression in the injured lung tissue 
suggesting the involvement of the inhibitory action of VPA on HDAC activity. To the best 
of our knowledge, this is the first study that showed preventive effects of VPA, a HDAC 
inhibitor, in a neonatal rat model of hyperoxic lung injury and reduced body growth. Our 
data suggest that VPA may be beneficial in treatment of hyperoxic lung injury in preterm 
infants in case its effectiveness and safety is proven in human studies. 
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Abstract 
Background: 
Bronchopulmonary dysplasia (BPD) is an important cause of morbidity. The aim of this 
study was to evaluate the preventive effect of cytidine 5'-diphosphocholine (CDP-choline) 
treatment on hyperoxic lung injury in a neonatal rat model. 
Methods: 
A total of 30 newborn pups were divided into control, hyperoxia, and hyperoxia + CDP-
choline groups. After birth, pups in the control group were kept in room air and received 
saline injections, whereas those in hyperoxia and hyperoxia + CDP-choline groups were 
exposed to 95% O2 and received daily injections of saline and CDP-choline throughout 
postnatal day 10, respectively. Histopathological scoring, radial alveolar count, lamellar 
body membrane protein expression, fibrosis, proinflammatory cytokine levels, lung tissue 
and bronchoalveolar lavage (BAL) fluid phospholipid content, and apoptosis were 
evaluated. 
Results: 
Hyperoxia-induced severe lung damage was reduced signify by CDP-choline treatment. 
Radial alveolar count and lamellar body membrane protein expression were significantly 
recovered, and the number of terminal deoxynucleotidyl transferase-mediated 
deoxyuridine triphosphate nick-end labelling-positive cells, active caspase-3 expression, 
and tissue proinflammatory cytokine levels were decreased by CDP-choline 
administration. Lung tissue and BAL phospholipid contents showed significant increases 
after CDP-choline administration. 
Conclusion: 
These data show that CDP-choline ameliorates hyperoxic lung injury in a neonatal rat 
model. It may therefore be suggested that CDP-choline may be a novel therapeutic option 
for the prevention of BPD. 
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Bronchopulmonary dysplasia (BPD) is an important cause of morbidity in preterm infants 
that results in prolonged hospitalization, discharge from hospital with oxygen therapy, 
frequent readmission to the hospital with respiratory problems, and increased 
neurodevelopmental risk (1). Although BPD has a multifactorial etiology, major risk 
factors for BPD development include preterm birth, lower gestational age and birth 
weight, need for supplemental oxygen and ventilatory support, oxygen toxicity, 
decreased host antioxidant defenses, patent ductus arteriosus, and pre- and postnatal 
infections (2). Therefore, treatment of evolving BPD may be challenging due to the 
complex balance between these contributing risk factors. Efficacy of parenteral 
administration of vitamin A or caffeine, the two successful treatments developed to 
prevent BPD, was supported by evidence from randomized controlled studies (3), 
whereas many other treatments aiming at preventing BPD have failed to demonstrate a 
reduction in BPD rates (2). Therefore, newer strategies and pharmacological approaches 
to prevent BPD are required in order to decrease BPD incidence and severity. 
Cytidine 5'-diphosphocholine (CDP-choline), which is composed of cytidine and 
choline linked by a diphosphate bridge, is an endogenous intermediate in the synthesis 
of the major membrane phospholipid, phosphatidylcholine (PC) (4). PC is quantitatively 
the most important phospholipid, accounting for 70-85% of the total surfactant 
phospholipids, which are major constituents of surfactant lipids (5). The primary function 
of surfactant is to decrease surface tension at the air-liquid surface in the alveoli and 
distal bronchioli, to promote lung expansion during inspiration in order to prevent 
atelectasis at end expiration. It also plays an important role in pulmonary host defense 
and local immunomodulation by enhancing the stability of the film that floats on the 
alveolar linings, facilitating mucociliary transport, exhibiting antioxidant activity with 
antibacterial/antiviral properties (5). Due to persisting surfactant abnormalities including 
an ongoing quantitative deficiency in surfactant components, decreased function of 
endogenous surfactant, and increased surfactant turnover in ventilated preterms with 
evolving BPD, surfactant therapy was suggested to show benefits in prevention of BPD 
(6). In addition, the beneficial effects of additional surfactant therapy for prevention of 
BPD were also evaluated (7). 
In addition, in a few studies with conflicting outcomes, CDP-choline was administered 
parenterally at a dose range of 100-300 mg/kg/d to preterm infants to increase the 
synthesis of lung phospholipids for alleviating the symptoms of respiratory distress 
syndrome (8,9). However, to the best of our knowledge, no study evaluated the efficacy 
of CDP-choline for preventing BPD. Therefore, the aim of this experimental study was to 
investigate the possible protective effect of CDP-choline against hyperoxic lung injury in 
a neonatal rat model. 
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RESULTS 
No significant difference was detected between mean birth weights of pups in the 
control, hyperoxia, and hyperoxia + CDP-choline groups (5.0 ± 0.4 vs. 4.9 ± 0.2 vs. 5.0 ± 
0.3 g, respectively) (P > 0.05). However, the mean body weight of pups in the hyperoxia 
+ CDP-choline group (15.2 ± 1.2 g) was significantly greater than that of pups in the
hyperoxia group (12.2 ± 0.9 g) (P = 0.02), but not in the control group (17.4 ± 1.6 g; P >
0.05) at end of the study (postnatal day (P)10). During the experimental procedures, two
pups in the hyperoxia group and one pup in the hyperoxia + CDP-choline group died.
However, no significant difference was found between these two groups in terms of
survival (P > 0.05).
Severity of lung damage was evaluated between grades 1 and 4 by histopathologic 
examination (Figures 1a-c and 2). Thickening of the alveolar septi or cell infitration was 
not observed in the control and hyperoxia + CDP-choline groups. CDP-choline treatment 
significantly improved histological grading of lung injury as compared with saline 
treatment in the hyperoxia group (P= 0.01) (Figure 1a-c). Masson’s trichrome stained 
sections also showed cell infiltration, edema, and fibrosis in the hyperoxia group, which 
were not noticeably observed in the control and hyperoxia + CDP-choline groups (Figure 
1d-f). Radial alveolar count, reflected by the number of intact alveoli, was also 
significantly greater in the hyperoxia + CDP-choline group as compared with the 
hyperoxia group (P < 0.05) (Figure 2). 
Although expression of P180 lamellar body membrane protein was decreased in the 
hyperoxia group, it was recovered by CDP- choline treatment (Figures 1g-i and 2). By 
contrast, the number of terminal deoxynucleotidyl transferase-mediated deoxyuridine 
triphosphate nick-end labeling (TUNEL)-positive cells per unit area (Figure 3) and active 
caspase-3 expression (209.2 ± 13.7% in the hyperoxia group vs. 127.9 ± 5.6% in the 
hyperoxia + CDP-choline group) (Figure 4) were lower in the hyperoxia + CDP-choline 
group as compared with those in the hyperoxia group (P < 0.05). Levels of β-actin, the 
protein that was used as a protein- loading control for gel electrophoresis, did not change 
between the groups. 
To further investigate the possible mechanism of action of CDP-choline treatment, 
lung tissue inflammatory cytokine levels were also analyzed. In the hyperoxia group, 
levels of interleukin (IL)-1β, IL-6, and tumor necrosis factor-α (TNF-α) were found to be 
increased as compared with those of the control group (P < 0.05), whereas CDP-choline 
treatment significantly reduced hyperoxia-associated elevations of IL-1β (from 148.9 ± 
12.4 to 112.1 ± 9.4 pg/ml), IL-6 (from 43.7 ± 4.5 to 28.6 ± 4.1 pg/ml), and TNF-α (from 
246.7 ± 30.9 to 146.2 ± 20.7 pg/ml) (P < 0.05) (Table 1), suggesting an anti-inflammatory 
effect of CDP-choline treatment. 
To investigate the effect of supplemented CDP-choline on surfactant components, a 
phospolipid assay was performed in bronchoalveolar lavage (BAL) fluid and lung tissue 
homogenates. As shown in Table 2, the content of total phospholipids and phospholipid 
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classes including PC, phosphatidylglycerol, and disaturated PC (DSPC) significantly 
decreased in both BAL and lung tissue samples of rat pups exposed to hyperoxia as 
compared with those in control pups, whereas CDP-choline treatment significantly 
increased the contents of the measured phospholipid classes (Table 2). 
In addition, biochemical analyses revealed that subjection to hyperoxia significantly 
decreased tissue superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) 
activities, whereas it increased tissue malondialdehyde (MDA) content and 
myeloperoxidase (MPO) activity (Table 3). By contrast, mean tissue SOD and GSH-Px 
activities were significantly higher in the hyperoxia + CDP-choline group as compared with 
the hyperoxia group (95.6 ± 6.1 vs. 63.7 ± 2.5 U/mg protein, P = 0.001 and 11.5 ± 1.5 vs. 
5.6 ± 1.8 U/g protein, P = 0.01, respectively), indicating the efficacy of CDP-choline on 
decreasing oxidative stress. Mean tissue MDA content and MPO activity (52.9 ± 3.2 vs. 
68.8 ± 7.4 nmol/g protein, P = 0.001 and 55.5 ± 6.8 vs. 76.2 ± 2.1 U/g protein, P = 0.001, 
respectively) were significantly lower in the hyperoxia + CDP-choline group as compared 
with those in the hyperoxia group, suggesting a CDP-choline effect on decreasing lipid 
peroxidation (Table 3). 
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Fig. 1. Representative images of (a-c) hematoxylin-eosin staining, (d-f) Masson’s trichrome staining, and (g-i) 
immunohistochemistry for lamellar body membrane protein. Histological appearance of the lungs in the 
hyperoxia group is characterized by partial destruction of the lung tissue (in b), cell infiltration, edema, and 
fibrosis (in b and e), which are not notably observed in the control (in a and d) and hyperoxia + CDP-choline (in 
c and f) groups. (g-i) Abundant positive immunohistochemistry for the lamellar body membrane protein for 
control and hyperoxia + CDP-choline groups (black arrows, DAB-positive lamellar body membrane protein 
immunoreactivities). Bars, 50 μm (in d–f); 25 μm (in a-c and g-i). CDP-choline, cytidine 5’-diphosphocholine; 
DAB, 3,3’-diaminobenzidine; H&E, hematoxylin-eosin staining; LBMP IHC, lamellar body membrane protein 
immunohistochemistry. 
Fig. 2. Bar graphs for (a) histopathologic evaluation, (b) radial alveolar count, and (c) lamellar body membrane 
protein expression. *P < 0.05, signifi- cantly different from control group; †P < 0.05, significantly different from 
hyperoxia group using one-way ANOVA followed by post hoc Holm-Sidak test. CDP-choline, cytidine 5’-
diphosphocholine; LBMP, lamellar body membrane protein. 
a 4  
  H
is
to
pa
th
ol
og
ic
al
 g
ra
de
 
3 
2 
1 
0 
Control Hyperoxia Hyperoxia + 
CDP-choline 
b 
10 
  M
ea
n 
ra
di
al
 a
lv
eo
la
r c
ou
nt
s 8 
6 
4 
2 
0 
Control Hyperoxia Hyperoxia + 
CDP-choline 
c 
LB
M
P 
pe
r u
ni
t a
re
a 
6 
4 
2 
0 
Control Hyperoxia Hyperoxia + 
CDP-choline 
a b c
d e f
g h i
Cytidine 5′-diphosphocholine ameliorates hyperoxic lung injury in a neonatal rat model 
41 
a b 
Fig. 3. TUNEL-positive cell counts. (a) Immunohistochemistry images and (b) bar graph for TUNEL-positive cell 
counts. Arrows indicate TUNEL-positive cells. *P < 0.05, significantly different from control group; †P < 0.05, 
significantly different from hyperoxia group using one-way ANOVA followed by post hoc Holm-Sidak test. Bar, 
25 μm. CDP-choline, cytidine 5’-diphosphocholine; TUNEL, terminal deoxynucleotidyl transferase-mediated 
deoxyuridine triphosphate nick-end labeling. 
Fig. 4. Bar graph showing the effect of CDP-choline treatment on active caspase-3 expression in hyperoxic lung 
injury. *P < 0.05, significantly different from control group; †P < 0.05, significantly different from hyperoxia 
group using one-way ANOVA followed by post hoc Holm-Sidak test. β-Actin was used as a protein-loading 
control. CDP-choline, cytidine 5’-diphosphocholine. 
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Table 1. Levels of cytokines in lung homogenates 
Hyperoxia + 
Cytokine levels, pg/ml Control group Hyperoxia group CDP-choline group 
IL-1β 91.2 ± 8.7 148.9 ± 12.4** 112.1 ± 9.4*** 
IL-6 24.4 ± 3.2 43.7 ± 4.5* 28.6 ± 4.1*** 
TNF- α 104.0 ± 20.3 246.7 ± 30.9** 146.2 ± 20.7*** 
CDP-choline, cytidine 5’-diphosphocholine; IL, interleukin; TNF, tumor necrosis factor. 
*P < 0.05; **P < 0.01 compared with control group; ***P < 0.05 compared with hyperoxia group using one-way 
ANOVA followed by post hoc Holm-Sidak test. 
Table 2. Lung tissue and bronchoalveolar lavage fluid phospholipid levels in the study groups 
Hyperoxia + 
Control group Hyperoxia group CDP-choline group 
Lung tissue phospholipids (nmol/mg protein) 
Total phospholipids 298.5 ± 6.4 220.8 ± 5.4** 271.8 ± 1.5† 
PC 146 ± 2.7 107.5 ± 3.2** 130 ± 1† 
DSPC 47.5 ± 1.2 35.5 ± 1** 42.5 ± 1† 
PG 9.5 ± 0.2 7.1 ± 0.2* 8.1 ± 0.2*** 
BAL fluid phospholipids (nmol/ml) 
Total phospholipids 31 ± 1.6 20.5 ± 0.6** 28.5 ± 0.7† 
PC 24.3 ± 0.5 17.9 ± 0.5** 21.7 ± 0.2† 
DSPC 15.8 ± 0.4 11.8 ± 0.3** 14.2 ± 0.1 
PG 3.2 ± 0.1 2.4 ± 0.1* 2.7 ± 0.1*** 
BAL, bronchoalveolar lavage; DSPC, disaturated phosphatidylcholine; PC, phosphatidylcholine;  PG,  
phosphatidylglycerol. 
*P < 0.05; **P < 0.01 compared with control group; ***P < 0.05; †P < 0.01 compared with hyperoxia group
using one-way ANOVA followed by post hoc Holm-Sidak test. 
Table 3. Lung tissue malondialdehyde (MDA) content and superoxide dismutase (SOD), glutathione peroxidase 
(GSH-Px), and myeloperoxidase (MPO) activities 
Cytokine levels, pg/ml 
Control 
group, n = 10 
Hyperoxia 
group, n = 10 
Hyperoxia + 
CDP-choline group 
n = 10 
Biochemical analyses 
MDA (nmol/g protein) 31.1 ± 3.7 68.8 ± 7.4** 52.9 ± 3.2*** 
SOD (U/mg protein) 114.4 ± 9.2 63.7 ± 2.5** 95.6 ± 6.1† 
GSH-Px (U/mg protein) 12.5 ± 1.4 5.6 ± 1.8* 11.5 ± 1.5*** 
MPO (U/g protein) 36.5 ± 2.3 76.2 ± 2.1** 55.5 ± 6.8† 
CDP-choline, cytidine 5’-diphosphocholine. 
*P < 0.05; **P < 0.01 compared with control group; ***P < 0.05; †P < 0.01 compared with hyperoxia group
using one-way ANOVA followed by post hoc Holm-Sidak test. 
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DISCUSSION 
These data show that CDP-choline treatment improves histopathological score, 
decreases fibrosis, improves alveolarization by preserving radial alveolar count and 
lamellar body protein expression in the alveoli, reduces TUNEL-positive cell counts and 
active caspase-3 expression, increases antioxidant activity, and decreases lipid 
peroxidation and inflammation in the injured lung tissues of neonatal rats. In addition, 
both lung tissue and BAL fluid phospholipid contents were significantly increased by CDP-
choline therapy. To the best of our knowledge, this is the first experimental study that 
reports amelioration of hyperoxic lung injury by CDP-choline treatment in a neonatal rat 
model.  
Preterm infants and their lungs are susceptible to injury as a result of resuscitation, 
mechanical ventilation, oxygen therapy, and surfactant deficiency (10). BPD is 
characterized by decreased alveolar and vascular lung development resulting in enlarged 
alveoli and is complicated by inflammation, abnormal coagulation, fibrinolysis, oxidative 
stress, and, at later stages, pulmonary hypertension (10). Neonatal exposure to hyperoxia 
in animals was reported to result in progressive lung disease that strongly resembles BPD 
in premature infants (11). Therefore, we used this experimental BPD model, which 
induces lung injury by exposure to hyperoxia. 
Hyperoxic injury caused both apoptotic and necrotic cell death in an adult murine 
model, and the number of apoptotic cells in the lung exposed to hyperoxia correlated 
with the degree of the injury (12). High concentrations of oxygen also resulted in 
apoptosis in the lungs in a neonatal mouse model in which the degree of apoptosis was 
found to be associated with the duration of hyperoxia and the degree of lung injury (13). 
Therefore, the authors suggested that apoptosis due to hyperoxia during the crucial 
period of lung development might adversely affect future lung growth. In accordance 
with these studies, our data showed that CDP-choline significantly decreased the number 
of TUNEL-positive cells and active caspase-3 expression in hyperoxic lung injury. 
Although BPD has a multifactorial etiology, pre- and postnatal infection and 
inflammation are the major contributors to its pathogenesis (2). Several studies showed 
increased protein levels and high mRNA expression of proinflammatory cytokines in 
airway secretions and bronchoalveolar cells of premature infants who developed BPD 
(14,15). We also observed in the current study that proinflammatory cytokines TNF-α, IL-
6, and IL-1β were increased due to exposure to hyperoxia in the lungs of neonatal rats. 
However, CDP-choline treatment significantly reduced the levels of these 
proinflammatory cytokines. CDP-choline is a choline donor because part of exogenously 
administered CDP-choline is metabolized to choline in the circulation (16). Choline is an 
essential nutrient and a precursor of the neurotransmitter acetylcholine (ACh) as well as 
various membrane phospholipids (17). Choline may have anti-inflammatory effects by 
activating α-7 nicotinic ACh receptors (18). In agreement, choline administration was 
shown to reduce the elevation of circulating TNF-α levels and attenuate endotoxin-
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induced multiple organ injury (19), whereas choline deficiency results in increased levels 
of proinflammatory cytokines such as TNF-α (20). Because exogenously administered 
CDP-choline is a source of choline (16), our observation that CDP-choline reduces tissue 
levels of proinflammatory cytokines might have resulted from the anti-inflammatory 
action of choline (through stimulation of α-7 nicotinic ACh receptors) that derived from 
CDP-choline metabolism. 
In addition, because choline is a precursor for the synthesis of ACh both in the brain 
and periphery, including nonneuronal cells in the respiratory tract (21), choline 
metabolized from CDP-choline might have enhanced ACh synthesis and cholinergic 
activity in our study. Recent findings suggest that through the cholinergic anti-
inflammatory pathway (22), ACh regulates additional functions in the airways, including 
inflammation and remodeling during inflammatory airway diseases (23,24). Therefore, 
because CDP-choline administration has been shown to exhibit body responses of a 
cholinergic nature (25), the anti-inflammatory effects of CDP-choline might have resulted 
from enhanced ACh synthesis and cholinergic activity. Another mechanism by which CDP-
choline prevented BPD in our study might include counteraction of cytokine effects on 
cellular membranes by CDP-choline. Exogenously administered CDP-choline enhances 
membrane phospholipid levels in the brain and lungs (8). Therefore, as a building block 
of PC, the major constituent of surfactant, CDP-choline might have shown benefit by 
enhancing surfactant synthesis in our study. Surfactant therapy was suggested to confer 
benefit in the prevention of BPD in previous studies that demonstrated persisting 
surfactant abnormalities including an ongoing quantitative deficiency in surfactant 
components (especially surfactant proteins), decreased function of endogenous 
surfactant for lowering surface tension, and increased surfactant turnover in ventilated 
preterms evolving BPD (6). In addition, expression of surfactant proteins A, B, and C were 
found to be altered in animal models of chronic exposure to high oxygen concentrations 
(26). The relative deficiencies of surfactant proteins were reported to be indicators of 
BPD for lower lung volume and infection in evolving BPD in a baboon model of BPD (27). 
In another study, surfactant function and contents of surfactant proteins were shown to 
be altered in mechanically ventilated preterm infants (6). In accordance with these data, 
temporary improvement in pulmonary function of preterm infants who required 
prolonged mechanical ventilation was achieved with exogenous surfactant 
supplementation (28), suggesting surfactant’s preventive effect on BPD development (7). 
Hence, we analyzed both lung tissue and BAL fluid phospholipid concentrations and 
showed that the phospholipid classes PC, phosphatidylglycerol, and DSPC reached near-
control levels after CDP-choline administration. Therefore, as a precursor of PC and 
surfactant synthesis, CDP-choline might have ameliorated the lung damage caused by 
BPD in our study by reducing membrane breakdown and enhancing phospholipid and, 
possibly, surfactant production. 
Oxygen toxicity, which has been suggested as a significant contributing factor for BPD 
development in premature infants (2), is associated with generation of hydroxyl radicals 
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and peroxidation of membrane lipids. It is well known that proinflammatory cytokines 
activate phospholipase A2 and PC-phospholipase C in order to hydrolize PC (4). PC 
hydrolysis by phospholipase A2 results in the release of lyso-PC, an inhibitor of CTP-
phosphocholine cytidylyltransferase enzyme, which is involved in PC synthesis, and free 
fatty acids including arachidonic acid, which is a significant source of reactive oxygen 
species. CDP-choline was previously reported to prevent membrane destruction, 
decrease free radical generation, and preserve the natural mechanisms against oxidative 
stress, particularly in hypoxia-ischemia models (4). In agreement with these observations, 
our data indicate that CDP-choline treatment preserves GSH-Px and SOD activities as well 
as reducing tissue MDA content and MPO activity, suggesting that one of the mechanisms 
by which CDP-choline decreases hyperoxic lung injury is enhancement of antioxidant 
activity and reduction of lipid peroxidation in a neonatal rat model of BPD. It may also 
suggest that the effect of CDP-choline on apoptosis might have resulted from attenuation 
of oxidative stress by restoration of antioxidant enzyme levels. 
A number of previous studies evaluated surfactant kinetics in preterm infants who did or 
did not develop BPD. One study reported that tracheal aspirate DSPC concentration 
decreased significantly in infants who subsequently developed BPD (29). The loss of DSPC 
palmitate from the alveolar pool was significantly higher, whereas recycling of DSPC 
palmitate through the intracellular pool was significantly lower (30). Therefore, our 
findings regarding the increased BAL fluid and lung tissue phospholipid contents after 
CDP-choline administration might explain the possible role of CDP-choline in the 
attenuation of hyperoxic lung injury in our experimental setting. 
To the best of our knowledge, two previous human studies evaluated CDP-choline 
treatment in preterm infants with respiratory distress syndrome (8,9). Although 
parenteral CDP-choline administration showed no beneficial effects at a 100 mg/kg 
dosage for 7 d (9), it was reported to reduce the severity of respiratory distress and 
oxygen requirement when it was administered at a 300 mg/kg dosage for a longer 
duration (8). Therefore, a higher dose and a longer duration of CDP-choline 
administration might explain the beneficial effect of CDP-choline against hyperoxic lung 
injury in our study and suggests its applicability in newborns with BPD. 
In conclusion, our study is the first to show the efficacy of CDP-choline treatment in 
hyperoxic lung injury in a neonatal rat model by several mechanisms including 
enhancement of phospholipid production as well as reduction of fibrosis, apoptosis, and 
lipid peroxidation. These findings might provide new insights into the prevention of BPD 
development by CDP-choline treatment in premature infants. Nevertheless, our study is 
limited by the lack of dose and time courses of CDP-choline effects, and future studies 
are warranted to further confirm its effects and reveal the mechanism of action of CDP-
choline treatment in hyperoxic lung injury and BPD. 
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METHODS 
Animals and Experimental Design 
This study was approved by the Experimental Animal Ethics Committee of Gulhane 
Military Medical Academy (Ankara, Turkey). In addition, the guidelines provided by the 
US National Institutes of Health (Bethesda, MD) for the care and use of laboratory animals 
were followed. 
Sprague Dawley rats with dated pregnancies were housed in individual cages with free 
access to water and laboratory chow. Pups born by spontaneous delivery to four time-
mated full-term Sprague Dawley pregnant rats were pooled, randomized, and delivered 
back to nursing dams. A total of 30 newborn pups were divided equally into three groups 
as follows: control group (composed of pups subjected to room air containing 21% O2 
and receiving saline), hyperoxia group (composed of pups subjected to 95% O2 and 
receiving saline), and hyperoxia + CDP-choline group (composed of pups subjected to 
95% O2 and receiving 300 mg/kg/d CDP-choline). 
Experiments began immediately after birth and continued throughout P10. Nursing 
dams were rotated between hyperoxia-exposed and room air-exposed litters every 24 h 
to prevent oxygen toxicity in the dams. In pups subjected to hyperoxia, continuous 95% 
O2 exposure was achieved in a Plexiglas chamber (70 × 60 × 30 cm) by a flow-through 
system. The oxygen level inside the Plexiglas chamber was monitored continuously with a 
Ceramatec oxygen analyzer (MAXO2; Ceramatec, Salt Lake City, UT) to maintain ≥95% O2 
saturation. CO2 was kept below 0.5% using a gas monitor (Apex; BW Technologies, 
Lincolnshire, IL). Temperature and humidity were maintained at 22-25°C and 60-70%, 
respectively. 
Intraperitoneal injections of saline (4 ml/kg) in the control and hyperoxia groups and 
those of CDP-choline (300 mg/kg) in the hyperoxia + CDP-choline group were performed 
daily from the first day of life (P1) through P10, when the study was terminated. The pups in 
each group were weighed daily using a sensitive scale of 0.01 g, and their weights were 
recorded. 
Lung Tissue Procurement 
Pups were killed at P10 under deep anesthesia by intraperitoneal injection of a 
combination of ketamine (100 mg/kg, Ketalar; Zentiva Saglik Urunleri, Kirklareli, Turkey) and 
xylazine (10 mg/kg, Xylazine Bio 2%; Bioveta, Ivanovice na Hane, Czech Republic). The thorax 
was opened and the lungs were exposed. Right lungs of rat pups were excised and weighed 
immediately for analyses of tissue cytokine levels, active caspase-3 expression, phospholipid 
content, and oxidant/antioxidant enzyme activities and MDA content, whereas left lungs 
were obtained after ligation of the right main bronchus and perfusion with a fixation solution 
for histopathologic and immunohistochemical evaluation. 
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Histopathologic and Immunohistochemical Evaluation of the Lungs 
Left lungs were perfused with 0.1 mol/l phosphate-buffered saline (PBS) containing 4% 
paraformaldehyde under a constant inflation pressure of 5 cm H2O maintained via a 
tracheal catheter. On completion of perfusion, the trachea was ligated with a surgical 
suture, and the lungs were incubated in fresh 4% paraformaldehyde-PBS solution on ice 
for 4-5 h. The perfusion solution was then replaced with two quick changes of cold PBS 
to remove exterior debris. The lungs were transferred to a filtered sterile PBS/30% 
sucrose solution and stored at 4°C until fully equilibrated. The lungs were then paraffin 
embedded, and these paraffin blocks were sliced into 5-μm sections. Sections were 
chosen according to a systematic random sampling procedure and then mounted onto 
poly-l-lysine-coated slides (Histobond adhesion slides; Paul Marienfeld, Lauda-
Konigshofen, Germany). 
Slides were stained with standard hematoxylin-eosin and Masson’s trichrome techniques 
for histopathologic evaluations and with ABC technique for the lamellar body membrane 
protein. For immunohistochemical detection of lamellar body membrane protein, sections 
were subjected to dehydration following treatment with 3% hydrogen peroxide for 30 min. 
After nonspecific blocking with goat serum for 30 min, the sections were incubated overnight 
with primary antibody against P180 lamellar body protein (Abcam, Cambridge, MA) at 4°C, 
followed by treatment with biotinylated antimouse secondary anti- body (1:200; Vector 
Laboratories, Peterborough, UK) for 30 min at room temperature. Following the avidin-biotin 
complex treatment, 3,3'-diaminobenzidine (Vector Laboratories) was used for color 
development. Negative control slides, omitting the primary antibody, were also included. 
The tissue sections were examined using a light microscope equipped with a digital camera. 
Positive cells per unit area were counted five times on 25 μm apart sections, 10 sections for 
each animal. Histopathologic examination and immunohistochemical scoring were 
performed in a blinded manner by the same investigator. Histopathologic grading was done 
as follows: grade 1, normal histology; grade 2, moderate leukocytic infiltration; grade 3, 
leukocytic infiltration, edema, and partial destruction; and grade 4, total destruction of the 
tissue as described previously (31). Radial alveolar count for the assessment of alveolar 
development was performed on the digital images of sections. Briefly, a line was 
superimposed from a center of a respiratory bronchiole to the nearest connective tissue 
septum at right angles to the epithelium, and the number of alveolar septi crossed by this 
line was counted on 3-4 sections for each animal (32). Apoptosis was evaluated by TUNEL 
technique using an in situ cell death detection POD kit (Roche Molecular Biochemicals, 
Mannheim, Germany). Sections were chosen according to a systematic random sampling 
procedure and then mounted onto poly-l-lysine-coated slides (Histobond adhesion slides; 
Paul Marienfeld). Sections were heated at 60°C for 45 min, followed by washing in xylene 
and rehydration through a graded series of alcohol (ethanol 100, 95, 80, and 70%), and 
washed in distilled water. They were then incubated in 20 μg/ml proteinase K solution 
(Roche Applied Sciences, Penzberg, Germany) for 20 min at room temperature and 
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immersed in 3% H2O2 in methanol for 10 min. Permeabilization with Triton X (Sigma-Aldrich, 
St Louis, MO) for 10 min was performed on ice. The sections were then incubated with 
TUNEL reaction mixture at 37°C in a humidified chamber for 1 h followed by converter-
peroxidase treatment at 37°C for 30 min. Diaminobenzidine tetrahydrochloride 
(diaminobenzidine/metal concentrate: peroxidase buffer; Roche Applied Sciences) was used 
as the chromogene, and the slides were counterstained with hematoxylin (Harris’s 
hematoxylin; Sigma-Aldrich) and coverslipped (DPX mountant; Fluka, St Louis, MO) for light 
microscopy. 
Active Caspase-3 Expression 
Right lungs were homogenized by 50-fold dilution (wt/vol) in ice- cold PBS (pH 7.2) using 
a homogenizer (T18 basic Ultra-Turrax; IKA, Staufen, Germany). Aliquots of homogenates 
were used for total protein analysis by bicinchoninic acid assay (Thermo Fisher Scientific, 
Rockford, IL). Aliquots of homogenates were mixed with equal volumes of Laemmi 
loading buffer and boiled for 5 min before gel electrophoresis. Equal amounts of protein 
were loaded and separated using sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (4-20%; Bio-Rad, Hercules, CA). Proteins were then transferred onto poly- 
vinylidene fluoride membranes (Immobilon-P; Millipore, Billerica, MA). The remaining 
binding sites were blocked with 4% nonfat dry milk (Carnation, Glendale, CA) for 30 min 
in Tris-buffered saline with Tween (TBST). Membranes were then rinsed five times in TBST 
buffer and incubated overnight in TBST solution containing the primary antibody against 
active caspase-3 (Abcam) and β-actin (Abcam), which was used as a loading control for 
lung homogenates. Following over-night incubation and five rinses in TBST buffer, blots 
were incubated for 1 h with the appropriate peroxidase-linked secondary antibody (GE 
Healthcare, Waukesha, WI). Blots were then rinsed in TBST buffer five times, and protein-
antibody complexes were detected and visualized using the enhanced 
chemiluminescence system (GE Healthcare) and developed on Kodak X-AR film (Kodak 
Turkiye, Istanbul, Turkey). Films were digitized using a Supervista S-12 scanner with a 
transparency adapter (UMAX Technologies, Freemont, CA). Immunoreactive bands were 
compared densitometrically using the public domain NIH Image program available on the 
Internet at http://rsbweb.nih.gov/ij/download.html. Areas under the absorbance curve 
were expressed as arbitrary units and normalized as percentages of those generated in 
the same blot using samples from lungs of control animals. 
Measurement of Lung Tissue Cytokine Content 
Aliquots of homogenates were centrifuged at 12,000g for 20 min at 4°C, and cell-free 
supernatants were used for determining lung tissue proinflammatory cytokine (TNF-α, IL-
6, and IL-1β) contents by specific enzyme-linked immunosorbent assay kits (R&D Systems, 
Minneapolis, MN) as described previously (33). 
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BAL Fluid Collection 
In separate experiments, rat pups anesthetized with intraperitoneal ketamine plus 
xylazine were placed in a supine position, and a cannula was inserted into the trachea. 
Ice-cold isotonic saline (1 ml) was gently instilled with a syringe into the lung via the 
trachea and then withdrawn 10 times. Recovered BAL fluid was immediately centrifuged 
at 5,000 rpm for 10 min to remove cells, and samples from four pups from each treatment 
group were pooled. 
Phospholipid Assay 
Phospholipids were extracted from lung tissue homogenates and BAL fluid using a 
chloroform-methanol-water mixture (2:1:1 vol/vol/vol) as described previously (34). 
These extracts were used for analyzing total phospholipid content and individual 
phospholipids (PC, phosphatidylglycerol, and DSPC). Total phospholipid content was 
analyzed by measuring phosphorus (35). Part of the remaining extracts was subjected to 
thin-layer chromatography using silica G plates (Adsorbosil Plus-1; Alltech, Deerfield, IL) 
and a system consisting of chloroform/ethanol/triethylamine/water (30:34:30:8) as the 
mobile phase to analyze PC and phosphatidylglycerol, whereas the other part was 
oxidized with osmium tetroxide (OsO4) before subjection to thin-layer chromatography 
to analyze DSPC, the major surfactant component, as described previously (36). The 
chromatography plates were sprayed with 0.1% diphenylhexatriene in petroleum ether, 
and phospholipid standards were used to identify the corresponding bands, which were 
scraped off the plates and extracted into methanol, dried under a vacuum, and assayed 
for phosphorus content as described previously (35). 
Analyses 
Activities of SOD, GSH-Px, and MPO, as well as MDA content of lung tissues, were 
measured using cell-free supernatants of right-lung homogenates by spectrophotometric 
(UV-1700; Shimadzu, Kyoto, Japan) analyses. 
Tissue SOD activity was determined by a method involving spectrophotometric 
detection of formazan production at 550 nm by inhibition of nitroblue tetrazolium 
reduction with xanthine-xanthine oxidase used as a superoxide generator as described 
previously (37). Tissue GSH-Px activity was determined by the dithio-dinitrobenzoic acid 
method at the absorbance of 412 nm as described previously (38). Tissue MDA content 
was determined by a method that is based on the reaction of MDA with thiobarbituric 
acid at 95°C as described previously (39). Tissue MPO activity was determined by a 
method based on the reduction of 5-thio-2-nitrobenzoic acid to 5-5'-dithiobis (2-
nitrobenzoic acid) by following the decrease of absorbance at 412 nm as described 
previously (40). 
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Statistical Analyses 
Statistical analyses were performed using SPSS 16.0 (SPSS, Chicago, IL). A level of P < 0.05 
was chosen to represent statistical significance. Experimental group means and SEs were 
determined using descriptive statistics, and data were expressed as mean ± SEM. Normal 
distributions of data were graphically examined with the Shapiro-Wilk test. Categorical 
variables were compared with the x2 test. Immunohistochemical scores were assessed by 
the Kruskal-Wallis test. Treatment groups were compared using one-way ANOVA, and 
significance was determined using a post hoc Holm-Sidak test or Bonferroni’s correction 
for multiple comparisons where applicable. 
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Abstract 
Background: 
Cytidine 5'-diphosphocholine (CDP-choline) is an endogenous intermediate in the 
biosynthesis of phosphatidylcholine, a contributor to the mucosal defense of the 
intestine. The aim of this study was to evaluate the possible cytoprotective effect of CDP-
choline treatment on intestinal cell damage, membrane phospholipid content, 
inﬂammation, and apoptosis in a neonatal rat model of necrotizing enterocolitis (NEC). 
Methods: 
We divided a total of 30 newborn pups into three groups: control, NEC, and NEC + CDP-
choline. We induced NEC by enteral formula feeding, exposure to hypoxia- hyperoxia, 
and cold stress. We administered CDP-choline intraperitoneally at 300 mg/kg/ d for 3 d 
starting from the ﬁrst day of life. We evaluated apoptosis macroscopically and 
histopathologically in combination with proinﬂammatory cytokines in the gut samples. 
Moreover, we determined membrane phospholipid levels as well as activities of xanthine 
oxidase, superoxide dismutase, glutathione peroxidase, and myeloperoxidase enzymes 
and the malondialdehyde content of intestinal tissue. 
Results: 
Mean clinical sickness score, macroscopic gut assessment score, and intestinal injury 
score were signiﬁcantly improved, whereas mean apoptosis score and caspase-3 levels 
were signiﬁcantly reduced in pups in the NEC + CDP-choline group compared with the 
NEC group. Tissue proinﬂammatory cytokine (interleukin-1β, interleukin-6, and tumor 
necrosis factor-α) levels as well as tissue malondialdehyde content and myeloperoxidase 
activities were reduced, whereas glutathione peroxidase and superoxide dismutase 
activities were preserved in the NEC + CDP-choline group. In addition, NEC damage 
reduced intestinal tissue membrane phospholipids, whereas CDP-choline signiﬁcantly 
enhanced total phospholipid and phosphatidylcholine levels. Long-term follow-up in 
additional experiments revealed increased body weight, decreased clinical sickness 
scores, and enhanced survival in CDP-choline-receiving versus saline-receiving pups with 
NEC lesions. 
Conclusions: 
Our study reports, for the first time, beneficial effects of CDP-choline treatment on 
intestinal injury in a neonatal rat model of NEC. Our data suggest that CDP-choline may 
be used as an effective therapeutic agent to prevent NEC.  
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1. Introduction
Necrotizing enterocolitis (NEC) is the most common and potentially most fatal 
gastrointestinal (GI) disease in neonates [1]. It remains a leading cause of mortality, with 
rates ranging from 10% to 50% [2]. The pathogenesis of NEC is likely multifactorial and is 
poorly understood. To date, prematurity, intestinal immaturity, hypoxia-ischemia, low 
perfusion states, formula feeding, and colonization with pathogenic bacteria were 
reported to lead the common pathway of bowel injury, intestinal inﬂammation, and 
release of proinﬂammatory cytokines, resulting in intestinal tissue damage including 
necrosis and apoptosis in intestinal tissue [3]. In addition, immature motility, digestion, 
absorption, immune defenses, barrier function, and circulatory regulation were reported 
to increase the risk of intestinal injury [4]. 
Based on clinical and experimental data, all risk factors initiate the activation of 
proinﬂammatory response, which leads to bowel necrosis and, in advanced cases, 
multiorgan dysfunction syndrome and death [5]. Previous studies showed an intestinal 
mucosal injury mediated by oxygen-derived free radicals, inﬂammatory mediators 
including platelet-activating factor, leukotrienes, and tumor necrosis factor-alpha (TNF-
α). As a result, an initial stress might trigger the release of platelet-activating factor, 
subsequent release of inﬂammatory cytokines, and migration of activated 
polymorphonuclear leukocytes, resulting in excess generation of reactive oxygen and 
nitrogen species. If the detrimental effects of these reactive species are not limited by 
antioxidant systems, cellular damage and subsequent cell death and necrosis might 
develop by several mechanisms, especially including the peroxidation of cellular 
membrane lipids and oxidation of cellular proteins [6,7]. 
Phospholipids are essential constituents of cell membranes with pivotal roles in 
maintenance of homeostasis, cell compartmentalization, and enzymatic activities 
associated with membrane systems and coupling between receptor and intracellular 
signaling [8]. Phospholipids also contribute to the roles of intestinal mucus in constituting 
a continuous layer at the luminal side of the mucus gel. Phosphatidylcholine (PC) is the 
major lipid of the GI mucus layer; it establishes a protective hydrophobic surface. This 
intestinal surfactant also has a key role in mucosal defense. The defective PC layer was 
suggested to contribute to the development of inﬂammation [9]. Necrotizing 
enterocolitis was also reported to result in signiﬁcant disruption of the intestinal barrier, 
which is associated with mucosal injury [10]. 
Cytidine 5'-diphosphocholine (CDP-choline) is an endogenous intermediate in the 
biosynthesis of the major membrane phospholipid PC via the Kennedy pathway [11]. 
Given exogenously, part of CDP-choline is metabolized in the circulation to cytidine and 
choline [12-15], which are then used for phospholipid synthesis [16] via the Kennedy 
pathway [9]. 
Although previous studies reported the beneﬁcial effects of CDP-choline treatment in 
several neurodegenerative conditions as well as hypoxia-ischemia and stroke [17,18], to 
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the best of our knowledge, no study has evaluated the effects of CDP-choline on intestinal 
ischemia, inﬂammation, and epithelial injury, a condition occurring in NEC. Therefore, the 
aim of this study was to investigate the possible cytoprotective effect of CDP-choline 
administration on inﬂammation, intestinal cell death, and apoptosis in a neonatal rat 
model of NEC. 
2. Materials and methods
2.1. Animals and experimental design 
We carried out this study out according to the guidelines of the Institutional Committee 
on the Care and Handling of Animals of the National Laboratory; it was approved by the 
Experimental Animal Ethics Committee at Gulhane Military Medical Academy, Ankara, 
Turkey. We kept pregnant rats in identical cages and gave them free access to regular 
laboratory chow and water ad libitum. We equally divided 30 newborn pups that were 
delivered spontaneously from pregnant Sprague-Dawley rats into three groups as 
follows: control (left with the mothers, breastfed freely and not subjected to stress), NEC 
(subjected to NEC and received saline intraperitoneally for 3 d), and NEC + CDP-choline 
(subjected to NEC and received CDP-choline intraperitoneally for 3 d). 
We prepared the NEC model by formula feeding, hypoxia, and cold stress, as 
described previously [6]. Brieﬂy, rat pups in NEC and NEC + CDP-choline groups were 
immediately separated from their mothers to avoid the preventive effects of mothers’ 
milk, and were kept at 37oC in a humidiﬁed incubator. We used a special rodent formula 
(15 g Similac 60/40; Ross Pediatrics, Columbus, OH) prepared with 75 mL puppy- canine 
milk (Beaphar-Bogena; BV Sedel, The Netherlands) to induce NEC. Feeding was started at 
0.2 mL every 3 h and increased gradually each time with 0.1-mL increments daily as 
tolerated. We also exposed these pups to 100% CO2 inhalation for 10 min, 4oC cold 
exposure for 5 min, and 97% O2 for 5 min twice daily for 3 d, for NEC development. We 
weighed all pups daily and recorded changes in their weight. 
Pups in the NEC + CDP-choline group received CDP-choline (Sigma, St. Louis, MO) 
dissolved in 0.9% saline by intraperitoneal route at a dose of 300 mg/kg/d; those in the 
NEC group received 0.9% saline at a volume of 2 mL/kg/d from the ﬁrst day through the 
third day of the study during the NEC procedure. An observer blinded to the protocol 
assessed the rats in terms of their behavior, using a modiﬁed neonatal rat clinical sickness 
score (0, best; 12, worst), including appearance, response to touch, natural activity, and 
color for each feeding sessions on each day, as previously described [19]. Number of 
deaths, approximate death time, and cause of death (owing to NEC or iatrogenic during 
the procedure) were recorded daily for all groups. 
In a separate experiment, we tested the long-term effects in terms of weight changes 
and clinical sickness score, as well as survival after NEC lesion. For this purpose, we 
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randomly arranged 30 rat pups into the control, NEC, and NEC + CDP-choline groups and 
followed the experimental procedure described above. We evaluated weight changes 
and clinical sickness scores in these pups on days 3, 5, 7, 10, and 14 postnatally and used 
the same time points to record the number of surviving pups. 
2.2. Macroscopic gut assessment 
We killed all pups on the fourth day of the study under deep anesthesia using ketamine-
xylazine (100 and 10 mg/kg, respectively). After we killed the pups, we opened the 
abdominal cavity and dissected the GI tract from duodenum to rectum free from the 
surrounding tissue; we straightened out the gut and placed it on a Petri dish containing 
phosphate-buffered saline (pH 7.2). We performed the macroscopic assessment of the 
gut to conﬁrm NEC using a new scoring system based on gut color, consistency, and 
dilatation [19]. 
2.3. Immunohistochemistry 
After macroscopic evaluation, we excised 2 cm of terminal ileum and ﬁxed it with 4% 
paraformaldehyde in 0.1 mol/L phosphate buffer for histopathological examination and 
apoptosis scoring, which were evaluated in a blinded fashion. We then excised the rest 
of the small intestines, washed them with physiological saline, and allocated them for 
biochemical analyses. 
We embedded ﬁxed intestinal tissues in parafﬁn and sliced the parafﬁn blocks into 4- 
to 5-mm sections. We stained slides with hematoxylin-eosin for histological evaluation 
and with transferase-mediated dUTP nick end labeling (TUNEL) using the in situ cell death 
detection POD kit (Roche Molecular Biochemicals, Mannheim, Germany) to evaluate 
apoptosis. We chose sections according to a systematic random sampling procedure and 
mounted them onto poly-L-lysine-coated slides (Histobond adhesion slides; Paul 
Marienfeld GmbH & Co., Lauda-Konigshofen, Germany). We heated these sections at 
60oC for 45 min followed by washing in xylene and rehydration through a graded series 
of alcohol (ethanol 100%, 95%, 80%, and 70%) and then washed them in distilled water. 
We then incubated the sections in 20 mg/mL proteinase K solution (Roche Applied 
Sciences, Penzberg, Germany) for 20 min at room temperature and immersed them in 
3% H2O2 in methanol for 10 min. After this procedure, we performed permeabilization 
with Triton X (Sigma-Aldrich, St. Louis, MO) for 10 min on ice. We then incubated the 
sections with the TUNEL reaction mixture at 37oC in a humidiﬁed chamber for 1 h 
followed by converter-POD treatment at 37oC for 30 min. We analyzed 
immunoﬂuorescence reaction and photographed it with an Olympus BX50 
photomicroscope before the POD treatment. We used diaminobenzidine 
tetrahydrochloride (diaminobenzidine/metal concentrate: peroxidase buffer; Roche 
Applied Sciences) as the chromogene, counterstained the slides with hematoxylin (Harris’ 
hematoxylin; Sigma-Aldrich), and coverslipped them (DPX mountant; Fluka, St. Louis, MO) 
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for light microscopy. We also incubated alternate sections in the absence of a TUNEL 
reaction mixture for negative controls. Histological ﬁndings were graded as follows: grade 
0, normal; grade 1, focal mild injury conﬁned to villous tips; grade 2, partial or total loss 
of villi; grade 3, necrosis extending to the submucosa; and grade 4, transmural necrosis 
[20]. We evaluated apoptosis as follows: grade 0, normal; grade 1, apoptotic nuclei 
presenting at villous tips; grade 2, apoptotic nuclei covering all villous tips but crypts 
protected; and grade 3, transmural spread of apoptotic nuclei [21]. 
2.4. Active caspase-3 expression 
We homogenized the remaining intestinal tissues that were not subjected to ﬁxation in 
50 vol ice-cold phosphate-buffered saline (pH 7.2) using a homogenizer (T18 basic Ultra-
Turrax; IKA, Staufen, Germany). We used aliquots of homogenates for total protein 
analysis by bicinchoninic acid assay (Thermo Fisher Scientiﬁc, Rockford, IL). Aliquots of 
homogenates were mixed with equal volumes of Laemmli loading buffer and boiled for 5 
min before gel electrophoresis. We loaded equal amounts of protein and separated them 
using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (4e20%; Bio-Rad, 
Hercules, CA). We then transferred proteins onto polyvinylidene ﬂuoride membranes 
(Immobilon-P; Millipore, Billerica, MA). The remaining binding sites were blocked with 4% 
nonfat dry milk (Carnation, Glendale, CA) for 30 min in Tris-buffered saline and Tween 20 
(TBST). We then rinsed membranes ﬁve times in TBST buffer and incubated them 
overnight in TBST solution containing the primary antibody against active caspase-3 
(Abcam, Cambridge, MA) and b-actin (Abcam), which we used as a loading control for 
intestinal homogenates. After overnight incubation and ﬁve rinses in TBST buffer, we 
incubated blots for 1 h with the appropriate peroxidase-linked secondary antibody (GE 
Healthcare, Waukesha, WI). We then rinsed blots in TBST buffer ﬁve times, and detected 
and visualized protein-antibody complexes using the enhanced chemiluminescence 
system (GE Healthcare) and developed them on Kodak X-AR ﬁlm (Rochester, NY). We 
digitized ﬁlms using a Supervista S-12 scanner with a transparency adapter (UMAX 
Technologies, Freemont, CA). We compared immunoreactive bands densitometrically 
using the Public Domain NIH Image program available on the internet at 
http://rsbweb.nih.gov/ij/download.html. Areas under the absorbance curve are 
expressed as arbitrary units and normalized as percentages of those generated in the 
same blot using samples from intestines of control animals. 
2.5. Measurement of intestinal tissue cytokine content 
We centrifuged aliquots of homogenates at 12,000g for 20 min at 4oC and used cell-free 
supernatants to determine intestinal tissue proinﬂammatory cytokine (TNF-α, interleukin 
[IL]-6, and IL-1β) contents by speciﬁc enzyme-linked immunosorbent assay kits (R&D 
Systems, Minneapolis, MN), as described previously [22]. 
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2.6. Biochemical analyses 
We measured the activity of superoxide dismutase (SOD), glutathione peroxidase (GSH-
Px), and myeloperoxidase (MPO), as well as the malondialdehyde (MDA) content of 
intestinal tissues, using cell-free supernatants of tissue homogenates by 
spectrophotometric analyses (UV-1700; Shimadzu, Kyoto, Japan). 
We determined tissue SOD activity using a method involving spectrophotometric 
detection of formazan production at 550 nm by inhibiting nitroblue tetrazolium reduction 
with xanthine-xanthine oxidase used as a superoxide generator, as described previously 
[23]. We also determined tissue GSH-Px activity by dithiodinitrobenzoic acid method at 
an absorbance of 412 nm, as described previously [24]. Tissue MDA content was 
determined by a method based on the reaction of MDA with thiobarbituric acid at 95oC, 
as described previously [25]. We determined tissue MPO activity using a method based 
on the reduction of 5-thio-2-nitrobenzoic acid to 5-5-dithiobis (2-nitrobenzoic acid) by 
following the decrease in absorbance at 412 nm, as described previously [26]. We 
extracted intestinal phospholipids and measured the according to the method of Folch et 
al [27]. Brieﬂy, we mixed 1 mL intestinal homogenate with 3 mL of a chloroform/methanol 
mixture (2:1 v/v) and vortexed it, followed by sequential addition of 3 mL 
chloroform/methanol mixture (2:1 v/v) and 1 mL ice-cold deionized water. The mixture 
was allowed to stand overnight at 4oC. Next day, we separated the organic (lower) and 
aqueous (upper) phases of the mixture by centrifugation (10 min at 4oC; 1000g). Aliquots 
(0.1-0.4 mL) of the organic phase were dried under vacuum. Residues of 0.4-mL aliquots 
of the organic phase were reconstituted in methanol and subjected to thin-layer 
chromatography using silica G plates (Adsorbosil Plus-1; Alltech, Nicholasville, KY) and a 
system consisting of chloroform/ethanol/triethylamine/water (30:34:30:8) as the mobile 
phase. We used phospholipid standards to identify the corresponding bands under 
ultraviolet light after we sprayed the plates with 0.1% diphenylhexatriene in petroleum 
ether. Bands for individual phospholipid classes such as PC, phosphatidylethanolamine 
(PE), phosphatidylserine (PS), sphingomyelin (SM), and phosphatidylinositol (PI) were 
scraped off the plates and extracted into 1 mL methanol, dried under vacuum, and 
assayed for phosphorus content. We assayed aliquots of intestinal homogenates for 
protein using a bicinchoninic acid reagent (Perkin Elmer, Norwalk, CT) and present 
phospholipid levels as nanomoles per milligram of protein. 
2.7. Statistical analysis 
We performed statistical analyses using SPSS statistical software (version 16.0; Chicago, 
IL). Data are expressed as the means ± standard error of mean. We analyzed biochemical 
and pathological parameters by analysis of variance, followed by appropriate post hoc 
tests including multiple-comparison and Holm-Sidak test. We used the Kruskal-Wallis 
one-way analysis of variance by ranks followed by Bonferroni correction for a 
simultaneous statistical test of the pathologic score for the NEC and NEC + CDP-choline 
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groups. We compared the groups using the Mann-Whitney nonparametric test for 
independent samples. P < 0.05 was considered statistically signiﬁcant. 
3. Results
Three rat pups (two in the NEC group and one in the NEC + CDP-choline group) died 
during the experimental procedures. The mean birth weight of pups did not differ 
signiﬁcantly between study groups and the control group. However, the mean weight of 
the pups in the control group (8.1 ± 0.4 g) and NEC + CDP-choline group (6.3 ± 0.2 g) were 
signiﬁcantly greater than that of the pups in the NEC group (5.4 ± 0.3 g) (both P < 0.05) 
on the fourth day, when the study was terminated. 
The mean clinical sickness score of the pups at the end of the study was signiﬁcantly 
lower in the NEC + CDP-choline group compared with the NEC group (8.6 ± 3.4 versus 4.6 
± 1.2) (P = 0.001), indicating a better clinical status in pups that received CDP-choline. 
Similarly, the mean macroscopic gut assessment score was signiﬁcantly lower in the NEC 
+ CDP-choline group compared with the NEC group (5 ± 2 versus 2 ± 1), indicating less
intestinal tissue damage in the treatment group (P = 0.01). We found no evidence of
macroscopic changes in tissues of rats in the control group (Table 1). We detected
intestinal necrosis and/or perforation in the post-mortem evaluation of intestinal tissues
of rats that died during the experimental procedures.
Intestinal injury scoring performed according to the histopathological evaluation also 
showed that the grade of histopathological damage was signiﬁcantly greater in the NEC 
group compared with the NEC + CDP-choline group (mean score, 2.6 ± 0.4 versus 1.5 ± 
0.2) (P = 0.003). We found no histological damage in tissue samples of the control group 
(Table 1). 
The mean apoptosis scores were signiﬁcantly lower in the NEC + CDP-choline group 
compared with those in the NEC group (mean score, 2.9 ± 0.6 versus 1.6 ± 0.4) (P = 0.002) 
(Table 1). Figure 1 shows immunoﬂuorescence images of TUNEL stains, as well as light 
microscopic images of TUNEL-diaminobenzidine tetrahydrochloride stains for the 
control, NEC, and NEC + CDP-choline groups. In addition, although the expression of 
active caspase-3, a biomarker of apoptosis, was doubled in the NEC group compared with 
the control group, it was reduced by about 30% in the NEC + CDP-choline group (Fig. 2) 
(P < 0.05). Levels of β-actin, a protein used as a protein loading control for gel 
electrophoresis, were not statistically different between groups. 
Whereas the levels of IL-1β, IL-6, and TNF-α were signiﬁcantly increased in the NEC 
group compared with those in the control group (P < 0.05), CDP-choline treatment 
signiﬁcantly reduced the inﬂammation-associated elevations of IL- 1β (from 1354 ± 88 to 
1142 ± 65 pg/mg protein), IL-6 (from 541 ± 28 to 436 ± 25 pg/mg protein), and TNF-α 
(from 567 ± 30 to 474 ± 26 pg/mg protein) (P < 0.05) (Table 2), which suggests an anti-
inﬂammatory effect of CDP-choline treatment in the neonatal rat model of NEC. 
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Tissue GSH-Px and SOD activities were signiﬁcantly preserved in the NEC + CDP-
choline group compared with those in the NEC group, which indicates the effect of CDP- 
choline on decreasing oxidative stress (P < 0.01) (Table 3). In addition, tissue MDA levels, 
as well as MPO and XO activities in the NEC + CDP-choline group, were signiﬁcantly lower 
than those in the NEC group, which suggests decreased lipid peroxidation after CDP-
choline treatment. However, MDA levels, as well as MPO and XO activities in intestinal 
tissues in the control group, were still signiﬁcantly greater than those in the NEC + CDP-
choline group (P < 0.01) (Table 3). 
Levels of total phospholipids, as well as those of the individual phospholipid classes 
PC, PE, PS, SM, and PI were reduced signiﬁcantly in intestinal tissues of pups in the NEC 
group compared with the control group (P < 0.01 for total phospholipids, PC, and PE; P < 
0.05 for PS, SM, and PI) (Table 4). In addition, CDP-choline treatment after NEC lesion 
signiﬁcantly increased levels of total phospholipids and PC (P < 0.05 for both). However, 
increases in levels of other phospholipid classes after CDP-choline treatment did not 
reach statistical signiﬁcance (Table 4). 
Table 1- Comparison of the study and control groups in terms of weight change, clinical sickness score, 
macroscopic assessment score, histopathological evaluation, and mortality. 
Variable Control group 
(n=10) 
NEC group 
(n=10) 
NEC + CDP-choline 
group (n=10) 
Birth weight (g), mean ± SD 5.2 ± 0.4 5.3 ± 0.5 5.2 ± 0.5 
Weight at the end of the study, mean ± SD 8.1 ± 0.4 5.4 ± 0.3* 6.3 ± 0.2y 
Clinical sickness score at the end of the study, 
mean ± SD 
0 8.6 ± 3.4z 4.6 ± 1.2y 
Macroscopic assessment score, mean ± SD 0 5 ± 2z 2 ± 1y 
Intestinal injury score, mean ± SD 0 2.6 ± 0.4* 1.5 ± 0.2y 
Apoptosis score, mean ± SD 0 (0-1) 2.9 ± 0.6* 1.6 ± 0.4y 
Mortality, n (%) 0 2 (20) 1 (10) 
*P < 0.05 compared with the control group. 
yP < 0.05 compared with the hyperoxia group using one-way analysis of variance followed by post-hoc Holm-
Sidak test. 
zP < 0.01 compared with the control group. 
Chapter 4 
62 
Fig. 1- Representative images of immunoﬂuorescence stains for the control (A), NEC (C), and NEC + CDP-choline 
(E) groups (x40 magniﬁcation) and light microscopic images of TUNEL-diaminobenzidine tetrahydrochloride
stains for the control (B), NEC (D), and NEC + CDP-choline (F) groups (x100 magniﬁcation). Arrows in (D) and (F) 
indicate apoptotic cells. (Color version of ﬁgure is available online.) 
Fig. 2- Changes in active caspase-3 expression in relation to the control group in the NEC and NEC + CDP-choline 
groups. *P < 0.05 and **P < 0.01 compared with the control group; #P < 0.05 compared with the NEC group 
using one-way analysis of variance followed by post-hoc Holm-Sidak test. 
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Table 2- Levels of cytokines in intestinal tissue homogenates. 
Cytokine levels 
(pg/mg protein) 
Control group NEC group NEC + 
CDP-choline group 
IL-1β 985 ± 47 1354 ± 88* 1142 ± 65y 
IL-6 390 ± 21 541 ± 28* 436 ± 25y 
TNF-α 452 ± 24 567 ± 30z 474 ± 26y 
* P < 0.01 compared with the control group. 
y P < 0.05 compared with the hyperoxia group using one-way analysis of variance followed by post-hoc Holm-
Sidak test. 
z P < 0.05 compared with the control group. 
Table 3-Intestinal tissue MDA content and SOD, GSH-Px, MPO, and XO activities. 
Biochemical 
analyses 
Control group 
(n=10) 
NEC group 
(n=10) 
NEC + CDP-choline 
group (n=10) 
MDA (nmol/g protein) 1.3 ± 0.2 1.9 ± 0.2* 1.4 ± 0.3y 
SOD (U/mg protein) 109.6 ± 7.4 71.0 ± 2.8* 108.0 ± 13.3y 
GSH-Px (U/mg protein) 12.5 ± 1.6 5.5 ± 1.0* 11.0 ± 1.2y,z 
MPO (U/g protein) 61.6 ± 6.1 148 ± 6.8* 93 ± 2.5*,z 
XO (U/mg protein). 0.8 ± 0.1 3.2 ± 0.2* 1.3 ± 0.2y,z 
* P < 0.01 compared with the control group. 
y P < 0.05 compared with the control group. 
z P < 0.05 compared with the NEC group using one-way analysis of variance followed by post-hoc Holm-Sidak 
test 
Table 4- Levels of intestinal phospholipids. 
Group Intestinal phospholipids (nmol/mg protein) 
Total PL PC PE PS SM PI 
Control 198 ± 6 86 ± 5 51 ± 2 20 ± 3 11.6 ± 0.7 4.2 ± 0.2 
NEC  121 ± 5* 48 ± 3* 20 ± 3* 13 ± 2y 6.9 ± 0.9y 3.6 ± 0.1y 
NEC + CDP-choline 166 ± 10z 70 ± 3z 29 ± 2y 14 ± 2y 8.6 ± 0.7y 3.8 ± 0.1y 
PL = phospholipid; PC = phosphatidylcholine; PE = phosphatidylethanolamine; PS = phosphatidylserine; SM = 
sphingomyelin; PI = phosphatidylinositol. 
* P < 0.01 compared with the control group. 
y P < 0.05 compared with the control group. 
z P < 0.05 compared with the NEC group using one-way analysis of variance followed by post-hoc Holm-Sidak 
test. 
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In separate experiments, in which we investigated long- term consequences of NEC 
lesion, we found that compared with the control group, birth weights were signiﬁcantly 
reduced and clinical sickness scores were signiﬁcantly enhanced from days 3 through 7 
in the NEC group, whereas CDP-choline treatment ameliorated the reduction in birth 
weight and the enhancement in clinical sickness scores (Table 5). We also found that no 
pups in the NEC group survived after day 7 in the further follow-up, whereas seven of 10 
pups in the CDP-choline group survived through day 14, when the survival experiment 
was completed (Fig. 3). 
Table 5- Comparison of weights and clinical sickness scores during 14-d follow-up. 
Variable Control NEC NEC + 
CDP-choline 
Birth weight (g) Weight 5.21 ± 0.42 5.23 ± 0.35 4.97 ± 0.20 
Day 3 (g) 
Day 5 (g) 
Day 7 (g) 
Day 10 (g) 
Day 14 (g) 
6.78 ± 0.30 
8.68 ± 0.81 
11.78 ± 1.18 
16.81 ± 0.65 
21.26 ± 1.04 
5.06 ± 0.13* 
4.85 ± 0.11* 
4.80 ± 0.10* 
5.68 ± 0.14*,y 
7.20 ± 0.33*,y 
8.44 ± 0.44*,y 
13.84 ± 0.86* 
19.00 ± 1.36* 
Clinical sickness score 
Day 3 
Day 5 
Day 7 
Day 10 
Day 14 
0.00 ± 0.00 
0.00 ± 0.00 
0.00 ± 0.00 
0.00 ± 0.00 
0.00 ± 0.00 
5.43 ± 0.79* 
6.33 ± 1.16* 
7.67 ± 0.58* 
3.89 ± 0.78*,y 
3.44 ± 0.53*,y 
2.78 ± 0.67*,y 
1.78 ± 0.67* 
0.00 ± 0.00 
* P < 0.01 compared with the control group. 
y P < 0.01 compared with the NEC group using one-way analysis of variance followed by post-hoc Holm-Sidak 
test. 
Fig. 3- Number of surviving rat pups in the control, NEC, and NEC + CDP-choline groups 
4. Discussion
These data show that CDP-choline administration reduces the clinical sickness score, 
ameliorates macroscopic and histopathological intestinal injury, decreases inﬂammation 
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and apoptosis, and increases intestinal tissue phospholipid levels in a neonatal rat model 
of NEC. Cytidine 5'-diphosphocholine therapy also decreases lipid peroxidation and 
oxidant status, while increasing antioxidant status in this model. To the best of our 
knowledge, this is the ﬁrst experimental study that showed beneﬁcial effects, both in the 
short and long term, of CDP-choline treatment on NEC development in newborn rats. 
Necrotizing enterocolitis is the most common GI emergency, with a considerable rate of 
morbidity and mortality in neonates, particularly, in preterm infants. Despite recent 
improvements in neonatal intensive care, no signiﬁcant advances have been achieved in 
the prevention, incidence, and mortality of NEC [2]. Therefore, newer therapeutic 
approaches are required to prevent and treat NEC [28]. 
Necrotizing enterocolitis is a multifactorial disease with a poorly understood complex 
pathophysiology. A combination of genetic predisposition, intestinal immaturity, abnormal 
intestinal microbial colonization, and highly immunoreactive intestinal mucosa was 
suggested to lead to a conﬂuence of predisposing factors [29]. In a recent National 
Institute of Child Health and Human Development workshop on NEC research, NEC was 
suggested to arise from an uncontrolled exuberant inﬂammatory response to bacterial 
colonization in the intestine of the preterm infants [30]. It was also suggested to represent 
overactivation of the immune system to insults such as ischemia, infection, enteral 
feeding, and abnormal bacterial colonization, leading to intestinal epithelial disruption, 
bacterial translocation, and overreaction of immature intestinal epithelial cells. These 
events might activate stress pathways and lead to suppression of inhibitory pathways, 
ﬁnally resulting in unfettered inﬂammatory response with harmful effects [31]. Therefore, 
if the detrimental effects of these reactive species cannot be limited by antioxidant 
systems, cellular damage and subsequent cell death and necrosis might develop by several 
mechanisms, including, in particular, peroxidation of cellular membrane lipids and 
oxidation of cellular proteins [6,7]. 
Phospholipids are essential constituents of cell membranes and are involved in 
membrane functions such as maintenance of cellular homeostasis, receptor functioning, 
and enzymatic activities [8]. Ischemic or hypoxic insults to tissues disrupt membrane 
integrity by several mechanisms including phospholipid breakdown by several 
phospholipases [8]. Therefore, phospholipid synthesis is crucially important under such 
circumstances. There is also increasing evidence that the mucus layer in the GI tract is a 
key factor for protection of the epithelia from luminal aggressors, microorganisms, and 
their noxious products [32]. Although phospholipids account for a minor part of GI mucus, 
they are indispensable in the maintenance of an intact barrier function [33]. 
Phosphatidylcholine, which represents the major phospholipid class with a ratio of 35%-
72% [33], is largely responsible for the establishment of the hydrophobic surface of the 
GI mucosa. In addition, PC was reported to interfere with cell signaling by attenuating 
apoptosis, and also showed anti-inﬂammatory properties [34,35]. Exogenous PC inhibited 
mucosal damage caused by acids and other noxious agents in the GI system [36,37]. 
Therefore, it was suggested that luminal PC had two possible functions: to establish the 
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surface hydrophobicity and to modulate the inﬂammatory signaling system [38]. Also, 
altered concentration and composition of PC were reported in patients with 
inﬂammatory bowel disease, and exogenous PC administration was shown to have a 
signiﬁcant therapeutic effect in the treatment of ulcerative colitis [33,39,40]. In the 
present study, we found that CDP-choline treatment enhanced levels of total 
phospholipids and PC in intestinal tissues of rat pups subjected to NEC lesion. These data 
are in good accord with the abovementioned previous studies that suggest a therapeutic 
effect of PC in intestinal injury models. Therefore, one mechanism by which CDP-choline 
exerts protective effects in a neonatal rat model of NEC might be the enhancement of PC 
levels in intestinal tissue. 
Necrotizing enterocolitis usually occurs in the small intestinal tract of preterm infants, 
and intestinal mucus protects the epithelial layer. As stated above, mucins are large 
glycoproteins that provide a physical barrier, facilitate removal of adherent bacteria, and 
concentrate enzymes near the epithelial surface to aid in host nutrient digestion [41]. The 
ileal portion of the small intestine expresses multiple mucin genes including Muc1, Muc3, 
Muc4, and Muc17, whereas Muc2 is the most abundant mucin in the small intestine that 
is secreted into the lumen [42]. Decreased Muc2-stained goblet cells was reported 
described in a rat model of NEC [10]; and in a recent study, mucus-containing goblet cells 
and Paneth cells also were signiﬁcantly decreased in infants with NEC [43]. It is therefore 
possible that the beneﬁcial effects of CDP-choline in our study could have resulted from 
enhanced PC and total phospholipid synthesis, and hence cellular membrane synthesis, 
which could have served to protect membrane integrity in rat pups with intestinal injury. 
It is widely accepted that elevated cytokines, major contributors to the inﬂammatory 
response, are principal modulators of the release of reactive oxygen species during NEC 
[44]. Therefore, treatments targeting the inﬂammatory response might be beneﬁcial in 
NEC. Recent studies have demonstrated anti-inﬂammatory properties of efferent vagus 
nerve activation, and the term “cholinergic antiinﬂammatory pathway” has been 
proposed [45]. It was also suggested that acetylcholine released from nonneuronal cells 
in the mucosa might target the muscarinic receptors there, and that mechanisms related 
to the noncholinergic system have a role in the remodeling process that occurs in the 
mucosa in inﬂammatory bowel diseases [46]. Cytidine 5'-diphosphocholine is a choline 
donor, because part of exogenous CDP-choline is metabolized to choline [12,13]. Choline 
is also a constituent of membranes and a precursor of the neurotransmitter acetylcholine 
[15]. Whereas choline deﬁciency results from increased levels of proinﬂammatory 
cytokines such as TNF-α [47], parenteral choline administration attenuates endotoxin-
induced multiple organ injury and the elevation in circulating TNF-α levels [48]. 
Phosphatidylcholine was also shown to inhibit TNF-α-induced proinﬂammatory 
responses by changing the compartmentation of TNF receptors to lipid rafts, inhibiting 
nuclear factor-kB activation, and preventing mitogen-activated protein kinase 
phosphorylation and subsequent activation [49]. In addition, mucus samples of patients 
with ulcerative colitis, a chronic inﬂammatory disorder of the colon, contained reduced 
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levels of PC, and the anti-inﬂammatory effects of PC were suggested to block TNF-α-
induced proinﬂammatory signaling [35,50]. In accordance with these ﬁndings, CDP-
choline signiﬁcantly reduced TNF-α, IL1-β, and IL-6 levels in the intestinal tissue of rat 
pups subjected to NEC, an effect that might well be mediated by elevated PC levels found 
in our study. 
Pathophysiologic changes in intestinal ischemia may also involve activation of the 
immune system by the release of inﬂammatory cytokines, resulting in excess generation 
of reactive oxygen and nitrogen species [44]. Under such circumstances including NEC, 
activities of antioxidant enzymes GSH-px and SOD are reduced, whereas activities of free 
radical-generating enzymes XO and MPO as well as the MDA content are increased, which 
indicates enhanced oxidant stress [51,52]. In our study, CDP-choline treatment enhanced 
decreased GSH-Px and SOD activities, whereas it reduced tissue MDA content as well as 
MPO and XO activities in a neonatal rat NEC model. This suggests that CDP-choline 
reduced the severity of NEC by reducing lipid peroxidation. In good agreement with our 
ﬁndings, oral PC pretreatment decreased ischemia-reperfusion-induced methane 
generation and intramucosal pH, and diminished MPO activity and the anti-inﬂammatory 
inﬂuence in the small intestine [53]. 
These observations suggest that CDP-choline might prevent membrane destruction, 
decrease free radical generation, and preserve natural mechanisms against oxidative 
stress [17]. Because CDP-choline is a source of choline and its administration causes 
bodily responses of a cholinergic nature [54,55], it could be speculated that one 
mechanism by which CDP-choline reduces free radical generation and the severity of NEC 
might be the action of choline that is released by CDP-choline breakdown on cytokine 
production. However, this hypothesis needs further investigation. 
Besides membrane breakdown and generation of reactive species, exposure to stress 
may also result in increased apoptosis in gastric and intestinal epithelial cells in neonatal 
rats [56,57]. Intestinal epithelium has a high turnover rate that necessitates the removal 
of apoptotic cells and a greater number of TUNEL-positive nuclei within the intestinal 
epithelium of animals exposed to hypoxia-reoxygenation [58]. Data obtained in our study 
showed that TUNEL-positive cell counts increased in neonatal rats in the NEC group, a 
ﬁnding that conﬁrms previous observations. Cytidine 5' -diphosphocholine may confer 
beneﬁt with regard to reducing apoptotic activity in cells subjected to ischemic and/or 
hypoxic insults. For example, CDP-choline decreased apoptosis in the brain by preventing 
caspase-3 activation by down-regulating the calpain-speciﬁc procaspase-3 breakdown 
product in a rat model of neonatal hypoxic-ischemic encephalopathy [59]. In good 
agreement with previous observations in brain tissue, we observed in our NEC model that 
CDP-choline treatment signiﬁcantly reduced the TUNEL-positive cell count as well as 
active caspase-3 levels, which indicates a protective effect of CDP-choline on apoptosis 
in the injured intestine. 
Vascular pathologies may also be associated with NEC. The diving seal reﬂex has been 
traditionally invoked as the mechanism responsible for intestinal ischemic injury and 
Chapter 4 
68 
necrosis. In addition, signiﬁcant reduction in the blood ﬂows of superior mesenteric 
artery and abdominal aorta in asphyxiated newborn pigs, subsequently leading to 
mesenteric endothelial dysfunction, was implicated in increased vascular permeability, 
edema formation, and NEC development [60]. Hypoxia also causes intensive selective 
vasoconstriction, and blood is preferentially shunted from the gut and kidney to vital 
organs such as heart and brain in the neonate. This reﬂex vasospasm also occurs in 
mesenteric vessels, resulting in ischemia of the bowel. Beneﬁcial effects of CDP-choline 
observed in our study might have resulted from CDP-choline’s action on intestinal blood 
ﬂow and/or systemic blood pressure. Previous studies showed that CDP-choline 
administration restores blood ﬂow of superior mesenteric and renal arteries in a dose- 
and time-dependent manner [61]. Moreover, intraperitoneal injection of CDP-choline 
increases systemic blood pressure in normal rats [10] and in rats subjected to 
hemorrhagic hypotension [62]. Therefore, CDP-choline might also provide prevention 
against NEC development by enhancing systemic blood pressure and restoring superior 
mesenteric artery ﬂow. 
In addition to short-term effects of CDP-choline administration in the present 
neonatal NEC model, we demonstrated that CDP-choline treatment enhances the mean 
weight of pups with NEC lesion and reduces their clinical sickness scores during long-term 
follow-up. We also showed that 7 of 10 pups that received CDP-choline survived for 14 d 
after NEC development, a considerable rate of survival. These data suggest that CDP-
choline might be beneﬁcial in terms of survival in the long term after NEC development. 
This long- term beneﬁcial effect of CDP-choline may be associated with protection of 
intestinal epithelium and prevention of membrane destruction and apoptosis. The anti-
inﬂammatory and antioxidant effects of CDP-choline may also be involved in long-term 
survival. 
In conclusion, this is the ﬁrst study to show the beneﬁcial effects of intraperitoneal 
CDP-choline treatment in a neonatal rat model of NEC. Cytidine 5'-diphosphocholine 
signiﬁcantly reduced the clinical sickness score, ameliorated macroscopic and 
histopathological intestinal injury, decreased inﬂammation and apoptosis, and increased 
intestinal tissue PC and total phospholipid content. Cytidine 5'-diphosphocholine therapy 
also decreased lipid peroxidation and oxidant status, whereas it improved antioxidant 
status. The biochemical, morphological, and molecular biological effects of CDP-choline 
treatment seem to be associated with long-term consequences such as decreased clinical 
sickness scores and greater survival. Therefore, CDP-choline may be considered a new 
and potentially effective therapy in the prevention and treatment of NEC. 
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Abstract 
Background:  
Necrotizing enterocolitis (NEC) is one of the most common gastrointestinal emergencies 
in newborn infants but up to now there is no completely effective treatment for it. 
Objective: 
In order to show that a combination of melatonin and prostaglandins may be useful to 
save lives, we use newborn rat as a model of necrotizing enterocolitis to test the 
hypothesis of using the combination therapy might have more potential effect on 
mucosal cytoprotection and healing. 
Patients and methods:  
A total of 60 newborn pups from 5 time-mated Sprague-Dawley pregnant rats were 
divided equally into 5 groups as follows: NEC (subjected to NEC), NEC + Melatonin, NEC 
+ Prostaglandin, NEC + Prostaglandin + Melatonin and control. These animals were fed
with hyperosmolar formula 3 times daily and subjected to 100% CO2 inhalation for 10
min, + 4 °C cold exposure for 5 min, and 97% O2 for 5 min twice daily to induce NEC. This
procedure was applied to the pups for 3 days.
Results: 
The macroscopic scoring, intestinal injury scoring and apoptosis index scoring were all 
found to be signiﬁcantly lower in NEC + Prostaglandin + Melatonin group compared with 
NEC group. Anti-oxidant enzyme activities were signiﬁcantly higher, whereas lipid 
peroxidation was signiﬁcantly lower in NEC + Prostaglandin + Melatonin group compared 
with NEC group. 
Conclusion: 
This combination therapy showed cytoprotective and healing effects on mucosa in the 
intestinal tissue of rat pups in necrotizing enterocolitis model. Therefore, this therapy 
might also show beneﬁt in preterm infants with NEC. After conﬁrmation of this data by 
other clinical and experimental studies, it may be a novel therapeutic option for the 
prevention of NEC in preterm infants. 
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1. Introduction
Necrotizing enterocolitis (NEC) is one of the most common gastrointestinal emergencies 
in newborn infants. Although NEC is most commonly observed in premature infants, 10% 
of the affected patients are born at term. Its incidence varies between 0.3 and 2.4 infants/ 
1000 live births and between 7% and 11% among infants of less than 1500 g. The 
pathophysiology of NEC remains poorly understood [1]. Several factors appear to play 
either a primary or a secondary role as follows: immature gut functions, impaired 
intestinal barrier, disturbed gastrointestinal motility, circulatory regulation, lack of some 
protective enzymes of cytokine-dependent injury, and undeveloped antioxidant capacity 
[2–4]. Intestinal ischemia, formula feeding and bacterial infections are also suggested to 
be the main risk factors initiating cellular injury in premature intestine [5]. Increased 
proinﬂammatory cytokines are found in intestinal samples from NEC cases, suggesting 
that these mediators also play a role in NEC development [1]. 
Melatonin activates various physiological functions causing sleep-propensity, 
sleep/wake rhythm, circadian rhythm, blood pressure control, immune system activity, 
detoxiﬁcation of free radicals, protection of gastrointestinal mucosa, control of tumor 
growth and many others. Melatonin is known as one of the most potential anti-oxidant 
substances in human body and especially synthesized in gastrointestinal tract after 
feeding [6]. The major mechanism of melatonin on cytoprotection effect includes free 
radical scavenging activity and activation of cyclooxygenase-prostaglandin enzyme 
system [7]. 
Misoprostol, a prostaglandin (PG) E1 analog, is used due to its cytoprotective activity 
on gastrointestinal system mucosa through inhibiting acid secretion and to stimulate 
bicarbonate and mucus secretion [8]. In addition to its cytoprotective activity, 
misoprostol has also preventive effects on bacterial invasion and reduces inﬂammation 
and tissue injury [9]. Because of this reason, we hypothesized that using the combination 
of melatonin and prostaglandin on NEC model in newborn rats might have more potential 
effect on mucosal cytoprotection and healing. 
In order to show that a combination of melatonin and PG may be useful to save lives, 
we used newborn rats as a NEC model and we aimed to test our hypothesis. 
2. Materials and methods
2.1 Animals and experimental design 
The project was approved by the Experimental Animal Ethics Committee at Gulhane 
Military Medical Academy (Ankara, Turkey) and the National Institutes of Health Guide 
(Washington, D.C., USA) for the Care and Use of Laboratory Animals was followed. The 
pregnant rats were kept in identical cages and were fed with regular laboratory chow and 
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water. 60 newborn pups from 5 time-mated Sprague-Dawley pregnant rats were divided 
equally into 5 groups as follows: NEC (subjected to NEC), NEC + Melatonin, NEC + 
Prostaglandin, NEC + Prostaglandin + Melatonin and control (left with their mother to 
breast feed freely). Ten of them died during this period. 
2.1.1. Necrotizing enterocolitis procedure 
In the NEC (subjected to NEC), NEC + Melatonin, NEC + Prostaglandin, and NEC + 
Prostaglandin + Melatonin groups, based on the preventive effect of mother milk, 
newborn pups were immediately separated from their mothers and kept at 37°C in a 
humidiﬁed incubator. These animals were fed 0.2 mL of special rodent formula (15 g 
Similac 60/40 [Ross Pediatrics, Columbus, Ohio]) prepared with 75 mL of puppy-canine 
milk replacement (Beaphar-Bogena, BV Sedel, Netherlands) 3 times daily and subjected 
to 100% CO2 inhalation for 10 min, + 4 °C cold exposure for 5 min, and 97% O2 for 5 min 
twice daily to induce NEC. This procedure was applied to the pups for 3 days. The pups 
were weighed daily, and their weight loss or gain was recorded. 
2.1.2. Melatonin and prostaglandin E1 therapy 
We used prostaglandin E1 (Prostavasin®, 100 _g amp; Schwarz- Pharma, Mannheim, 
Germany; 75 _g/kg intra peritoneal), melatonin (Melatonin®, 1 g ﬂacon;N-acetyl-5-
methoxytryptamine; Sigma Chemicals Co.; 10 mg/kg intraperitoneal). 
2.2. Biochemical analysis 
The efﬁcacy of melatonin and prostaglandin was assessed by the tissue level of 
malondialdehyde (MDA) as described by Draper et al. [10], superoxide dysmutase (SOD) 
as described by Sun et al. [11], and glutathione peroxidase (GSH-Px) as described by Paglia 
and Valentine [12]. 
2.3. Macroscopic scoring, histopathologic examination and apoptosis evaluation 
A macroscopic assessment of the resected gut was performed using a scoring system 
based on gut color, consistency and degree of dilatation. Macroscopic scoring was graded 
as follows: grade 0, normal; grade 1, moderately friable, patchy discoloration, and patchy 
dilatation; grade 2, extremely friable (jelly like), extensive discoloration, and extensive 
dilatation [13]. Tissue histopathologic examination and apoptosis scoring were evaluated 
by the same pathologist in blinded fashion. For each tissue specimen, corresponding 
blocks of both hematoxylin and eosin (H&E) and transferase mediated dUTP nick end 
labeling (TUNEL) staining were scored. For both light microscopy and apoptosis 
evaluation, the distal ileum was kept in 10% neutral buffered formalin solution. 
Specimens were parafﬁn embedded, and blocks were sliced into 5-μm portions and 
stained with H&E. The histopathologic evaluation was graded as follows: grade 0, normal; 
grade 1 (mild), separation of villous core, without other abnormalities; grade 2 
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(moderate), villous core separation, submucosal edema, and epithelial sloughing; and 
grade 3 (severe), denudation of epithelium with loss of villous, full thickness necrosis, or 
perforation [14]. For apoptosis evaluation, the sections were deparafﬁnized and 
rehydrated through graded alcohols to water. The sections were then incubated with 20 
mg/mL of proteinase K (Dako, Glostrup, Den- mark) for 10 min at room temperature (RT). 
Endogenous peroxidase activity was quenched by incubation with 3% H2O2 in phosphate 
buffer solution (PBS) (50 mmol/L sodium phosphate, pH 7.4, 200 mmol/L NaCl) for 5 min 
at RT. After washing with deionized water (dH2O), the equilibration buffer was incubated 
for 10 s. Enzymatic incorporation of nucleotides labeled with Working Strength TdT 
(ApopTag Per- oxidase in situ Apoptosis Detection Kit, S7101, Millipore, Billerica, MA, 
USA) were placed at 37°C in a humidiﬁed chamber for 60 min. Then the sections were 
treated with Working Strength Stop/Wash buffer for 10 min at RT. The slides were 
washed twice in PBS. They were incubated with antidigoxigenin peroxidase at RT in a 
humidiﬁed chamber for 30 min. They were washed with PBS and then they were 
incubated with 3,3 9-diaminobenzidine tetrahydrochloride (DAB) (0.5 mg/mL), which was 
used as chromogen substrate, for 6 min at RT in a humidiﬁed chamber. Tissue sections 
were lightly counterstained with 0.5% methyl green to reveal nuclei, and the slides were 
examined using an Axiolab microscope (Carl Zeiss, Jena, Germany). Apoptosis scoring was 
graded as follows: grade 0, normal; grade 1, apoptotic nuclei present at villous tips; grade 
2, apoptotic nuclei covering all villous tips but crypts protected; and grade 3, transmural 
spread of apoptotic nuclei [15]. 
3. Results 
We showed biochemical evaluations for each group in Table 1. SOD and GSH-Px levels 
(1965 ± 42 vs. 1041 ± 102 U/g protein, p < 0.001; 70 ± 2.6 vs. 49.7 ± 3.5 U/g protein, p < 
0.001) were signiﬁcantly higher and MDA levels (0.86 ± 0.1 vs. 1.6 ± 0.2 nmol/g protein, 
p < 0.001) were signiﬁcantly lower in NEC + Prostaglandin + Melatonin group comparing 
to NEC group. 
We showed comparison of histopathologic evaluation of groups in Table 2 and Fig. 1. 
We found signiﬁcantly lower macroscopic scoring, intestinal injury scoring (Fig. 2), and 
apoptosis index scoring (0.3 ± 0.1 vs1.7 ± 0.4, p < 0.001; 1.5 ± 0.8 vs. 2.6 ± 0.5, p < 0.001 
and 0.8 ± 0.2 vs. 2.4 ± 0.6, p < 0.001; respectively) in NEC + Prostaglandin + Melatonin 
group compared with NEC group. NEC + Prostaglandin + Melatonin group had also more 
beneﬁcial results in terms of biochemical and histopathologic evaluations compared with 
NEC + Melatonin and NEC + Prostaglandin groups. 
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Table 1 Biochemical evaluations for each group. 
Control  
(n = 12) 
NEC (n = 9) NEC + Melatonin  
(n = 10) 
NEC + Prostaglandin  
(n = 9) 
NEC + Melatonin + 
Prostaglandin 
(n = 10) 
MDA (nmol/g 
protein)  
0.5 ± 0.08 1.6 ± 0.2 1.1 ± 0.1⁎†† 1.3 ± 0.1†∞ 0.86 ± 0.1‡ 
SOD (U/g protein) 2486 ± 107 1041 ± 102 1878 ± 85⁎†† 1774 ± 105†∞ 1965 ± 42 
GSH-Px (U/g protein) 84.2 ± 1.9 49.7 ± 3.5 65.5 ± 1.6⁎†† 62 ± 2.7†∞ 70 ± 2.6‡ 
* p < 0.001 NEC + Melatonin vs. NEC. 
† p < 0.001 NEC + Prostaglandin vs. NEC. 
‡ p < 0.001 NEC + Melatonin + Prostaglandin vs. NEC. 
†† p < 0.05 NEC + Melatonin + Prostaglandin vs. NEC + Melatonin. 
∞ p < 0.05 NEC + Melatonin + Prostaglandin vs. NEC + Prostaglandin. 
Table 2 Comparison of histopathologic evaluation. 
Macroscopic scoring Intestinal injury scoring Apoptosis index scoring 
Control (n = 12) 0 ± 0.0 0 ± 0.0 0 ± 0.0 
NEC (n = 9) 1.7 ± 0.4 2.6 ± 0.5 2.4 ± 0.6 
NEC + Melatonin (n = 10) 0.5 ± 0.4 7⁎ 1.3 ± 0.4⁎††  
NEC + Prostaglandin (n = 9) 0.6 ± 0.4† 2.1 ± 1† 1.7 ± 0.3†∞ 
NEC + Melatonin + 
Prostaglandin (n = 10) 
0.3 ± 0.1‡ 1.5 ± 0.8‡ 0.8 ± 0.2‡ 
* p < 0.001 NEC + Melatonin vs. NEC. 
† p < 0.001 NEC + Prostaglandin vs. NEC. 
‡ p < 0.001 NEC + Melatonin + Prostaglandin vs. NEC. 
†† p < 0.05 NEC + Melatonin + Prostaglandin vs. NEC + Melatonin. 
∞ p < 0.05 NEC + Melatonin + Prostaglandin vs. NEC + Prostaglandin 
Evaluation of melatonin and prostaglandin E1 combination 
79 
H&E TUNEL stained TUNEL-fluorescent 
Fig. 1. Pathologic ﬁgures (ﬁrst line control, second line NEC, third line melatonin, fourth line prostaglandin, ﬁfth 
line combination). 
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Fig. 2. Intestinal injury scores of the groups. 
4. Discussion
In this study, we evaluated the efﬁcacy of both single and combined therapies of 
melatonin and prostaglandin in a neonatal NEC rat model and we found signiﬁcantly 
increased anti-oxidant and also decreased lipid peroxidation in combination therapy 
compared with the NEC, NEC + Melatonin groups and NEC + Prostaglandin groups. 
Macroscopic scoring, intestinal injury scoring and apoptosis index scoring were also 
signiﬁcantly lower in combination group compared with other groups. These data suggest 
the use of combination therapy in preterm infants with NEC after similar experimental 
and clinical studies. 
It is well known that besides the beneﬁcial effect of oxygen and its derivates, they 
may also exert a harmful action, because of the super oxide anion radical, hydrogen 
peroxide and hydroxyl radicals. There are numerous endogenous and exogenous factors 
such as acid, pepsin, bile salts, and nonsteroidal anti-inﬂammatory drugs and stress 
factors such as ischemia, hypoxia, and infections which lead to impaired gastrointestinal 
mucosal barriers by acting through the production of radical oxygen species and radical 
nitrogen species [7,16-18]. 
Melatonin is known as one of the most potential antioxidant substances in human 
body and it is especially synthesized in gastrointestinal (GI) tract after feeding [6]. Firstly, 
Raikhlin and Kvetoy [19] showed that GI system produced melatonin mainly in serotonin-
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rich entero-endocrine cells (especially enterechromafﬁn cells). They also stated that it 
acted as a paracrine molecule and hormone released into the portal vein [19]. Melatonin 
concentration in GI system is 100-400 times higher than the blood plasma levels and this 
production of melatonin increases after food intake [20]. Especially in recent years, there 
are many studies in literature about using this antioxidant effect of melatonin in many 
pathological conditions. For example, Pereira reported that dietary supplementation of 
melatonin resulted in remarkable remission in gastroesophageal reﬂux disease [21]. 
Reiter et al. [22] showed that melatonin had an effect for scavenging oxidant substances. 
Kesik et al. [23] showed the healing effect of melatonin in ischemia-reperfusion model in 
rats [23]. In another study, Reiter et al. [22] showed that melatonin decreased the free 
radical formation via inhibiting the prooxidant enzymes, and activating the antioxidant 
enzymes; and thus it supports the antioxidant system. Melatonin sticks to the outer 
surface of the bi-layer lipid membrane when it comes in contact with the cell, and works 
as a free radical scavenger. It protects the cell and the membrane in this way [24,25]. In 
agreement with this data, we found that both melatonin and melatonin + prostaglandin 
increased the levels of anti-oxidant enzymes in this experimental study. 
Stress factors such as ischemia, hypoxia, and infections may cause partial inactivation 
of cycloooxgenase-1 (COX-1) and reduce the generation of gastroprotective PGs 
(especially PGE1, PGE2, PGI2) that occur throughout the GI mucosa and inhibit gastric 
acid secretion, and increase mucosal blood ﬂow. Expression of COX-2 may be actually 
increased under stress conditions due to reduction activity of COX-1, which normally 
exerts tonic inhibitory inﬂuence on COX-2 expression so the PG content in gastric mucosa 
remains low [25]. Misoprostol is an analog of prostaglandin E1. Mechanisms for the 
cytoprotective activity of misoprostol have still not been entirely revealed despite 
extensive studies. Misoprostol prevented gastric or duodenal ulcer in most of the patients 
using non-steroidal anti-inﬂammatory drugs and decreased gastrointestinal symptoms, 
in addition to its mucosal protective effects [26]. In our study, we found signiﬁcantly 
higher SOD and GSH-Px levels and lower MDA levels in PG group than control and NEC 
groups. Macroscopic scoring, intestinal injury scoring and apoptosis index scoring were 
also signiﬁcantly lower in PG group than in control and NEC groups. Topcu et al. [27] 
reported beneﬁcial effect of misoprostol in ischemia-reperfusion induced intestinal injury 
in adult rats. In another study, Topsakal et al. [28] found that prostaglandin E1 and 
melatonin were effective for the prevention of lipid peroxidation in a spinal cord injury 
model in rats. Similar to these data, PG alone or especially in combination with melatonin 
was found as beneﬁcial treatment options in NEC by decreasing lipid peroxidation, 
increasing anti-oxidant enzyme activities and ameliorating histopathological changes. 
In recent years, multimodal therapeutic approach interfering at different levels of 
hypoxia-ischemia, inﬂammation and apoptosis were suggested to be more effective for 
preventing diseases with a multifactorial etiology such as hypoxic-ischemic 
encephalopathy. Cetinkaya et al. [29] reported that melatonin alone or in combination 
with magnesium sulfate had beneﬁcial effect for preventing hypoxic ischemic brain injury 
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in a rat model. The same group also found that both melatonin and topiramate that were 
administered alone or in combination were effective as neuroprotective agents [30]. 
Therefore, as hypoxia-ischemia is one of the major risk factors in NEC and has a similar 
multifactorial pathogenesis of hypoxic-ischemic brain injury, we hypothesized that the 
combination of two agents, melatonin, a free radical scavenger and anti-oxidant, and 
misoprostol, mucosal gastroprotective, would have show protective effect against NEC 
development and preformed this experimental study. In agreement with these studies, 
our study showed that the combination therapy provided signiﬁcantly more beneﬁcial 
effects for the prevention of NEC compared with the single administration of melatonin 
and misoprostol. Therefore, we suggest that the combined therapies that have different 
actions in the pathogenesis of NEC may be used in infants with NEC after conﬁrmation of 
our data. In conclusion, to our best of knowledge, this is the ﬁrst study that showed a 
signiﬁcant protective effect of combination therapy of misoprostol and melatonin, two 
agents acting on different stages of NEC. These data may also be used as a reference 
point in the clinical treatment of preterm infants with NEC. 
However, to make such a recommendation, much more experimental and clinical 
studies are needed. 
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Abstract 
Neonatal hypoxic-ischemic encephalopathy (HIE) is a major cause of neurological 
disability requiring newer therapeutic strategies. Uridine is the principal circulating 
pyrimidine in humans and a substrate for nucleotides and membrane phospholipids. The 
objective of this study was to investigate the effects of uridine in a neonatal rat model of 
HIE. Rat pups subjected to hypoxic-ischemic insult on postnatal day 7 were injected 
intraperitoneally with either saline or uridine (100, 300 or 500 mg/kg) for three 
consecutive days and brains were collected for evaluation of brain infarct volume and 
apoptosis. Compared with Control group, uridine at 300 and 500 mg/kg doses 
signiﬁcantly reduced percent infarct volume, TUNEL (+) cell ratio and active Caspase-3 
immunoreactivity in the cortex, as well as in CA1 and CA3 regions of the hippocampus. 
Uridine (300 and 500 mg/kg) also decreased active Caspase-3 expression in the ipsilateral 
hemisphere. These data indicate that uridine dose-dependently reduces brain injury in a 
rat model of neonatal HIE by decreasing apoptosis. 
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1. Introduction 
Hypoxic-ischemic (HI) insult in newborns causes brain injury with signiﬁcant 
consequences including motor and cognitive deﬁcits and seizures [32]. Every 2 newborns 
per 1000 term births are affected by neonatal hypoxic-ischemic encephalopathy (HIE) 
[17] which causes death and neurological morbidities [29]. Although many strategies 
have been proposed in treatment of HIE, newer approaches are required to ameliorate 
the severity of brain pathology, and reduce mortality and morbidity. 
Uridine is the principal circulating pyrimidine nucleoside in humans [4,35] and a 
constituent of breast milk [26]. It is also a precursor of brain membrane phosphatides via 
the Kennedy pathway [16] as a building block of uridine-5'-triphosphate (UTP). Uridine 
administration enhances cytidine-5'-diphosphocholine (CDP-choline) levels in PC12 cells 
[23], striatal slices [27] and rodent brains [8]. CDP-choline has been reported to exhibit 
beneﬁcial effects in experimental and clinical studies of stroke and other 
neurodegenerative states [1] including HIE [13]. 
Uridine nucleotides (UTP and uridine-5'-diphosphate [UDP]) are ligands to P2Y 
receptors (P2Y2, P2Y4 and P2Y6), stimulation of which provides neuroprotection by 
reducing apoptosis [5,18]. Uridine administration leads to enhancement in UTP levels in 
PC12 cells [22] and rodent brains [8]. 
Since uridine is a precursor to uridine nucleotides and CDP-choline, we aimed to 
investigate the effects of uridine administration in a rat model of neonatal HIE. Our data 
show for the ﬁrst time that intraperitoneal (i.p.) uridine administration for 3 consecutive 
days following HI brain insult reduces infarct volume, TUNEL (+) cell ratio and active 
Caspase-3 expression in the cortex as well as CA1 and CA3 regions of the hippocampus in 
newborn rats. 
2. Materials and methods 
Experimental protocols were approved by the Animal Care and Use Committee of Uludag 
University, Bursa, Turkey (2009-07/4), and the experiments conformed to the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publications 
No. 80-23) revised 1996 and EC Directive 86/609/EEC. 
Model for perinatal HI brain injury was adapted from Vanucci and Vanucci [30]. A total 
of 51 pups were born to 5 dated pregnant Sprague-Dawley rats which were housed in 
individual cages with free access to food and water with 12 h light/dark cycle. The day of 
birth was considered postnatal day 0 (PND0) and experiments were initiated on day 7 
(PND7), at which day the brain maturation of rats coincides with that of 32- to 34-week-
old human [31]. 
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2.1. Induction of HI brain injury 
Out of the initial 51 pups, 8 pups were excluded due to low weight on PND7 and 3 pups 
were excluded due to bleeding after surgery. Forty rat pups of either sex (55% males [n = 
22] and 45% females [n = 18]) weighing 12-16 g on PND7 were used in the experiments.
Under isoﬂurane anesthesia, right common carotid arteries of pups were ligated and
coagulated. Following a 2-h period of nesting, three pups from each dam were placed
into chambers partially submerged in a 37◦C water bath and exposed to hypoxia (8%
oxygen balanced with nitrogen mixture) for 150 min (Fig. 1A). Hypoxic chambers were
attached to an anesthesia device (AMS Minor 612, GMS Generra Medikal, Ankara,
Turkey) and the gas ﬂow was monitored using a gas ﬂow analyzer (VT-PLUS HF, Fluke
Biomedical, Everett, WA) before each experiment.
Fig. 1. Schematic diagrams of the experimental procedure (A) and the areas utilized for determining TUNEL (+) 
cell ratio and Caspase-3 immunoreactivity (B). “a”, count area in cortex; “b” count area in CA1 region; “c” count 
area in CA3 region. 
2.2. Treatment groups 
PND7 rats (n = 32) were divided randomly, ensuring that all treatment groups were 
represented by pups from each dam, into 4 groups and injected i.p. with the following: 
saline (0.9% NaCl,0.1 ml [Control group]), uridine (100 mg/kg [U100 group]), uridine (300 
mg/kg [U300 group]), and uridine (500 mg/kg [U500 group]) (dissolved in saline and 
injected 0.1 ml) (Fig. 1A). No behavioral changes were observed after HI insult or uridine 
treatments. Sham operation by exposing the common carotid artery without ligation and 
hypoxia was performed on another set of rat pups (n = 8). The dose range of uridine used 
in the present study has been selected in the light of a previous report which tested CDP-
choline [13] in a neonatal rat model of HIE, as well as our preliminary observations with 
300 mg/kg uridine with three consecutive injections. 
2.3 Brain tissue procurement 
Following completion of experiments, pups were divided into 2 groups on PND10; under 
deep anesthesia, pups were either decapitated and brain tissues were removed (n = 20) 
or sacriﬁced following transcardiac perfusion with 4% paraformaldehyde dissolved in 
phosphate-buffered saline (PBS) (pH 7.4) (n = 20) for western blotting or 
immunohistochemistry, respectively. 
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2.4. Measurement of brain infarct volume 
One in every ﬁve 20 µm-thick brain sections selected with a deﬁned range was stained 
with 0.5% cresyl violet (Acros Organics, Geel, Belgium) in order to evaluate brain infarct 
volume for each pup using images captured at a magniﬁcation of 1.25× (Fig. 2). Volume 
fraction of the infarct (corresponding to percent infarct volume [12]) in ipsilateral 
hemisphere was estimated by Cavalieri principle by a blinded investigator using a 
combined point-counting grid as described previously [9,12,14]. 
2.5. In situ cell death detection 
DNA fragmentation was detected using an in situ cell death detection POD kit (Roche 
Molecular Biochemicals, 11684817910, Germany) for TUNEL (terminal deoxynucleotidyl 
transferase (TdT)-mediated deoxyuridine triphosphate (dUTP)-biotin nick end-labeling) 
technique in cryosections. Slides were counter- stained with Harris’s hematoxylin (Sigma-
Aldrich, St. Louis, MO). 
TUNEL (+) cell count was performed on sections from four different levels in 
rostrocaudal plane of cortex as well as CA1 and CA3 areas of the hippocampus that 
corresponded approximately to panels 11-14 according to the Atlas of Prenatal Rat Brain 
Development [2]. 
Images with size of 4080 × 3072 square pixels were captured with CCD camera 
(Olympus DP71 CCD color camera, 1.5 million pixel) attached to a light microscope at 
100× magniﬁcation (Olympus BX50). Four areas in cortex and regions of the hippocampus 
were hemilaterally analyzed (Fig. 1B). After top of the section of the selected microscopic 
ﬁeld was found, eight consecutive focal planes with a distance of 2 µm were scanned 
between the top and the bottom surfaces. Images of focal planes were superimposed 
prior to counting the nuclei and percent TUNEL (+) cells over all cells were calculated for 
each pup and data were presented as TUNEL (+) cell ratio (Fig. 3). 
In addition, four different coronal sections adjacent to those utilized for TUNEL staining 
were chosen for active Caspase-3 immunohistochemistry. Sections  were labeled with 
rabbit anti-cleaved Caspase-3 (1:200; Asp-175, Cell Signaling Technology Inc., Danvers, 
MA) and incubated with an appropriate secondary antibody (biotinylated anti-rabbit IgG, 
Jackson Immuno Research Laboratories Inc., West Grove, PA) before treatment with 
avidine biotin complex (ABC Vectastain Elite ABC Kit, Vector Laboratories Inc., 
Burlingame, CA) and visualization using DAB substrate. 
The number of Caspase-3 positive cells was counted by a 10,000 µm2 -sized counting 
frame that was viewed through a 100× magniﬁcation at captured images (Fig. 4) 
repeating the steps performed for TUNEL (+) cell counts and cell counts of 4 sections 
were averaged for each region in each pup. 
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2.6. Active Caspase-3 protein expression 
Ipsilateral hemispheres were homogenized in ice-cold PBS (pH 7.4). Equal amounts of 
protein were loaded and separated using SDS-PAGE (4-20%; Bio-Rad, Hercules, CA). Each 
gel contained homogenates of four individual pups at each treatment group. Proteins 
were transferred onto membranes which were then incubated overnight with the 
primary antibody against active Caspase-3 (1:1000, Abcam, Cambridge, MA) and then 
with the appropriate peroxidase-linked secondary antibody (1:5000, GE Healthcare, 
Waukesha, WI). Protein-antibody complexes were visualized using the enhanced-
chemiluminescence system (GE Healthcare, Waukesha, WI) and developed on Kodak X-
AR ﬁlms which were digitized using a scanner with a transparency adapter (UMAX 
Technologies, Freemont, CA). Immunoreactive bands were compared densitometrically 
using the NIH Image-J program. Areas under the absorbance curve were expressed as 
arbitrary units and normalized as percentages of control samples. Same blots were 
stripped and incubated with β-tubulin (1:1000, Abcam, Cambridge, MA), used as a 
loading control. 
2.7. Statistics 
Statistical analyses were performed using Sigma Plot 12.0 soft- ware. Data were 
expressed as mean ± standard error of means (SEM). Difference between groups was 
determined by one-way ANOVA followed by post hoc Tukey test. p < 0.05 was considered 
statistically signiﬁcant. 
3. Results
3.1. Effect of uridine treatment on brain infarct volume 
Percent infarct volume in ipsilateral hemispheres of Control pups (66 ± 3.8%) was reduced 
in U300 or U500 groups to 34.1 ± 7.9% (p < 0.05) or 32.7 ± 3.5% (p < 0.05), respectively 
(Fig. 2, lower right panel). We also detected 20 ± 0.6% and 18 ± 0.4% infarct volume in 
non-ischemic hemispheres of pups in Control and U100 groups, respectively, while no 
infarction was observed in those in the U300 and U500 groups (data not shown). 
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Fig. 2. Representative images of coronal sections stained with Cresyl Violet indicating brain infarct volume in 
sham-operated, control and uridine-treated pups (upper panels plus lower left and middle panel) and graph 
depicting percent infarct volume in ipsilateral hemisphere (lower right panel). *p < 0.05 compared with Control 
group. U100, U300 and U500 represent i.p. uridine treatments at 100, 300 and 500 mg/kg, respectively. 
3.2. Effect of uridine treatment on TUNEL (+) cell ratio 
Compared with the Control group, TUNEL (+) cell ratio was decreased signiﬁcantly in 
U300 or U500 groups in the cortex (by 27.1% [p < 0.05] or by 32.6% [p < 0.05], 
respectively), as well as CA1 (by 39% [p < 0.001] or by 39.6% [p < 0.001], respectively) 
and CA3 (by 31.8% [p < 0.05] or by 32.5% [p < 0.05], respectively) regions of the 
hippocampus (Fig. 3B). 
3.3. Effects of uridine treatment on active Caspase-3 immunoreactivity 
Number of active Caspase-3 immunoreactive cells was reduced in U300 or U500 groups in 
the cortex (by 20.9 [p < 0.001] or by 22 [p < 0.001], respectively), as well as CA1 (by 21.7 
[p < 0.001] or by 23.8 [p < 0.001], respectively) and CA3 (by 9.8 [p < 0.001] or by 12 [p < 
0.001], respectively) regions of the hippocampus compared with Control group (Fig. 4B). 
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Fig. 3. Representative images of TUNEL staining in the 
cortex, as well as CA1 and CA3 regions of the 
hippocampus (A) and graph depicting TUNEL (+) cell 
ratio (B). 
*p < 0.05 and **p < 0.001 compared to values 
obtained in Control group; † p < 0.05 
and ‡ p < 0.001 compared to values obtained in U100
group. 
Fig. 4. Representative images of Caspase-3 
immunoreactivity in the cortex, as well as CA1 and 
CA3 regions of the hippocampus (A) and graph 
depicting Caspase-3 immunoreactive cell count (B). 
**p < 0.001 compared to values obtained in Control 
group; † p < 0.05 and ‡ p < 0.001 compared to values 
obtained in U100 group. 
3.4. Effects of uridine treatment on active Caspase-3 protein levels 
Compared with Control group, active Caspase-3 levels in ipsilateral hemispheres were 
decreased in U300 (by 22.5%; p < 0.05) or U500 (by 32.5%; p < 0.05) group, but not U100 
group (Fig. 5). Levels of β-tubulin did not change indicating equal protein load. 
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Fig. 5. Graph depicting active Caspase-3 expression as percentage of control values. Active Caspase-3 was 
investigated by running homogenates of ipsilateral hemispheres from four individual pups at each treatment 
group. β-Tubulin was used as protein loading control. *p < 0.05 compared with Control. 
4. Discussion
Our data show, for the ﬁrst time, that parenteral uridine administration for three 
consecutive days dose-dependently reduces percent brain infarct volume, TUNEL (+) cell 
ratio as well as active Caspase-3 immunoreactive cell counts and protein levels in a rat 
model of HIE. These data suggest that uridine might ameliorate brain lesion in newborns 
with HI insult.  
Neonatal brain injury due to HIE remains a great challenge due to causing brain injury 
leading to motor and cognitive deﬁcits, and seizures [32]. Many strategies including 
erythropoietin administration [36] and therapeutic hypothermia [25] have been 
proposed for the management of HIE. However, these strategies have several 
complications; erythropoietin may lead to such conditions as retinopathy of prematurity, 
hypertension, coagulation and hemangioma, and cause detrimental effects for normal 
development [36]. In addition, mild hypothermia which could be used within strict 
protocols and appropriate training on correct diagnosis in only neonatal intensive care 
units [15], seems efﬁcient in only some asphyxiated newborns, but not in all [33]. 
Therefore, safer and more accessible approaches are required to reduce the severity of 
brain pathology in newborns with HIE. 
Uridine is the principal circulating pyrimidine nucleoside in humans [4,35] and a 
constituent of breast milk [26]. Uridine also serves as a precursor of membrane 
phosphatides and exogenous administration of uridine enhances CDP-choline levels in 
PC12 cells [23], striatal slices [27] and rodent brains [8]. Chronic supplementation with 
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uridine-5-monophosphate (UMP) increases levels of phospholipids, synaptic proteins and 
leads to synaptogenesis in adult [24,34] and newborn rodents [6]. Evidence that uridine 
might confer beneﬁt under degenerative conditions has been provided by in vitro glucose 
deprivation studies [10,11] as well as in vivo rat model of Parkinson’s [7]. 
Therefore, we tested uridine in a rat model of HIE. Our results indicate that i.p. uridine 
administration for three consecutive days after the onset of HI insult in PND7 pups 
reduced percent brain infarct volume in a dose-dependent manner. Uridine treatment at 
300 and 500 mg/kg doses also ameliorated the infarction observed in Control and U100 
groups in the non-ischemic contralateral hemisphere, suggesting that uridine is effective 
against the lesion caused by hypoxia alone. In addition, uridine also dose-dependently 
decreased TUNEL (+) cell ratio in the cortex, as well as CA1 and CA3 regions of 
hippocampus indicating that uridine may limit the apoptotic process in newborns with 
HIE. This suggestion was further conﬁrmed by signiﬁcantly reduced expression and levels 
of active Caspase-3, an indicator of apoptosis, by uridine administration. 
The mechanism(s) by which uridine ameliorate brain injury and reduce apoptosis in 
HI insult remain to be determined. Uridine is a precursor to CDP-choline which has proven 
beneﬁcial in in vitro models of neurodegeneration [20] and has long been tested in stroke 
and other neurodegenerative states in experimental animals and humans [1]. CDP-
choline exhibits cerebroprotection in a rat model of HIE through a reduction in active 
Caspase-3 levels [13] which is in agreement with our present ﬁndings. In addition, uridine 
is a precursor to UTP and UDP, pyrimidine nucleotides that are formed through 
phosphorylation of uridine. UTP and UDP are ligands to various P2Y receptors (P2Y2, P2Y4 
and P2Y6), stimulation of which provides neuroprotection by several mechanisms 
including reduction of apoptosis [5,18] involving intracellular signaling molecules 
including ERK and Akt [3,5]. It could also be speculated that uridine’s cerebroprotection 
involves hypothermia, as has been demonstrated previously [21]. It is also possible that 
the cerebroprotective effects of uridine observed in the present study might have arisen 
from the action of uridine phosphorylase, which provided protection from glucose 
deprivation-induced death of immunostimulated astrocytes [10] and cortical neurons 
[11] and have involved both neurons and astrocytes. However, precise mechanism(s) of
uridine action in this model needs further investigation.
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5. Conclusions
In conclusion, uridine administration dose-dependently reduces brain infarct volume, 
TUNEL (+) cell ratio and Caspase-3 levels in newborn rats subjected to HI insult. To the 
best of our knowledge, our study is the ﬁrst to report beneﬁcial effects of uridine on brain 
injury and apoptosis in a rat model of HIE. Previous human studies demonstrated that 
uridine can be tolerated at least up to 10 g/m2 for a single oral dose [28] and for 
intravenous injection [19]. Hence, uridine might confer beneﬁt as an easily accessible, 
safe and efﬁcient therapeutic agent in human newborns with HIE. 
Conﬂict of interest 
The authors state no conﬂict of interest. 
Acknowledgement 
This study was supported by Uludag University Scientiﬁc Research Projects grant number: 
T/U 2009-2. 
Chapter 6 
96 
References 
1. R.M. Adibhatla, J.F. Hatcher, Cytidine 51 -diphosphocholine (CDP-Choline) in stroke and other CNS
disorders, Neurochem. Res. 30 (2005) 15–23. 
2. J. Altman, S.A. Bayer, Atlas of Prenatal Rat Brain Development, CRC Press, Boca Raton, FL, 1995. 
3. D.B. Arthur, S. Georgi, K. Akassoglou, P.A. Insel, Inhibition of apoptosis by P2Y2 receptor activation: novel 
pathways for neuronal survival, J. Neurosci. 26 (2006) 3798–3804. 
4. M. Cansev, Uridine and cytidine in the brain: their transport and utilization, Brain Res. Rev. 52 (2006) 389–
397. 
5. M. Cansev, Involvement of uridine-nucleotide-stimulated P2Y receptors in neuronal growth and function, 
Cent. Nerv. Sys. Agents Med. Chem. 7 (2007) 223–229. 
6. M. Cansev, G. Marzloff, T. Sakamoto, I.H. Ulus, R.J. Wurtman, Giving uridine and/or docosahexaenoic acid 
orally to rat dams during gestation and nurs- ing increases synaptic elements in brains of weanling pups, 
Dev. Neurosci. 31 (2009)  181–192. 
7. M. Cansev, I.H. Ulus, L. Wang, T.J. Maher, R.J. Wurtman, Restorative effects of uri- dine plus
docosahexaenoic acid in a rat model of Parkinson’s disease, Neurosci. Res.  62  (2008)  206–209. 
8. M.  Cansev,  C.J.  Watkins,  E.M.  van  der  Beek,  R.J.  Wurtman,  Oral  Uridine  51 monophosphate (UMP) 
increases brain CDP-choline levels in gerbils, Brain Res. 1058  (2005)  101–108. 
9. J. Chia, A. Baddeley, Accuracy of estimates of volume fraction, Image Anal. Stereol. 19 (2000) 199–204. 
10. J.W. Choi, B.K. Yoo, C.Y. Shin, M.K. Ryu, J.H. Ryu, M.H. el Kouni, J.C. Lee, W.K. Kim, K.H. Ko, Uridine prevents 
the glucose deprivation-induced death of immunos- timulated astrocytes via the action of uridine
phosphorylase, Neurosci. Res. 56 (2006)  111–118. 
11. J.W. Choi, C.Y. Shin, M.S. Choi, S.Y. Yoon, J.H. Ryu, J.C. Lee, W.K. Kim, M.H. el Kouni, K.H. Ko, Uridine protects 
cortical neurons from glucose deprivation- induced death: possible role of uridine phosphorylase, J.
Neurotrauma 25 (2008)  695–707. 
12. N. Ekinci, N. Acer, A. Akkaya, S. Sankur, T. Kabadayi, B. Sahin, Volumetric evalu- ation of the relations among 
the cerebrum, cerebellum and brain stem in young subjects: a combination of stereology and magnetic
resonance imaging, Surg. Radiol. Anat. 30 (2008) 489–494. 
13. M. Fiedorowicz, D. Makarewicz, K.I. Stan´ czak-Mrozek, P. Grieb, CDP-choline (citicoline) attenuates brain 
damage in a rat model of birth asphyxia, Acta Neurobiol. Exp. 68 (2008) 389–397. 
14. H.J. Gundersen, T.F. Bendtsen, L. Korbo, N. Marcussen, A. Møller, K. Nielsen, 
15. J.R. Nyengaard, B. Pakkenberg, F.B. Sørensen, A. Vesterby, Some new, simple and efﬁcient stereological 
methods and their use in pathological research and diagnosis, APMIS 96 (1988) 379–394. 
16. S.E. Jacobs, C.J. Morley, T.E. Inder, M.J. Stewart, K.R. Smith, P.J. McNamara, I.M. Wright, H.M. Kirpalani,
B.A. Darlow, L.W. Doyle, Infant Cooling Evaluation Col- laboration, Whole-body hypothermia for term and 
near-term newborns with hypoxic–ischemic encephalopathy: a randomized controlled trial, Arch. Pedi- atr. 
Adolesc. Med. 165 (2011) 692–700. 
17. E.M. Kennedy, S.B. Weiss, The function of cytidine coenzymes in the biosynthe- sis of phospholipids, J. Biol. 
Chem. 222 (1956) 193–214. 
18. J.J. Kurinczuk, M. White-Koning, N. Badawi, Epidemiology of neonatal encephalopathy and hypoxic–
ischaemic encephalopathy, Early Hum. Dev. 86 (2010)  329–338. 
19. D. Lecca, S. Ceruti, Uracil nucleotides: from metabolic intermediates to neuroprotection and
neuroinﬂammation, Biochem. Pharmacol. 75 (2008) 1869–1881. 
20. Leyva, C.J. van Groeningen, I. Kraal, H. Gall, G.J. Peters, J. Lankelma, H.M. Pinedo, Phase I and
pharmacokinetic studies of high-dose uridine intended for rescue from 5-ﬂuorouracil toxicity, Cancer Res. 
44 (1984) 5928–5933. 
21. Mir, J. Clotet, R. Aledo, N. Durany, J. Argemi, R. Lozano, J. Cervos-Navarro, N. Casals, CDP-choline prevents
glutamate-mediated cell death in cerebellar granule neurons, J. Mol. Neurosci. 20 (2003) 53–60. 
Neuroprotective effects of uridine 
97 
22. G.J. Peters, C.J. van Groeningen, E.J. Laurensse, J. Lankelma, A. Leyva, H.M. Pinedo, Uridine-induced 
hypothermia in mice and rats in relation to plasma and tissue levels of uridine and its metabolites, Cancer 
Chemother. Pharmacol. 20 (1987) 101–108. 
23. A.M. Pooler, D.H. Guez, R. Benedictus, R.J. Wurtman, Uridine enhances neu- rite outgrowth in nerve growth
factor-differentiated pheochromocytoma cells, Neuroscience 134 (2005) 207–214. 
24. U.I. Richardson, C.J. Watkins, C. Pierre, I.H. Ulus, R.J. Wurtman, Stimulation of CDP-choline synthesis by
uridine or cytidine in PC12 rat pheochromocytoma cells, Brain Res. 971 (2003) 161–167. 
25. T. Sakamoto, M. Cansev, R.J. Wurtman, Oral supplementation with docosahe- xaenoic acid and uridine-51
-monophosphate increases dendritic spine density in adult gerbil hippocampus, Brain Res. 1182 (2007) 50–
59. 
26. M.A. Tagin, C.G. Woolcott, M.J. Vincer, R.K. Whyte, D.A. Stinson, Hypother- mia for neonatal hypoxic
ischemic encephalopathy: an updated system- atic review and meta-analysis, Arch. Pediatr. Adolesc. Med. 
166 (2012) 558–566. 
27. L. Thorell, L-B. Sjoberg, O. Hernell,  Nucleotides  in  human  milk:  sources and  metabolism  by  the  newborn 
infant, Pediatric Res. 40 (1996) 845–852. 
28. I.H. Ulus, C.J. Watkins, M. Cansev, R.J. Wurtman, Cytidine and uridine increase striatal CDP-choline levels 
without decreasing acetylcholine synthesis or release, Cell. Mol. Neurobiol. 26 (2006) 563–577. 
29. C.J. van Groeningen, G.J. Peters, J.C. Nadal, E. Laurensse, H.M. Pinedo, Clinical and pharmacologic study of 
orally administered uridine, J. Natl. Cancer Inst. 83 (1991)  437–441. 
30. S.J. Vanucci, H. Hagberg, Hypoxia–ischemia in the immature brain, J. Exp. Biol. 207 (2004) 3149–3154. 
31. R.C. Vannucci, S.J. Vanucci, A model of perinatal hypoxic–ischemic brain dam- age, Ann. N.Y. Acad. Sci. 835 
(1997) 234–429. 
32. R.C. Vannucci, S.J. Vanucci, Perinatal hypoxic–ischemic brain damage: evolu- tion of an animal model, Dev. 
Neurosci. 27 (2005) 81–86. 
33. J.J. Volpe, Hypoxic–ischemic encephalopathy, in: J.J. Volpe (Ed.), Neurology of the Newborn, WB Saunders, 
Philadelphia, PA, 2001, pp. 245–480. 
34. P. Wintermark, Current controversies in newer therapies to treat birth asphyxia, Int. J. Pediatr. 2011 (2011) 
848413. 
35. R.J. Wurtman, M. Cansev, T. Sakamoto, I.H. Ulus, Use of phosphatide precursors to promote
synaptogenesis, Annu. Rev. Nutr. 29 (2009) 59–87. 
36. R.J. Wurtman, M. Regan, I.H. Ulus, L. Yu, Effect of oral CDP-choline on plasma choline and uridine levels in
humans, Biochem. Pharmacol. 60 (2000) 989–992. 
37. T. Xiong, Y. Qu, D. Mu, D. Ferriero, Erythropoietin for neonatal brain injury: opportunity and challenge, Int. 
J. Dev. Neurosci. 29 (2011) 583–591. 

99 
Chapter 7
Possible neuroprotective effects of 
magnesium sulphate and melatonin as both 
pre- and post-treatment in a neonatal 
hypoxic-ischemic rat model 
Published as: Cetinkaya M, Alkan T, Ozyener F, Kafa IM, Kurt MA, Koksal N. Possible 
neuroprotective effects of magnesium sulphate and melatonin as both pre- and post- 
treatment in a neonatal hypoxic-ischemic rat model. Neonatology 2011; 99: 302-310 
Chapter 7 
100 
Abstract 
Background:  
Perinatal hypoxia-ischemia is a major cause of mortality and long-term neurological 
deficits.  
Objectives: 
The objective of this study was to compare the effects of two neuroprotective agents; 
magnesium sulfate and melatonin, administered alone or in combination, on brain infarct 
volume and TUNEL positivity in a neonatal hypoxic-ischemic (HI) rat model.  
Methods: 
After being anesthetized, 7-day-old pups (n = 80) underwent ischemia followed by 
exposure to hypoxia for 2 h. The pups were then divided equally and randomly into 4 
groups in order to receive the vehicle (saline, control group), magnesium sulfate, 
melatonin or a combination of magnesium sulfate and melatonin. Treatments were 
administered intraperitoneally three times; the first being just before ischemia, the 
second after hypoxia and the third 24 h after the second dose. The pups were sacrificed 
on postnatal day 10, their brains harvested and evaluated for infarct volume and neuronal 
apoptosis.  
Results: 
Percent infarcted brain volume was significantly reduced in pups receiving the drugs 
(either magnesium sulfate, melatonin or their combination) compared with those 
receiving the vehicle. In addition, TUNEL staining showed markedly reduced numbers of 
TUNEL-positive cells per unit area in the CA1, CA3 and dentate gyrus regions of the 
hippocampus and in the cortex. However, no statistically significant differences were 
found regarding percent infarcted brain volume and number of TUNEL-positive cells 
among the drug-treated groups.  
Conclusions: 
Magnesium sulfate and melatonin, two agents acting at different stages of HI brain 
damage, administered either alone or in combination, significantly reduced the percent 
infarcted brain volume and TUNEL positivity, suggesting that these agents may confer a 
possible benefit in the treatment of infants with HI encephalopathy. 
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Introduction 
Perinatal hypoxic-ischemic (HI) brain damage is a major cause of neonatal mortality and 
severe long-term neurological deficits [1, 2]. HI insult is an evolving process that is 
initiated during the insult and extends into the recovery period which is amenable to 
neuroprotective interventions [3, 4]. 
Magnesium sulfate (MgSO4) is an NMDA receptor antagonist which prevents 
excitotoxic calcium-induced injury through the noncompetitive voltage-dependent 
inhibition of NMDA receptor, which reduces calcium entry into the cell [5]. Although 
conflicting data exist on the beneficial effects of magnesium in experimental and clinical 
neonatal HI models [6-17], magnesium bears major advantages as a neuroprotective 
agent in that it can be safely administered to newborn infants with severe perinatal 
asphyxia [8, 9]. 
Melatonin is an endogenously produced indoleamine that is primarily formed by the 
pineal gland. It is a potent free radical scavenger which also acts as an indirect anti- 
oxidant [18, 19]. Melatonin has the ability of crossing all morphophysiological barriers 
and therefore is distributed widely in tissues, cells and subcellular compartments 
including the brain. Various studies reported that melatonin might act as a 
neuroprotective agent in neonatal hypoxia-ischemia [20-22] and, like MgSO4, melatonin 
has also been used clinically in neonates [23-25]. 
The aim of this study was to evaluate the effects of two neuroprotective agents, 
MgSO4 and melatonin, administered alone or in combination, on brain infarct area and 
TUNEL positivity with the expectation that these two agents might prevent apoptosis and 
provide possible neuroprotection in a neonatal HI rat model. 
Materials and Methods 
Animals 
All experimental protocols and procedures were reviewed by the Animal Care and Use 
Committee of the Uludag University, Faculty of Medicine, and all were in accordance with 
the guidelines provided by the Experimental Animal Laboratory. A modification of Levine-
Rice preparation was used as a model for perinatal HI brain injury as previously reported 
[26]. Dated pregnant Sprague-Dawley rats were housed in individual cages under 
standard conditions with free access to water and laboratory chow. The day of 
spontaneous vaginal delivery was considered postnatal day 1 (PND1) for the pups and a 
total of 80 offspring were reared with their dams until initiation of the experiments on 
day 7 (PND7), which coincides with 32- to 34-week-old preterm human brains [27]. Rat 
pups of either sex weighing 12-16 g were used in the experiments. 
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Study Design 
PND7 rats (n = 80) subjected to HI were divided equally and randomly into 4 groups and 
injected intraperitoneally with the following: vehicle (saline, 0.1 ml), magnesium sulfate 
(MgSO4, 275 mg/kg), melatonin (Mel, 20 mg/kg) and a combination of magnesium sulfate 
and melatonin (MgSO4 [275 mg/kg] + Mel [20 mg/kg]). Treatments were given three times; 
the first being just before ischemia, the second after hypoxia and the third 24 h after the 
second dose. Given the ability that they are able to cross the placenta [28,29], these agents 
were chosen in that they might provide neuroprotection at the initial stage of hypoxia-
ischemia. A schematic diagram of the experimental protocol is shown in figure 1. 
The dose of magnesium sulfate used in our study (275 mg/kg) was slightly higher than 
those used in previous experimental and clinical models of perinatal HI brain injury [7, 8, 
30]. Moreover, the dose of melatonin used in our study (20 mg/kg) was also within the 
upper range of melatonin doses which were reported to exhibit the greatest 
neuroprotection in previous studies (range 5-20 mg/kg) [20-22]. 
Melatonin (Sigma, St. Louis, Mo., USA) was dissolved freshly in absolute ethanol and 
liquidized in isotonic sodium chloride (0.9% NaCl) to obtain a final concentration of 1:10 
solution. 
Fig. 1. Experimental steps. 
Induction of HI Brain Injury and Treatment Groups 
Pups were anesthetized lightly with inhaled isoflurane, the right carotid artery was 
identified through a longitudinal neck incision, isolated from the nerve and vein, and 
permanent surgical ligation with 5.0 surgical silk plus coagulation of carotid artery was 
performed. The procedure was performed at room temperature (RT) and total time of 
surgery never exceeded 3 min. Animals exhibiting bleeding during ligation or respiratory 
arrest due to anesthesia were excluded from the study. After closure of the neck incision, 
pups were allowed to recover for 15 min and then returned to the nest temperature. 
Following a 2-hour period of nesting, the pups were placed into chambers partially 
submerged in a 37°C water bath to maintain a constant thermal environment and 
exposed to hypoxia with a warm humidified 8/92% oxygen/ nitrogen mixture for 2 h. 
Upon retrieval from the hypoxia chambers, the pups were allowed to recover for 72 h 
with their dams. Following deep isoflurane anesthesia, cardiac perfusion was performed 
with phosphate buffer solution containing 4% paraformaldehyde and brains were 
removed for evaluation of hypoxic damage and immunohistochemical analysis. 
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Measurement of Infarcted Volume 
Cardiac perfusion was performed 72 h after hypoxia (PND10). Pups were sacrificed 
immediately (n = 6, each group), and the brains were quickly removed, placed in ice-cold 
saline for 5 min, and 2 mm-thick coronal sections were obtained starting from the frontal 
pole using a neonatal brain matrix (Ted Pella, Calif., USA). The slices were incubated in 
2% 2,3,5-triphenyl-tetrazolium chloride (TTC, dissolved in saline) for 15 min at 37°C, fixed 
by immersion in 10% formalin, and images acquired with a Sony Cybershot DSC-F717 
digital camera attached to a Nikon 4S-2 Alphaphot light microscope. The white areas of 
infarct were quantified using image-analysis software (Scion Corporation version 4.02; 
NIH, Bethesda, Md., USA). The mean infarct volume per slice was obtained from the 
product of the average thickness of a slice (2 mm) and the area of infarct in that section. 
The percent infarcted volume was calculated with an indirect method described by 
Swanson et al. [31]. 
Immunohistochemistry 
Rats anesthetized by inhaled isoflurane were perfused with 4% paraformaldehyde in 0.1 
M phosphate-buffered saline (PBS) (pH 7.4). Brains were then removed, postfixed 
overnight, embedded in paraffin and 5-µm coronal sections were obtained using a 
microtome. Sections were chosen according to a systematic random sampling procedure, 
and then mounted onto poly-L-lysine-coated slides (Histobond adhesion slides, 
Marienfeld, Germany). An in situ cell death detection POD kit (Roche Molecular 
Biochemicals, 11684817910, Germany) was used for TUNEL technique (terminal 
deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate (dUTP)-biotin 
nick end-labeling) and the sections stained according to the manufacturer’s protocol for 
paraffin-embedded tissues. Briefly, sections were heated at 60°C for 45 min followed by 
washing in xylene and rehydration through graded series of alcohol (ethanol 100, 95, 80, 
70 and 40%) and washed in distilled water. They were then incubated in 20 µg/ml 
proteinase K solution (Roche Applied Sciences, 031158444001, Germany) for 20 min at 
RT and immersed in 3% H2O2 in methanol for 10 min. Permeabilization with Triton X 
(Sigma-Aldrich, T-9284, USA) for 10 min was performed on ice. The sections were then 
incubated with 35 µl TUNEL reaction mixture at 37°C in a humidified chamber for 1 h 
followed by converter-POD treatment at 37°C for 30 min. Diaminobenzidine 
tetrahydrochloride (DAB) (50 µl 1:9, diaminobenzidine/ metal concentrate: peroxidase 
buffer, Roche Applied Sciences, 11718096001, Germany) was used as the chromogene 
and the slides were counterstained with hematoxylin (Harris’s hematoxylin, Sigma-
Aldrich, HHS16, USA), and coverslipped (DPX mountant, Fluka, 44581, USA). 35 µl DNase 
(200 µg/ml DNase I (Roche Applied Sciences, Germany) in DNase buffer (40 mM Tris HCl, 
pH 7.6 10 mM NaCl, 6 mM MgCl2, 10 mM CaCl2) was used for positive controls for 10 min 
at 37°C, while alternate sections were incubated in the absence of a TUNEL reaction 
mixture for negative controls. TUNEL-positive cells with characteristic nuclear 
Chapter 7 
104 
morphological changes including chromatin condensation, hypersegmentation of nuclear 
chromatin and shrunken (pyknotic) appearance were counted using an ocular 
micrometer grid randomly on the CA1, CA3 and dentate gyrus (DG) areas of the 
hippocampus. 
Immunohistochemistry staining for caspase-3 was performed using the avidin biotin 
complex (ABC) technique. Sections were heated at 60°C for 1 h followed by washing in 
xylene and rehydration through graded series of alcohol (ethanol 100, 95, 80, 70 and 
40%) and washed in distilled water. They were then placed in 10 mM citrate buffer at pH 
6.0 and treated with 750 W in a microwave for 10 min for antigen retrieval and cooled 
for 20 min at RT. Slides were then immersed in 3% H2O2 for 10 min and incubated in 10% 
goat serum in Tris buffer (0.01 M Tris HCl, pH 7.4, 1 mM CaCl2, 1 mM MgCl2, 0.1% Triton 
X-100) for 30 min at RT. After blocking, slides were stained with caspase-3 (1:100;
Chemicon, AB3623-rabbit, USA) antibody which is diluted in same blocking buffer,
overnight at 4°C. Secondary antibody (biotinylated anti-rabbit IgG, Vectastain Elite ABC
Kit, USA) was applied for 1 h at RT. Sections were then treated with 100 µl of ABC
(Vectastain Elite ABC Kit) and finally visualized using DAB (50 µl 1:9, diamino- 
benzidine/metal concentrate : peroxidase buffer) and counter- stained with hematoxylin.
Cell Count 
A total of at least 200 cells counted in 7 fields were chosen randomly at x400 
magnification for evaluation of TUNEL-positive cells’ index with respect to their 
morphological characteristics. In addition, all positive cells for caspase-3 
immunoreactivity were counted at x200 magnification. 
Statistics 
Data regarding the ‘percent infarcted volume’ obtained by TTC staining were analyzed 
using ‘Kruskal-Wallis one-way ANOVA’ between groups. Further analysis between groups 
were made using the ‘Mann-Whitney U test’ if significant differences were found by 
ANOVA. TUNEL-positive cell counts were also analyzed using ‘Kruskal-Wallis one-way 
ANOVA’ and ‘Mann-Whitney U test’. Sigma-stat 3.0 and SPPS 16.0 programs were used 
for the statistical tests and significance assumed at 95% confidence (p < 0.05). 
Results 
Percent infarcted volume was significantly reduced following melatonin (18.39 ± 1.31), 
MgSO4 (18.81 ± 2.25) or melatonin + MgSO4 (14.66 ± 2.97) administration compared with 
that in control ischemic animals (42.45 ± 4.63). There was no statistically significant 
difference in terms of percent infarcted volume between the melatonin, MgSO4 and 
melatonin + MgSO4 treated groups (p >0.05) (fig. 2, 3). 
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TUNEL stain revealed markedly reduced numbers of TUNEL-positive cells in the CA1, 
CA3 and DG regions of the hippocampus in pups receiving the drugs (p<0.001). A similar 
reduction in TUNEL-positive cell count per unit area was also observed in the cortex of 
the melatonin (2.19 ± 0.13), MgSO4 (4.91 ± 0.44) and melatonin + MgSO4 (2.15 ± 0.25) 
treated groups compared with that in control ischemic animals (33.78 ± 1.75) (fig. 4-6). 
However, no statistically significant difference was found for TUNEL-positive cell count 
between the melatonin, MgSO4 and melatonin + MgSO4 treated groups (p>0.05). In 
addition, the number of caspase-3-positive cells was significantly lower in the drug-
treated groups compared with the control group (fig. 7, 8); again no significant difference 
was found among treated groups in terms of caspase-3 immunoreactivity. 
 
 
Fig. 2. TTC-stained coronal sections from each experimental group. 
 
 
Fig. 3. Percent infarcted volumes from brains of rat pups in each experimental group. * p ~ 0.05. 
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Fig. 4. TUNEL-positive cell count per unit area of cortex and hippocampus in each experimental group. * p ~ 
0.05. 
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Fig. 5. TUNEL staining in the hippocampus. 
Fig. 6. TUNEL staining in the cortex. 
Melatonin 
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Fig. 7. Caspase-3-positive cell count per unit area of cortex and hippocampus in each experimental group. * p ~ 
0.05. 
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Fig.8. Caspase-3 immunoreactivity in cortex and hippocampal areas of each group. 
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Discussion 
These data show that MgSO4 and melatonin, agents acting on different levels of the 
hypoxia-ischemia cascade, exhibit significant neuroprotection in a neonatal HI rat model 
by reducing the TUNEL-positive cell count and brain injury when administered either 
alone or in combination. However, there was no additive benefit from combination 
treatment beyond that observed after individual administration of either MgSO4 or 
melatonin. 
The studies that investigated the potential neuroprotective effect of magnesium have 
revealed conflicting data [3, 6-17]. MgSO4 given 1, 12 and 24 h after HI insult did not 
decrease the severity of delayed cerebral energy failure [12]. Similarly, MgSO4 treatment 
did not induce neuroprotection in several brain regions including hippocampus, 
cerebellum, cerebral cortex, caudate nucleus, thalamus and striatum [13]. In a study on 
lambs, repeated doses of MgSO4 given before and during hypoxia did not provide 
significant neuroprotection [16]. In contrast, discernible neuroprotective effects of 
MgSO4 have been demonstrated in other neonatal studies [7, 30, 32]. Turkyilmaz et al. 
[7] reported that MgSO4 (200 mg/kg/dose) administered before the HI insult reduced
apoptosis in the hippocampus in a neonatal HI rat model, while a similar dose given after
HI insult did not show any significant neuroprotective effect. Post-asphyxial MgSO4
treatment resulted in significant decreases in both the incidence of cyst formation and
the severity of neuronal loss in cerebral cortex and hippocampus [30]. Recently, MgSO4
administration after HI insult was reported to limit the neuronal damage and also
prevented the sensorimotor deficits and brain injury induced by hypoxia- ischemia [32].
In our study, MgSO4 given just before ischemia and after hypoxia significantly decreased
brain infarct volume and TUNEL-positive cell count in a rat model of neonatal HI brain
damage employing rat pups of 7 days of age (PND7) which coincides with 32- to 34-week-
old preterm human brain [27]. The conflicting results on the effects of magnesium in
experimental neonatal HI brain injury models may be associated with administration time 
and dose of the drug or, alternatively, with the design of studies.
The neuroprotective effect of magnesium was also evaluated clinically in infants with 
HI encephalopathy (HIE). Groenendaal et al. [11] first reported that MgSO4 did not have 
a positive effect on the electroencephalography patterns of asphyxiated term infants. 
However, postnatal MgSO4 infusion (250 mg/kg/dose for 6 h) for 3 days after hypoxia 
improved short-term outcomes of infants with severe birth asphyxia [8]. In addition, 
postnatal magnesium treatment decreased mortality and morbidity as well as it improved 
the neurodevelopmental out- come of infants with severe asphyxia [33]. Recently, 3 
doses of MgSO4 infusion after perinatal hypoxia resulted in improved neurological 
outcomes of infants with severe perinatal asphyxia [9]. The treatment regimen employed 
in the present study, i.e. administering three consecutive doses the first of which was 
given just before the HI insult, was derived from the above-mentioned previous studies 
[8, 9, 33]. 
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MgSO4 may induce systemic hypotension, especially at high doses [33, 34]. Levene et 
al. [34] reported that high dose (400 mg/kg) MgSO4 administration was associated with 
an increased risk of hypotension, whereas a lower dose (250 mg/kg) did not induce 
hypotension except in respiratory depression. Ichiba et al. [33] administered MgSO4 
infusion (250 mg/kg) in combination with dopamine infusion and reported no 
hypotension in infants with severe birth asphyxia. Therefore, caution is required in the 
administration of high doses of MgSO4 to avoid systemic hypotension. 
Melatonin was reported to be beneficial in neonatal HI brain damage [20]. Recently, 
melatonin, administered before and after hypoxia, was reported to exhibit a significant 
neuroprotective effect and also decrease behavioral problems and learning deficits at 
long-term follow-up [22]. In the present study, administration of melatonin resulted in a 
significant neuroprotective effect in a rat model of HI brain damage. A major advantage 
of melatonin is its wide and safe usage in neonates in clinical situations such as sepsis, 
bronchopulmonary dysplasia and asphyxia [23–25]. 
To our knowledge, the neuroprotective effect of melatonin as a part of combination 
therapy in a neonatal HI model has not yet been investigated. Therefore, there are no 
data about the effectiveness of melatonin as a combination therapy in hypoxia-ischemia. 
The results of the present study showed a significant neuroprotective effect of melatonin 
and MgSO4 combination therapy. In a transient global ischemia model, MgSO4 had 
neuroprotective effect only when it was combined with mild hypothermia [35]. It was 
also reported that post-ischemic combination treatment with 24-hour hypothermia and 
magnesium infusion was more effective in reducing CA1 neuronal death than either 
treatment used alone [36]. Consistently, that combined neuroprotective therapies might 
be necessary for increasing the therapeutic time window for protection and repair in 
neonatal HI brain damage studies was recently suggested [37]. In addition, in a recent 
review, Fatemi et al. [38] suggested that the best outcome might be achieved with a 
multimodal therapeutic approach such as a combination of glutamate receptor 
antagonists with antioxidants and hypothermia. Consistent with these suggestions, in the 
present study, combination of MgSO4 as an NMDA antagonist with melatonin exhibited a 
significant neuroprotective effect. However, this benefit was not superior to that 
observed after single therapies. Hagberg et al. [39] proposed that all stages of the HI 
cascade might cause mitochondrial stress which subsequently results in mitochondrial 
outer membrane permeabilization that leads to irreversible caspase- and non-caspase-
dependent cell death. This raises the possibility that MgSO4 and melatonin might have 
worked through a common pathway and, hence, did not provide any complimentary 
effect in our experimental setting. Therefore, future studies are warranted to evaluate 
the effectiveness of multimodal treatment models in neonatal HI brain damage. 
The experimental procedure in our study was designed in a way that it mimicked the 
clinical presentation of HIE and the treatments were given three times (the first being 
just before ischemia, the second after hypoxia and the third 24 h after the second dose). 
Inasmuch as the treatments were first given just before ischemia, data obtained in our 
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prophylaxis study might reflect a possible neuroprotective effect of MgSO4 and 
melatonin. Since these agents are capable of crossing the placenta [28, 29], they might 
confer benefit in the treatment of hypoxia- ischemia in the case that HIE is recognized in 
utero. Consistent with this suggestion, previous studies reported beneficial effects of 
either melatonin or MgSO4 in HIE when given prophylactically to mothers. In a recent 
study in a spiny mouse model, melatonin administered to mothers in late pregnancy as a 
prophylaxis treatment provided neuroprotection in pups subjected to birth asphyxia [29]. 
Similarly, maternal administration of melatonin within 1 h after an ischemic/oxidative 
episode was found to be preventive against cerebral damage in neonatal rats [40]. 
Zylinska et al. [28] reported that antenatal MgSO4 treatment might affect calcium 
homeostasis and antioxidant reserve in the erythrocytes of preterm infants. This might 
reflect the possible neuroprotective effect of agents crossing the placenta such as 
melatonin and MgSO4 in neonatal HI brain damage, suggesting that these agents could 
be administered to dams prophylactically if in utero hypoxia is suspected. 
However, the limitation of the present study is that our experimental procedure did 
not allow us to test whether administration of MgSO4 and melatonin following HI is 
preventive. Therefore, we are unable to suggest that treatment with these agents may 
also confer benefit in treatment of HIE in the case that HI is not determined in utero. 
Magnesium was shown to increase cerebral blood flow in humans and animals and was 
suggested to cause dilation of smaller arteries or collateral and/or anastomotic blood flow 
pathways [41]. Acute melatonin administration was suggested to diminish the 
hypoperfusion-induced cerebral ischemia by increasing the cerebrovascular dilatory capacity 
in rats [42]. Therefore, MgSO4 and/or melatonin might have exhibited a possible 
neuroprotective effect by improving cerebrovascular blood flow and anastomotic perfusion. 
In conclusion, both MgSO4 and melatonin, two agents acting at different stages of HI, 
used either alone or in combination, significantly decreased the percent infarcted area 
and TUNEL positivity in a neonatal HI rat model. However, the combination therapy did 
not show any superior neuroprotective effect compared with that observed after 
individual administration of either MgSO4 or melatonin. Although it would be premature 
to draw any strict parallels between the neuroprotective effect of combined MgSO4 and 
melatonin therapy in a rat model of HI brain injury and clinical treatment of hypoxia-
ischemia in infants, the data provided here render a valuable reference point for future 
clinical investigation and these two agents may be used in combination in the clinical 
treatment of infants with HIE. 
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Abstract. 
Purpose: 
The objective of this study was to compare the effects of two neuroprotective agents; 
melatonin, a free radical scavenger and topiramate, AMPA/kainate receptor antagonist, 
administered alone or in combination in neonatal hypoxic- ischemic model. 
Methods: 
After being anesthetized, 7-day-old pups underwent ischemia followed by exposure to 
hypoxia. The pups were divided into 4 groups in order to receive the vehicle, melatonin, 
topiramate and combination of topiramate and melatonin. These were administered 
intraperitoneally for three times; the ﬁrst before ischemia, the second after hypoxia and 
the third 24 hours after the second dose. After sacriﬁcation, infarct volume and apoptosis 
were evaluated. 
Results: 
Percent infarcted brain volume was signiﬁcantly reduced in rats which received drugs 
compared with those which received the vehicle. The number of TUNEL positive cells per 
unit area in hippocampus and cortex were markedly reduced in drug treated groups 
compared with control group. No signiﬁcant differences were found regarding percent 
infarcted brain volume and number of TUNEL positive cells among drug-treated groups. 
Conclusions: 
Melatonin and topiramate, administered either alone or in combination signiﬁcantly 
reduced the percent infarcted brain volume and number of TUNEL positive cells 
suggesting that these agents may confer beneﬁt in treatment of infants with hypoxic-
ischemic encephalopathy. 
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1. Introduction
Hypoxic-ischemic (HI) brain damage is a major cause of neurological morbidity and 
mortality in neonates and results with sequelae such as cerebral palsy, mental 
retardation, epilepsy and learning disabilities (Vannucci and Hagberg, 2004). Although 
several mechanisms have been proposed to cause perinatal brain damage, most 
important of them include excitotoxicity induced by glutamate, inﬂux of calcium Ca2+, 
production of free radicals and subsequent apoptosis and cell death (Jensen et al., 2003). 
The excessive glutamate release and overactivation of glutamate receptors contribute to 
the pathogenesis of HI brain injury. Three subtypes of ionotropic glutamate receptors 
namely, N-methyl-D-aspartate (NMDA) receptors, C-3-amino-hydroxy-5-methyl-4- 
isoxazole propionic acid (AMPA) receptors and kainate (KA) receptors are involved in HI 
process (Lu et al.,1996). Excitotoxic injury occurs secondary to glutamate-triggered Ca2+
inﬂux through NMDA channels, voltage-sensitive Ca2+ channels, and Ca2+-permeable 
AMPA/KA channels. Therefore, it was suggested that blocking these receptors might 
provide neuroprotective effects (Lee, Kim and Kim, 2000). Although, NMDA receptor 
antagonists such as MK801, magnesium, and memantine were shown to be 
neuroprotective in several animal models (Alkan et al., 2001; Turkyılmaz et al., 2002; 
Volbracht et al., 2006), there is growing recent recognition regarding the neuroprotective 
role of AMPA/KA antagonists such as topiramate on neonatal HI brain injury (Noh et al., 
2006; Schubert et al., 2005; Sfaello et al., 2005). 
Melatonin is an endogenously produced indoleamine which is primarily formed by the 
pineal gland in higher amount in adults than in neonates and is a potent free radical 
scavenger, and also an indirect antioxidant. Melatonin has the ability of distributing 
extensively in tissues, cells, subcellular compartments including brain since it crosses all 
morphophysiological barriers easily (Tan et al., 2005). A number of studies reported that 
melatonin could be used as a neuroprotective agent in neonatal HI brain injury (Carloni 
et al., 2008; Tutunculer et al., 2005; Welin et al., 2007). Topiramate, a well-tolerated and 
clinically widely-used antiepileptic drug provides neuroprotection by blocking AMPA/KA 
receptors and use-dependent sodium Na+ channel in developing rat brain without serious 
side effects. Current studies, though limited in number, reported the probable 
neuroprotective effects of topiramate in neonatal HI brain damage (Noh et al., 2006; 
Schubert et al., 2005; Sfaello et al., 2005). It was also suggested that topiramate exhibited 
protective activities on developing white matter by shielding cultured pre-
oligodendrocytes from AMPA/kainate receptor-mediated damage (Follett et al., 2004). 
Furthermore, topiramate was shown to be protective against hyperoxic brain injury in 
the developing brain (Kurul et al., 2009). 
It was reported that intervening one particular pathway would not completely 
prevent HI brain damage, therefore, using combination of drugs interfering at different 
levels of HI cascade was suggested to have a greater neuroprotective effect compared 
with a single therapy intended for a single pathway (Peeters and van Bel, 2001). 
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Therefore, we aimed to investigate the effects of two neuroprotective agents, having 
two different actions on HI cascade, topiramate as an antiglutamatergic agent and 
melatonin as a free radical scavenger, either solely or in combination in neonatal HI rat 
model. We expected that the combination would yield a greater therapeutic beneﬁt 
compared to that obtained with either agent alone. 
2. Materials and methods
2.1. Animals 
This study was performed in accordance with the guidelines provided by the 
Experimental Animal Laboratory and all experimental protocols and procedures were 
approved by the Animal Care and Use Committee of the Uludag University, Faculty of 
Medicine. A modiﬁed Levine-Rice preparation was used as a model for perinatal HI brain 
injury as previously reported (Vannucci and Vannucci, 1997). Dated pregnant Sprague-
Dawley rats were housed in individual cages under standard conditions with free access 
to water and laboratory chow. The day of spontaneous vaginal delivery was considered 
postnatal day 1 (PND1) for the pups and a total of 80 offsprings were reared with their 
dams until initiation of experiments on day 7 (PND7). Rat pups of either sex weighing 12-
16 g were used in the experiments. 
2.2. Study design 
PND7 rats (n=80) that were subjected to hypoxia- ischemia were divided randomly and 
equally into 4 groups and injected intraperitoneally (IP) with the following: vehicle saline, 
0.1 ml; melatonin (Mel, 20 mg/kg), topiramate (TPM, 30 mg/kg) and a combination of 
melatonin and topiramate [(Mel, 20 mg/kg) + (TPM, 30 mg/kg)]. Treatments were given 
three times; the ﬁrst being just before ischemia, the second after hypoxia and the third 
24 hours after the second dose. The schematic diagram of the experimental protocol is 
shown in Fig. 1. 
The dose of topiramate used in our study (30 mg/kg) was similar to those used in 
previous experimental models of neonatal HI brain injury (Follett et al., 2004; Liu et al., 
2004). Similarly, melatonin dose (20 mg/kg) was also within the upper range of melatonin 
doses which were reported to exhibit the greatest neuroprotection in previous studies 
(ranging 5 to 20 mg/kg) (Carloni et al., 2008; Tutunculer et al., 2005; Welin et al., 2007). 
Topiramate (Sigma-Aldrich, USA) was provided as a powder and a solution was 
prepared by dissolving in phosphate buffered saline (PBS) according to the instructions 
of the manufacturer as the ﬁnal solution included a concentration of topiramate was 30 
mg/kg per microliter. Melatonin (Sigma, St. Louis, MO) was dissolved freshly in absolute 
ethanol and liquidized in isotonic sodium chloride (0.9% NaCl) to obtain a ﬁnal 
concentration of 1:10 solution form. 
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Fig. 1.  Schematic diagram of experimental steps. 
2.3. Induction of HI brain injury and treatment groups 
Pups were anesthetized lightly with inhaled isoﬂurane, the right carotid artery was 
accessed through a longitudinal neck incision, isolated from the nerve and vein, and 
permanent surgical ligation with 5.0 surgical silk plus coagulation of carotid artery was 
performed. This procedure lasted no longer than 3 minutes and it was performed at room 
temperature. Animals exhibiting bleeding during ligation or respiratory arrest due to 
anesthesia were excluded from the study. After closure of the neck incision, pups were 
allowed to recover for 15 minutes under a heating lamp and then returned to the nest 
temperature. Following a 2 hour period of nesting, the pups were placed into chambers 
that were partially submerged in a 37◦C water bath to maintain a constant thermal 
environment and exposed to hypoxia with warm humidiﬁed 8%/92% oxygen/nitrogen 
mixture for 2 hours. Upon retrieval from the hypoxia chambers, the pups were allowed 
to recover for 72 h with their dams. Following deep isoﬂurane anesthesia, cardiac 
perfusion was performed with phosphate buffer solution containing 4% 
paraformaldehyde and their brains were removed for evaluation of hypoxic damage and 
immunohistochemical analysis. 
2.4. Measurement of infarcted volume 
Infarct volume was evaluated as previously described (Vannucci et al., 1999). Cardiac 
perfusion was performed 72 hours after hypoxia (PND10). Pups were sacriﬁced 
immediately (n = 6, each group), and the brains were quickly removed, placed in ice-cold 
saline for 5 min, and 2 mm-thick coronal sections were obtained starting from the frontal 
pole using neonatal brain matrix (Ted Pella, CA, USA). The slices were incubated in 2% 2-
, 3-, 5-triphenyl-tetrazolium chloride (TTC, dissolved in saline) for 15 min at 37◦C, ﬁxed by 
immersion in 10% formalin, and images acquired with Sony Cybershot DSC-F717 digital 
camera attached to a Nikon 4S-2 Alphaphot light microscope. The white areas of infarct 
were quantiﬁed using an image-analysis software (Scion Corporation version 4.02, NIH, 
Bethesda, MD, USA). The mean infarct volume per slice was obtained from the product 
of the average thickness of a slice (2 mm) and the area of infarct in that section. 
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2.5. Immunohistochemistry 
Rats were anesthetized by inhaled isoﬂurane and perfused with 4% paraformaldehyde in 
0.1 M PBS (pH 7.4). Their brains were then removed, post-ﬁxed overnight, embedded in 
parafﬁn and 5 µm coronal sections were obtained using a microtome. Sections were 
chosen according to systematic random sampling procedure, which were then mounted 
onto poly-L-lysine-coated slides (Histobond adhesion slides, Marienfeld, Germany). In situ 
cell death detection POD kit (Roche Molecular Bochemicals, 11684817910, Germany) 
was used for TUNEL technique [terminal deoxynucleotidyl transferase (TdT)- mediated 
deoxyuridine triphosphate (dUTP)-biotin nick end-labeling] and the sections stained 
according to the manufacturer’s protocol for parafﬁn embedded tissues. Brieﬂy, sections 
were heated at 60◦C for 45 min followed by washing in xylene and rehydration through 
graded series of alcohol (ethanol; 100%, 95%, 80%, 70%, 40%) and washed in distilled 
water. They were then incubated in 20 µg/mL proteinase K solution (Roche Applied 
Sciences, 031158444001, Germany) for 20 min at room temperature (RT), immersed in 
3% H2O2 in methanol for 10 minutes. Permeabilization with Triton X (Sigma-Aldrich, T-
9284, USA) for 10 min was performed on ice. The sections were then incubated with 35 
µl TUNEL reaction mixture at  37◦C  in  a  humidiﬁed  chamber  for  1  hour  followed by 
converter-POD treatment at 37◦C for 30 min. Diamino benzidine tetrahydrochlioride 
(DAB) (50 µl 1:9,  diaminobenzidine/metal  concentrate:  peroxidase buffer, Roche 
Applied Sciences, 11718096001, Germany) was used as the chromogene and the slides 
were counterstained with hematoxylin (Harris’s hematoxylin, Sigma-Aldrich, HHS16, 
USA), and coverslipped (DPX mountant, Fluka, 44581, USA). 35 µl DNase (200 µg/ml 
DNase I (Roche Applied Sciences, Germany) in DNase buffer (40 mM Tris HCl, pH 7.6 10 
mM NaCl, 6 mM MgCl2, 10 mMCaCl2) was used for positive controls for 10 min at 37◦C, 
while, alternate sections were incubated in the absence of TUNEL reaction mixture for 
negative controls. TUNEL positive cells with characteristic nuclear morphological changes 
including chromatin condensation, hypersegmentation of nuclear chromatin and 
shrunken (pyknotic) appearance were counted on using an ocular micrometer grid 
randomly on the CA1, CA3 and dentate gyrus (DG) areas of hippocampus and cerebral 
cortex (especially parietal cortex). 
Immunohistochemistry staining for caspase-3 was performed using the Avidin Biotin 
Complex (ABC) technique. Sections were heated at 60◦C for 1 hr followed by washing in 
xylene and rehydration through graded series of alcohol (ethanol; 100%, 95%, 80%, 70%, 
40%) and washed in distilled water. They were then placed in 10 mM citrate buffer at pH 
6.0 and treated with 750 W microwave for 10 min for antigen retrieval and cooled for 20 
min at RT. Then slides were immersed in 3% H2O2 for 10 minutes and incubated in 10% 
goat serum in tris buffer (0.01 mM tris HCl, pH 7.4, 1 mM CaCl2, 1 mM MgCl2, % 0.1 Triton 
X-100) for 30 min at RT. After blocking, slides were stained with Caspase-3 (1: 100;
Chemicon, AB3623-rabbit, USA) antibody which is diluted in same blocking buffer,
overnight at 4oC. Secondary antibody (biotinylated anti-rabbit IgG, Vectastain Elite ABC
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Kit, USA) was applied for 1 hr at RT. Sections were then treated with 100 µl of avidine 
biotin complex (ABC Vectastain Elite ABC Kit, USA) and ﬁnally visualized using DAB (50 µl 
1:9, diaminobenzidine/metal concentrate: peroxidase buffer) and counterstained with 
hematoxylin. 
2.6. Cell count 
A total of at least 200 cells counted in 7 ﬁelds were chosen randomly at 400× 
magniﬁcation for evaluation of TUNEL positive cells’ index with respect to their 
morphological characteristics. In addition, all positive cells for Caspase-3 
immunoreactivity were counted at 200x magniﬁcation (Kafa et al., 2010). 
2.7. Statistical analysis 
Data regarding the “percent infarcted volume” obtained by TTC staining were analyzed 
using “Kruskal–Wallis one-way ANOVA” between groups (n = 12 for each group). Further 
analysis between groups were made using “Mann-Whitney U Test” if signiﬁcant 
differences were found by ANOVA. TUNEL-positive cell counts were also analyzed using 
“Kruskal-Wallis one-way ANOVA” and “Mann- Whitney U Test”. Sigma-stat 3.0 and SPPS 
16.0 programs were used for the statistical tests and signiﬁcance assumed at 95% 
conﬁdence (p < 0.05). 
3. Results
Melatonin (17.4 ± 5.6, p<0.001), Topiramate (25.4 ± 3.0, p<0.01) and Melatonin + 
Topiramate (14.0 ± 5.7, p<0.001) administration signiﬁcantly reduced “the percent 
infarcted volume”, compared to control ischemic animals (49.1 ± 7.6) (Figs. 2, 3).  There 
was no statistically signiﬁcant difference between Melatonin, Topiramate and Melatonin 
+ Topiramate treated groups (p>0.05). TUNEL stain showed markedly reduced numbers
of TUNEL positive cells at CA1, CA3 and DG areas of hippocampus at drug treated groups
(p<0.001). The mean number of TUNEL positive cells at CA1, CA3 and DG areas of
hippocampus at control group were 33.2 ± 1.9, 26.7 ± 2.0, 18.9 ± 3.4, whereas these were
signiﬁcantly  reduced  as  2.4 ± 0.7,  1.3 ± 0.1, 4.3 ± 1.1 in Melatonin group, 1.6 ± 0.2, 1.4
± 0.2, ± 0.1 in Topiramate group and 1.5 ± 0.3, 1.3 ± 0.2, ± 0.2 in Melatonin + Topiramate
group, respectively (all p<0.001, in study groups compared with control group). No
statistically signiﬁcant difference was found for TUNEL-positive cell count between drug
treated groups (p>0.05) (Fig. 4). There were also small number of neurons stained
positively in cortex at Melatonin, Topiramate and Melatonin + Topiramate groups (4.91
± 0.44, 2.19 ± 0.13, 2.15 ± 0.25, respectively) compared to control ischemic animals
(33.78 ± 1.25) at unit area (p<0.001). However, there was no signiﬁcant difference
between three treatment groups (p>0.05) (Fig. 5). In addition, the number of caspase-3
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positive cells was signiﬁcantly lower in drug treated groups compared with the control 
group (p<0.001) (Figs. 6 and 7); again no signiﬁcant difference was found among treated 
groups in terms of caspase-3 immunoreactivity (p>0.05). 
 
 
Fig. 2. Percent infarcted volume of brains of pups in each group. 
*p < 0.05 compared to control. 
 
 
Fig. 3. Figure showing TTC stained coronal sections from each experimental group with representative images 
of TUNEL staining in hippocampus.  
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Fig. 4. TUNEL positive cell count per unit area of cortex and hippocampus in each experimental group. *p < 0.05 
compared with control group. 
Fig. 5. Representative images of TUNEL staining in cortex for each group. 
Chapter 8 
124 
Fig. 6. Caspase-3 positive cell count per unit area of cortex and hippocampus in each experimental group. *p < 
0.05 compared with control group. 
Fig. 7.  Caspase-3 immunoreactivity in cortex and hippocampal areas of each group. 
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5. Discussion
These data indicate that both melatonin and topiramate, two different agents acting on 
different levels of HI cascade signiﬁcantly reduced the percent infarcted volume and 
apoptosis after either single or combined administration in neonatal HI rat model. 
Although the reduction in infarct volume was greater after the combined therapy 
compared with the single use of these agents, the difference was not statistically 
signiﬁcant. Topiramate has been approved to be used as an antiepileptic agent in children 
older than 2 years of age and was recently suggested that it might provide 
neuroprotection by blocking AMPA/KA receptors in neonatal HI brain injury (Glauser, 
1999; Noh et al., 2006; Schubert et al., 2005; Sfaello et al., 2005). Noh et al. (2006) 
reported that IP or peroral topiramate pre-treatment signiﬁcantly reduced the brain 
damage and subsequent cognitive impairment induced by hypoxia- ischemia in neonatal 
rats. Similarly, Sfaello et al. (2005) found that topiramate had dose-dependent and long 
lasting neuroprotection in the excitotoxic newborn mouse model and suggested that 
topiramate provided neuroprotection by increasing survival of pre-oligodendrocytes, 
decreasing neuronal apoptosis, inhibiting microglial activation and astrogliosis, and 
decreasing seizure activity. Lately, topiramate was found to be neuroprotective in 
neonatal hyperoxic brain injury model, too (Kurul et al., 2009). In this study, we found 
that topiramate administered just before ischemia and right after hypoxia signiﬁcantly 
decreased brain infarct volume and neuronal apoptosis.  
Free oxygen radicals generated during and after hypoxia-ischemia also play an 
important role in the pathogenesis of neonatal HI brain injury. Since melatonin could 
cross all morphophysiological barriers, as a potent free radical scavenger and an indirect 
antioxidant, it was presumed to be a neuroprotective agent in neonatal HI brain damage 
(Carloni et al., 2008; Tutunculer et al., 2005; Welin et al., 2007). Melatonin also 
signiﬁcantly reduced inﬂammation and cell death following fetal umbilical cord occlusion 
(Welin et al., 2007). Recently, melatonin, administered before and after hypoxia, 
exhibited signiﬁcant neuroprotective effect and lessened behavioral problems and 
learning deﬁcits in long-term follow-up (Carloni et al., 2008). In adult rats, melatonin that 
was given after ischemia was reported to lead long-term preservation of both the neural 
substrate, and the capability for integration of spatial learning and memory, mainly 
dependent on a normal hippocampal functioning (Letechipıa-Vallejo et al., 2007). In the 
present study, administration of melatonin demonstrated a signiﬁcant neuroprotective 
effect in a neonatal rat model of HI brain damage. 
Combination of drugs intervening at different levels of the HI cascade instead of a 
single therapy aiming at a single pathway was suggested to have a greater 
neuroprotective effect (Peeters and van Bel, 2001). In a recent review, it was proposed 
that the best outcome in neonatal HI brain injury might be achieved with a multimodal 
therapeutic approach such as a combination of glutamate receptor antagonists with 
antioxidants and hypothermia (Fatemi et al., 2009). Subsequently, it was also suggested 
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that combined neuroprotective therapies might be necessary for increasing the 
therapeutic time window for protection and repair in neonatal HI brain damage (Gonzalez 
and Ferriero, 2009). Therefore, we aimed to evaluate the neuroprotective effects of a 
combination of melatonin and topiramate in neonatal HI brain injury. 
In our previous study, we investigated the neuroprotective effect of melatonin as part 
of a combination therapy in neonatal HI rat model (Cetinkaya et al., 2011). That study 
showed that magnesium sulfate and melatonin, two agents also acting at different stages 
of HI brain damage, administered either alone or in combination signiﬁcantly reduced the 
percent infarcted brain volume and TUNEL positivity. It was, therefore, suggested that 
these agents might confer possible beneﬁt in treatment of infants with HI 
encephalopathy (HIE). Similarly, the results of the present study show a signiﬁcant 
neuroprotective effect of melatonin and topiramate combination therapy. 
Limited number of studies evaluated the neuroprotective efﬁcacy of topiramate in 
combination with other agents in neonatal HI brain injury. Early post-HI administration of 
topiramate in combination with hypothermia resulted with sustained reduction in brain 
injury and improved functional performance in a neonatal rat stroke model (Liu et al., 
2004). Recently, combination of memantine, a non-competitive NMDA receptor blocker 
with topiramate also safely and effectively reduced brain damage compared with each 
agents given alone in neonatal HI brain injury (Liu et al., 2009). In a recent study, oral 
topiramate (either low or high dose) in combination with hypothermia (either mild or 
deep) showed similar neuroprotective effects and the authors concluded that oral 
topimarate could be used clinically in neonates with asphyxia in order to beneﬁt its 
possible additive neuroprotective effect (Filippi et al., 2010). Although our results are in 
agreement with these data, however, the neuroprotective effect of combination therapy 
was not statistically different from that exhibited by each agent on its own. This 
insigniﬁcance could have resulted from administration time and dose of the drug or, 
alternatively, with the design of studies. Recent evidence suggested that therapies might 
be combined to enhance the protective and reperative processes and administration 
time seemed to be the crucial point for increasing the success of the combined therapies. 
Also, as the injury might evolve for a long period with different mechanistic phases, 
combined therapies aiming at these temporally evolving targets might also be 
administered over long periods of time (Gonzalez and Ferriero, 2009). Therefore, the 
insigniﬁcance of combined therapy in our study might be associated with the relatively 
short duration of therapies. It might also be related with the administration time of both 
drugs. Rather than administering both agents simultaneously, as we did, it could be 
possible to achieve signiﬁcant results by giving topiramate ﬁrst as an antiglutamatergic 
agent, and then melatonin as an antioxidant agent. 
In this study, we especially evaluated these two agents as both melatonin and 
topiramate could be used in neonates clinically. Melatonin was used safely and efﬁciently 
in treatment of sepsis, bronchopulmonary dysplasia and asphyxia in newborn infants 
(Fulia et al., 2001; Gitto et al., 2001; Gitto et al., 2004). Topiramate was also started to be 
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choice of therapy both in infants with neonatal seizures and neonatal HIE (Filippi et al., 
2010; Silverstein and Ferriero, 2008). Therefore, the results of this study seem to support 
the idea of using these agents for the clinical treatment of infants with HIE. 
The limitation of this research was that we could not evaluate other indices of HI injury 
such as cellular regeneration and inﬂammation. Moreover, due to technical 
shortcomings, neuroprotective effects of both agents were evaluated for a brief period 
of time. Consequently, we were unable to observe possible long term neuroprotective 
effects of melatonin and topiramate. Therefore, we suggest that long term behavioral 
studies are also warranted to assess the potential synergistic effect of the combined 
therapies. 
In conclusion, both melatonin and topiramate, two agents acting on different stages 
of hypoxia-ischemia, used either alone or in combination, signiﬁcantly decreased the 
percent infarcted area, apoptotic cell death in neonatal HI rat model. Although the 
combination therapy had a superior effect on decreasing percent infracted area and 
apoptotic cell count compared with single use of these two agents, this effect was not 
significantly superior to mono therapies. Therefore, it would be reasonable to investigate 
the different doses and different application times of these agents as combination 
therapy for a signiﬁcantly and more effective neuroprotection. The data provided here 
may render a valuable reference source for future clinical investigation and these two 
agents may be used safely in combination for clinical treatment of infants with HIE. 
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In this thesis, we tested different approaches to prevent and or treat severe neonatal 
diseases. We studied medical interventions that exploit different mechanisms of 
multifactorial neonatal conditions in appropriate animal models. In particular, we tested 
not only postnatal interventions but also prenatal interventions since many neonatal 
diseases have an antenatal origin that may be aggravated postnatally (Gantert et al., 
2010). Therefore, we hypothesize that novel appropriate perinatal interventions for 
prevention and/or treatment of severe morbidities with multifactorial pathogenesis in 
experimental models may be translated into clinical experience in future. This may also 
lead to a decrease in the frequency and severity of these morbidities. 
BPD is a good example for the complexity of perinatal disease. BPD has a multifactorial 
etiology including preterm birth, lower gestational age and birth weight, need for 
supplemental oxygen and ventilator support, oxygen toxicity, decreased host antioxidant 
defenses, patent ductus arteriosus, and pre- and postnatal infections. In addition to the 
increase in the number of surviving preterm infants associated with the improvement in 
neonatal care, the incidence of BPD did not show a significant decrease (Stoll et al., 2015). 
This may also be associated with the lack of effective prevention and treatment 
interventions (Poets and Lorenz, 2018). Although postnatal steroids, caffeine, 
azithromycin, and vitamin A were reported to confer benefit for prevention of BPD in 
ELBW infants, none of them provides cure due to the multifactorial pathogenesis of the 
disease (Poets and Lorenz, 2018). Because postnatal steroids have significant 
neurological adverse effects for this high-risk patient population, newer strategies and 
pharmacological approaches are required in order to decrease BPD incidence and 
severity without induction of comorbidities (Jensen et al., 2015). 
Role of epigenetic mechanisms in development of BPD 
Epigenetics can be defined as the partially heritable changes in gene function that occur 
without any change in deoxyribonucleic acid (DNA) sequence through changes in 
chromatin structure (Li et al., 2007). DNA methylation, histone modification and gene 
silencing by non-coding RNAs constitute the main epigenetic modifications (Figure 1) 
(Fonseca et al., 2018).  These epigenetic mechanisms were suggested to play a major role 
in the susceptibility to both the pathogenesis and to the progression of several 
inflammatory respiratory diseases (Barnes, 2009). Epigenetic mechanisms were reported 
to be influenced by specific genetic polymorphisms, nutritional effects, inflammation, 
exposure to toxins and ventilator treatments in critically ill infants and were suggested to 
have profound effects on lung development that contribute to BPD development (Merritt 
et al., 2012). 
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Figure 1. Major epigenetic modifications altering gene expression via multiple mechanisms (adapted from 
Fonseca et al., 2018). 
 
Several triggers that promote transcription of pro-inflammatory cytokines (Tratter 
and Archer, 2007) can maintain chronic inflammation, which is the hallmark of hyperoxic 
lung injury. Transcription factors target gene transcription after activation and recruit 
transcriptional co-activators and chromatin-remodeling enzymes that allow subsequent 
inflammatory gene expression (Tratter and Archer, 2007). Therefore, inflammatory lung 
diseases were reported to be characterized by increased expression of several 
inflammatory genes that have been regulated by pro-inflammatory transcription factors 
(Adcock, 2005). Changes in histone acetylation are involved in induction of pro- 
inflammatory genes in human lung cells. Histone acetyltransferases (HATs) are expressed 
and activated in an abnormal fashion in inflammatory diseases and, histone deacetylase 
(HDAC) inhibitors show anti-inflammatory effects (Barnes et al.,2005). As chronic 
inflammation alters HAT/HDAC ratio and results in histone hypoacetylation, HDAC 
inhibitors were suggested to change the acetylation status of histones in order to prevent 
these changes (Ito et al., 2007). 
Although this association between epigenetic mechanism and inflammation was well 
established in the pathogenesis of some adult inflammatory lung diseases including 
asthma and chronic obstructive lung disease, there is very limited data about this topic in 
neonatal diseases (Barnes, 2009; Barnes et al., 2005; Ito et al., 2007). The first clinical 
study to evaluate the role of molecular signatures in development of BPD in ELBW infants 
was designed by Cohen et al. (Cohen et al., 2007). This study showed that infants who 
subsequently developed BPD had distinct signatures involving chromatin remodeling and 
histone acetylation in umbilical cord samples of infants. The authors concluded that 
newer therapeutic modalities might be developed for BPD as chromatin-remodeling 
pathways appeared to be differentially regulated in umbilical cord tissues of the 
subsequently BPD-developed preterm infants (Cohen et al., 2007). Therefore, the idea of 
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using HDAC inhibitors for prevention of BPD development was suggested as a potential 
therapy by some authors in the presence of studies showing the role of epigenetic 
mechanisms, especially histone acetylation/deacetylation changes in BPD development 
(Cohen et al., 2007; Merritt et al., 2009). In addition, reduced lung and brain injury was 
reported in preterm lambs treated with HDAC inhibitors during mechanical ventilation. 
In this experimental study, histone deacetylation inhibition significantly improved 
alveolar formation in the lung associated with changes in specific histone modifications. 
Herein, mechanical ventilation was suggested to cause epigenetic alterations that can be 
reversed pharmacologically with therapeutic benefit (Hamvas et al., 2014). In the 
presence of all these data suggesting the possible role of epigenetic mechanisms in 
development of neonatal lung disease, we evaluated the effect of a HDAC inhibitor for 
prevention of BPD in a rodent model.  Valproic acid (VPA) is a class I and II HDAC inhibitor 
that is clinically used as an anti- epileptic and mood-stabilizing agent. VPA has also anti-
inflammatory properties (Kim et al., 2007). Therefore, we tested the hypothesis that 
epigenetic mechanisms including histone acetylation-deacetylation process might play an 
important role in development of BPD. To this end, we used a neonatal rat model of 
hyperoxic lung injury in which we evaluated the efficacy of valproic acid as an HDAC 
inhibitor. VPA treatment had an effect on many aspects of inflammation but also 
significantly improved weight gain.   
The effects on the lung were improvement of histopathologic grade and radial 
alveolar count and the expression of lamellar body membrane protein, while it decreased 
the number of TUNEL (+) cells and active Caspase-3 expression in the rat pups exposed 
to hyperoxia. Expressions of TGFβ3 and phospho-SMAD2 proteins and levels of tissue 
proinflammatory cytokines as well as lipid peroxidation biomarkers were reduced, while 
anti-oxidative enzyme activities were enhanced by VPA treatment. VPA administration 
also reduced HDAC activity while increasing acetylated H3 and H4 protein expressions. 
VPA treatment improved alveolarization, reduced fibrosis and inflammation, enhanced 
antioxidant activity, all of which suggested the inhibitory action of VPA on HDAC activity. 
In conclusion, we reported that VPA treatment might be a new therapeutic strategy for 
prevention of BPD by ameliorating lung damage through HDAC inhibition (Cetinkaya et 
al., 2015). Although VPA has been used for treatment of refractory neonatal convulsions, 
it may be associated with cognitive deficits, progressive hyperammonemia, cerebral 
edema and diminished level of consciousness (Unal et al., 2007). Therefore, more 
experimental and clinical data about the safety of VPA treatment are required before the 
clinical usage in neonates. As a result, we suggest that more experimental and clinical 
studies evaluating the role of epigenetic mechanisms and newer therapeutic agents 
acting on these pathways are required to support our findings. 
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CDP-choline for prevention of BPD 
Another drug-based approach to prevent BPD might be to influence the composition of 
the alveolar membrane. Cytidine 5′-diphosphocholine (CDP-choline), composed of 
cytidine and choline linked by a diphosphate bridge, is an endogenous intermediate in 
the synthesis of the major membrane phospholipid, phosphatidylcholine (PC). PC 
constitutes the most important phospholipid, accounting for 70-85% of the total 
surfactant phospholipids (Adibhatla et al., 2005; Zimmermann et al., 2005). In preterm 
infants with evolving BPD, some persisting surfactant abnormalities including an ongoing 
quantitative deficiency in surfactant components, decreased function of endogenous 
surfactant, and increased surfactant turnover were established. Therefore, to investigate 
the effects of surfactant replacement on BPD development, surfactant was administered 
in preterm infants still on mechanical ventilation for >1 weeks of life. As a result, decrease 
in FiO2 requirement, transient improvement in oxygenation, and increase in survival 
without BPD were all reported (Laughon et al., 2009; Merrill et al., 2011). However, no 
study evaluated the role of CDP-choline for prevention of BPD as primary endpoint. We 
therefore tested the hypothesis that exogenous administration of CDP-choline, an 
endogenous intermediate in the synthesis of the major surfactant component 
phosphatidylcholine, might be protective against hyperoxic lung injury in a neonatal rat 
model. In this experimental study, CDP-choline treatment significantly reduced 
hyperoxia-induced severe lung damage. Radial alveolar count and expression of lamellar 
body membrane protein were significantly recovered, and the number of apoptotic cells, 
active caspase-3 expression, and tissue proinflammatory cytokine levels were decreased 
by CDP-choline administration. Lung tissue and BAL phospholipid contents also showed 
significant increases after CDP-choline therapy. Therefore, this study suggested for the 
first time that CDP-choline should be a novel therapeutic option for the prevention of 
BPD (Cetinkaya et al., 2013). This drug may be easily tested in clinical trials since it was 
previously clinically used for treatment of RDS in preterm infants (Colombo et al., 1976; 
Valls i Soler et al., 1988). 
As stated above, we suggest that newer therapies acting on different stages and 
mechanisms of BPD development, such as VPA and CDP-choline may be promising for 
future. However, more experimental and especially clinical studies are required to 
support our findings and facilitate the transmission of our experimental data on clinical 
usage. 
New strategies for prevention of NEC 
NEC is the most frequent and devastating gastrointestinal disease in preterm infants. It 
has a complex and multifactorial pathogenesis including intestinal immaturity associated 
with prematurity, formula feeding, abnormal intestinal microbial colonization, hypoxia- 
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ischemia in the gut, and an excessive inflammatory response (Cassir et al., 2016). NEC 
was suggested to develop as a consequence of intestinal hyper-responsiveness to 
microbial ligands that initiates a cascade of inflammatory pathway (Hodzic et al., 2017). 
The intestinal epithelium maintains barrier integrity and provides a defense layer against 
pathogens (Ramanan and Cadwell, 2016). PC is the major lipid of GI mucus layer that 
establishes a protective surface and plays a key role in mucosal defense. Because 
defective PC layers were suggested to contribute to the development of inflammation 
and because NEC patients show significant disruption in the intestinal epithelium, we 
evaluated the cytoprotective effect of CDP-choline for treatment of NEC in a rat model 
(Cetinkaya et al., 2013; Hodzic et al., 2017; Stremmel et al., 2010). In this experimental 
study, CDP-choline administered for 3 days significantly ameliorated intestinal injury, 
decreased inflammation and apoptosis, and increased intestinal tissue phospholipid 
levels. It also decreased lipid peroxidation and improved antioxidant status. This study 
showed the important role of phospholipids and PC in the maintenance and protection 
of gastrointestinal mucosa in NEC (Cetinkaya et al., 2013). We therefore suggested, for 
the first time, that CDP-choline is preventive against NEC development and might be 
offered as a novel therapeutic option for prevention of NEC through amelioration of 
disruption in GI mucosa and epithelium. 
The combination of anti-oxidant and anti-inflammatory treatment in 
necrotizing enterocolitis 
Excessive inflammation is an important factor in the pathogenesis of NEC and animal 
studies established the role of several inflammatory mediators and oxidative stress 
resulting with the subsequent apoptosis and tissue necrosis (De Plaen, 2013). The 
reactive oxygen species and free radicals were also suggested to result with disruption of 
gut barrier as an important factor in the multifactorial pathogenesis. In addition, it is well 
known that premature infants have immature antioxidant defense systems (Marseglia et 
al., 2015; Perrone et al, 2014). Therefore, the efficacy of potential anti-inflammatory 
therapies was evaluated for limiting this inflammatory cascade in NEC. To date, only 
breast milk and probiotics were suggested to have potential anti-inflammatory properties 
for prevention of NEC (Gupta and Paria, 2016). As mentioned above, CDP-choline showed 
preventive effects by decreasing inflammation in a neonatal NEC model (Cetinkaya et al, 
2013). All these data suggested that anti-inflammatory interventions might be beneficial 
for the prevention of NEC. However, as there is no single effective treatment strategy 
against NEC, newer therapeutic options are required to decrease the incidence of this 
multifactorial disease. Because combination therapies that interfere with different stages 
of pathogenesis showed beneficial effects in neonatal morbidities including HIE, we 
tested in a neonatal experimental NEC model the hypothesis that the combination of an 
anti-oxidant, cytoprotective agent with an anti-inflammatory one might be protective 
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(Cekmez et al, 2013). In this research, we evaluated the effect of melatonin and 
prostaglandin E1 combination for the prevention of NEC. Melatonin is an effective potent 
antioxidant and free radical scavenger. It also has the capability to modulate 
inflammation. Misoprostol, a prostaglandin E1 analog, has a cytoprotective effect on 
intestinal mucosa (Davies et al., 2001). In addition, it also reduces inflammation and tissue 
injury. Therefore, we investigated the efficacy of either single and combination therapies 
of melatonin and misoprostol in a neonatal rat NEC model. The combination therapy 
exerted better protective effect compared with single administration of these agents. 
This was the first study that showed the preventive effect of combination therapy acting 
on different stages of NEC. Hence, this study may lead to evaluation of other combination 
therapies for prevention and/or treatment of NEC in future. 
Therapies targeting epigenetic mechanisms in hypoxic-ischemic 
encephalopathy 
Perinatal hypoxic-ischemic (HI) brain injury is an important cause of mortality and adverse 
neurological outcomes in term and near term infants. Fetal ischemia and hypoxia lead to 
activation of ion channels, glutamate release, activation of several enzymes, formation of 
free radicals, inflammation, and mitochondrial damage resulting with necrosis and 
apoptosis (McLean and Ferriero, 2004). During this HI brain injury cascade, a therapeutic 
window has been defined that range until 6 hours of life where neuroprotective agents 
can confer benefit to reduce either mortality or adverse neurological consequences. 
Although, the only established therapy for neuroprotection in term and near term infants 
is hypothermia, approximately 50% of affected infants still die or suffer from long-term 
neurological adverse outcomes (Jacobs et al., 2013). Therefore, newer strategies are 
required to decline the adverse outcomes associated with HI brain injury. However, it is 
important to elucidate the potentially harmful molecular pathways and newer 
neuroprotective agents that have capability to inhibit these destructive mechanisms (Bel 
and Groenendaal, 2016). For this purpose, we aimed to evaluate the possible epigenetic 
effect of uridine in a neonatal HI brain injury model in rats. Uridine, the principal 
circulating pyrimidine nucleoside and precursor of brain membrane phospholipids, was 
shown to decrease HI brain injury dose-dependently in a neonatal rat model by our group 
(Cansev et al., 2013). We therefore aimed to investigate the possible epigenetic 
regulation effect of uridine on histone acetylation/ deacetylation balance in neonatal HI 
brain injury as HDAC inhibitors were shown to reduce oxidation, inflammation and 
apoptosis (Wang et al., 2012). The neonatal HI brain injury model was used in this 
experimental setting. After HI insult, postnatal D7 rat pups were given uridine for 3 
consecutive days intraperitoneally. Uridine treatment reduced brain infarct volume and 
apoptosis. In addition, uridine decreased HDAC activity and increased the expression of 
acetylated histone-3 and -4 protein levels (Koyuncuoglu et al., 2015). To the best of our 
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knowledge, this was the first study that reported the HDAC inhibition mechanism of 
uridine in HI brain injury that was also associated with reduction of brain infarct and 
apoptosis. As a result, we suggest that HDAC inhibition may be important for prevention 
and/or treatment of neonatal HI brain injury and that neuroprotective agents which 
interfere with this cascade may confer benefit in the treatment of HI brain insult in future. 
Combination of neuroprotective therapies for HIE 
As mentioned above, although therapeutic hypothermia reduces the risk of death and 
major neurodevelopmental disability, it neither does provide complete neuroprotection 
nor stimulates the repair necessary for normal neurodevelopmental outcome (Cilio and 
Ferriero, 2010). The cellular mechanisms including excitotoxicity, free radical toxicity, 
lipid peroxidation, and inflammation resulting with neuronal cell death were suggested 
to be prevented by combination therapies acting on the different levels of this complex 
cascade (Juul and Ferriero, 2014; Peters and van Bel, 2001). To evaluate the combination 
therapy in HIE, two agents acting on different stages of HI brain injury were used in a 
modified Levine-Rice model. It was tested whether the early stage of HIE could be 
prevented by means of combining magnesium sulfate (MgSO4), an N-methyl-D- aspartate 
(NMDA) receptor antagonist acting on the early stage of excitotoxicity with melatonin as 
an indirect antioxidant and potent free radical scavenger that acts on the later stage of 
HI injury (Cetinkaya et al., 2011). In this experimental study, MgSO4 and melatonin, having 
different actions on the HI brain injury cascade, significantly reduced the infarcted brain 
volume and apoptosis, either alone or in combination. However, we could not show any 
additive benefit of this combination therapy (Cetinkaya et al., 2011). Following this study, 
we tested the neuroprotective effect of topiramate, an antiepileptic and AMPA/kainate 
receptor antagonist in HI brain injury. We evaluated its efficacy either alone or in 
combination with melatonin. We again hypothesized that combination of two 
neuroprotective agents acting on different stages of HIE might confer additional therapy. 
Herein, topiramate and melatonin either alone or in combination, significantly 
reduced the size of infarcted area and apoptosis. However, the combination therapy did 
not show superiority to the single therapies (Ozyener et al., 2012). In recent years, in 
accordance with our hypothesis and results, most authors have suggested using 
combination therapy options that act on multiple mechanistic processes (Dixon et al., 
2015; Zalewska et al., 2015). For this purpose, it may be reasonable to suggest combining 
a neuroprotective agent with hypothermia or combining two neuroprotective agents that 
are known to act on different phases of HI injury to achieve better neuroprotection in 
infants with severe HIE (Dixon et al., 2015; Zalewska et al., 2015). Therefore, future 
studies are warranted investigating the best synergistic combination therapy for effective 
treatment of HIE. 
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The importance of experimental studies in neonatology 
Since performing clinical studies in neonates are extremely challenging due to ethical 
issues and risks associated with unproven therapies, performing well-planned basic 
experiments on animal models is essential beforehand. Experimental data obtained from 
animal models can be translated into clinical practice with the goal of establishing novel 
treatment options in sophisticated human studies. However, we must keep in mind that 
a large number of potential therapies that were effective in animals were not proven 
effective in subsequent clinical trials. Therefore, it is important to perform well-designed 
experimental models that closely mimic the human diseases. We suggest that 
translational research from the experimental animal laboratory to the human clinic is 
essential to improve neonatal outcomes for both prevention and treatment of several 
morbidities with multifactorial pathogenesis and limited therapeutic options. The main 
advantages of our experimental studies include the possibility of usage of these 
treatments clinically in neonates, thereby translating results from bench to bedside. 
Conclusion and future perspectives 
Advances in neonatology resulted in increased survival rates of infants. In parallel, BPD, 
NEC and adverse neurological outcomes among ELBW infants as well as perinatal 
asphyxia in term infants remain a significant problem.  Therefore, the aim for the future 
is to decrease rates of these morbidities in both term and preterm survivors. 
In view of the currently available data, we know that there is no single effective 
therapy for neither BPD, nor NEC or HIE. We therefore need alternative and more 
efficacious therapies for treatment as well as prevention of these morbidities. Based on 
our experimental studies, we suggest a potential role for CDP-choline in the prevention 
of both BPD and NEC. As the injury in the lung and gastrointestinal system usually disrupts 
the epithelium and show a distribution from the injured epithelium, we evaluated the 
preventive and therapeutic efficacy of CDP-choline as an agent to improve the injured 
epithelial and mucosal layer in the developmental process of BPD and NEC. Our studies 
were the first in the literature that reported the beneficial effects of CDP-choline on the 
maintenance of normal membrane structure and prevention of inflammation and lipid 
peroxidation, the hallmarks of BPD and NEC. As the importance of genetic and epigenetic 
mechanisms were identified in the development of neonatal morbidities in recent years, 
therapeutic approaches targeting epigenetic mechanisms should be considered in 
prevention of BPD and HIE. Valproic acid and uridine treatments reduced HDAC activity 
and increased the expression of acetylated histone proteins and were therefore found to 
be effective for prevention and treatment of BPD and HIE in our studies. Although the 
HDAC activity of valproic acid was well known, our group showed the HDAC activity of 
uridine in neonatal HI brain injury for the first time. These were the first studies in the 
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literature that reported the beneficial effects of therapeutic agents acting on epigenetic 
mechanisms for treatment and/or prevention of BPD and HIE. The agents acting on the 
similar pathways with the same pathogenesis may confer benefits in the prevention 
and/or treatment of different neonatal diseases such as HIE, BPD and NEC. Although the 
combination therapy with magnesium sulfate, topiramate, and melatonin was found to 
be neuroprotective in experimental HI brain injury models, we still need to find the best 
combination therapy, possibly in conjunction with hypothermia and appropriate timing. 
Therefore, greater number of experimental studies are required to establish novel and 
effective therapies for prevention and/or treatment of conditions like BPD, NEC and HIE 
before going into clinical trials. 
We believe that investigating therapeutic potential of easily accessible and non- toxic 
agents that target and modulate pathogenic mechanisms of neonatal diseases, alone or 
in combination, in well-established animal models will certainly provide extensive 
information on the extent and quality of the treatment strategy that is tested. Data 
derived from these studies must further be utilized in clinical studies in order to translate 
the knowledge from bench to bedside and help to reduce neonatal mortality and 
morbidity by testing new therapeutic strategies against BPD, NEC and HIE. It may be 
speculated that the success of translational research in neonates leading to discovery of 
novel beneficial therapeutic approaches will be related with the quality of well-designed 
and universally accepted experimental models as well as with the choice of right agents. 
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This valorization chapter describes how the outcomes of this thesis contribute to 
neonatal units, parents, society as well as research and industry. The results described in 
this thesis enable new treatment and prevention modalities in both term and premature 
infants. 
Societal Importance 
Preterm birth is a very important public health priority worldwide; approximately 15 
million babies are born preterm every year and preterm birth complications are the 
leading cause of death among children under 5 years of age (Liu et al., 2016). In addition, 
preterm birth is also associated with increased morbidity as well as with increased health 
care costs because of longer hospital stays and a greater need for intensive care due to 
medical care related to morbidities of prematurity. In a study from the US, the 
disproportionate share of neonatal care was highlighted (Barradas et al., 2016). Although 
9.1% of all hospitalizations were associated with preterm birth, these hospitalizations 
accounted for 43.4% of total costs. In addition, 5.9% of the same cohort required re-
hospitalization, the costs of which accounted for 22.6% of all costs. Therefore, we need 
evidence-based strategies to prevent prematurity and prematurity-related morbidities. 
As more immature infants survive due to the advances in neonatal care, the incidences 
of bronchopulmonary dysplasia (BPD) and necrotizing enterocolitis (NEC) do not decrease 
(Stoll et al., 2015). Hence, it is reasonable and also cost-effective to develop targeted 
therapies against morbidities such as BPD and NEC. 
In addition to prematurity, neonatal hypoxic ischemic encephalopathy (HIE) presents 
also a significant clinical burden with its persistent high mortality and morbidity rates. 
Worldwide, four million newborn infants experience birth asphyxia each year, accounting 
for an estimated one million deaths and 42 million disability-adjusted life years (Nair, J., 
and Kumar, V.H.S., 2018). Although therapeutic hypothermia has been accepted as the 
standard of care for infants with moderate to severe HIE, it has not definitively changed 
overall outcomes in severe HIE. HIE has a multifactorial pathogenesis and multiple cellular 
events including excitotoxicity, inflammation and oxidative stress lead to cellular damage. 
Due to this complex events cascade, combination therapies acting on different stages of 
hypoxic ischemic injury were suggested as a novel approach to reach different targets in 
the setting of HIE. These therapy targets in HIE include prevention of acute lesions, 
increase in size of the therapeutic time window for protection, and enhanced repair in 
the long term (Cilio, M.R. and Ferriero, D.M., 2010). Therefore, development of 
alternative therapies, especially the combined use of neuroprotective agents, were 
suggested to provide more benefit for prevention of HIE-related devastating neurological 
disability (Douglas-Escobar, M., and Weiss M.D., 2015). 
Since prematurity, prematurity-related morbidities and HIE contribute to a 
significantly higher burden of neonatal mortality and morbidity globally, there is a need 
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for alternative and supplementary therapeutic agents. In order to have global 
applicability, therapies need to have low costs and should be easily and readily available 
(Costa et al., 2018). However, research involving critically ill neonates is very hard to 
perform due to some unique ethical concerns. The design of trials, the informed consent 
process, and the implementation of studies in critically ill neonates is very difficult 
because these subjects are vulnerable and critically ill, have a significant risk of dying or 
a poor prognosis when surviving. Despite these ethical concerns, it is very crucial to 
perform research trials for introduction of new drugs, devices, and interventions and to 
develop the necessary evidence of efficacy and toxicity to support the use of these 
medications (Fleischman, A.R., 2016). It is also important to establish the safety and 
efficacy of such drugs in preterm infants, especially in the hospitalized population with 
lower birth weight and gestational age who are actually on multiple drugs (Costa et al., 
2018). The drug-drug interactions in these patients are not well studied and may be 
further complicated by prematurity as such. From the ethical side, the main problem is 
to increase the effectiveness and to improve short- and long-term effects of these 
promising modalities in preterm infants while conducting drug studies in neonates within 
the ethical framework of respect for persons, justice, and beneficence (Ward, R.M., and 
Sherwin, R.C., 2015). To bypass these ethical problems related to clinical studies, we can 
perform experimental studies in the preclinical stage, the results of which can be 
translated into clinical usage. The experimental studies for prevention and treatment of 
important prematurity-associated neonatal morbidities and HIE that were reported in 
this thesis showed promising results for the possible therapeutic usage of some agents 
such as valproic acid, CDP-choline, melatonin, prostaglandin E1, uridine and topiramate. 
After those encouraging results from our experimental studies, the efficacy and safety of 
these therapies should be evaluated in this vulnerable group with further clinical studies. 
In accordance with this idea, limited number of clinical studies that evaluated the use of 
melatonin in HIE and neonatal sepsis in newborns have been published (Aly et al., 2015 
and El Frargy, et al. 2015). Similarly, the safety and efficacy of topiramate was also 
evaluated in a recent feasibility study (Filippi et al., 2018). Therefore, I suggest that these 
preliminary studies may work as a pioneer for planning further larger clinical studies that 
may result with translation of our experimental results to clinical usage for these agents. 
Contributions of this thesis to understanding of neonatal diseases and 
planning future studies for health professional societies 
The findings in this thesis are of importance and of additional value for current 
understanding and further research in the prevention of prematurity related morbidities 
and HIE in term babies. Prematurity-related morbidities including BPD and NEC have 
multifactorial pathogenesis. Therefore, there is no single curative treatment for these 
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morbidities and new therapeutic agents are required to prevent and/or treat these 
morbidities. 
Epigenetic mechanisms including DNA base modifications such as methylation, 
alteration of histones resulting in chromatin modification, as well as the actions of 
noncoding RNA are required for both lung modelling and remodeling. Recently, 
epigenetic regulation was also suggested to play an important role in development of 
chronic lung diseases including BPD (Merritt et al., 2011). In this thesis, valproic acid, 
which is a histone deacetylase inhibitor, was suggested as an alternative preventive 
treatment approach for neonatal hyperoxic lung injury in preterm infants due to its 
epigenetic effects. Since valproic acid was reported to be used as a therapeutic agent for 
treatment of severe neonatal seizures, its effectiveness against BPD in preterm infants 
should be evaluated in future clinical studies in the presence of the data provided by our 
preclinical study. 
The complex multifactorial pathogenesis of NEC results in intestinal dysfunction, 
inflammation, injury and necrosis. All these events result in the disruption of cell 
membranes in all organ systems including lung and intestine. Therefore, restoration of 
cell membrane functions may provide benefits in these conditions. Herein, CDP-choline, 
an endogenous intermediate of major membrane phospholipids, was shown to reduce 
both hyperoxic lung injury and NEC by several different mechanisms of action. As CDP-
choline was administered to preterm infants for treatment of respiratory distress 
syndrome, its usage for either prevention and/or treatment of both NEC and BPD in these 
infants may be evaluated by future clinical studies. As mentioned above, due to the 
complex pathogenesis of these morbidities, combinations of therapies instead of a single 
therapeutic agent should also be evaluated for both treatment and/or prevention of BPD 
and NEC in preterm infants. This combination therapeutic approach may also be tested 
for newer treatment strategies for HIE as mentioned in the thesis. Especially, combination 
of some inexpensive therapies such as magnesium sulfate and melatonin as mentioned 
in the thesis may enable neonatologists to provide an effective therapy in developing 
countries that lack therapeutic hypothermia. The results of this thesis will encourage 
clinical researchers to test therapeutic approaches best suited for the resources in their 
environment. 
Contributions of this thesis to health economics and hospital costs 
Preterm birth and prematurity represent a global economic problem due to longer 
hospitalization periods and re-hospitalizations after discharge. In addition, prematurity-
related increased neurological and pulmonary conditions such as cerebral palsy, asthma 
and learning difficulties may lead to an economic burden due to the increased health 
costs. Therefore, the newer and inexpensive therapeutic approaches and the 
combination of therapies described in this thesis may help to decrease the health care 
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costs in these infants, which is important for both the family, and the society in a country. 
These experimental therapeutic approaches may offer new treatment strategies in the 
NICU perspective by either decreasing the duration of hospitalization or decreasing the 
incidence and/or severity of adverse outcomes associated with these morbidities. It may 
also reduce the need of re-hospitalization associated with the effects of abnormal lung 
injury or intestinal damage during hospitalization. 
Contributions of this thesis to parents 
Preterm birth has also been linked to increased parental stress, depression, and anxiety 
(Pace et al., 2016). Parental anxiety can be decreased by detailed discussion of expected 
prematurity-related issues and possible treatment strategies. Herein, the results of this 
thesis may offer understanding and hope for their infants to have a possible cure in the 
presence of risk factors for BPD or NEC development. 
Future perspectives 
This thesis provides a combination of several therapeutic approaches for the prevention 
of important neonatal morbidities in both term and preterm infants. The reported 
experimental studies justify clinical applications and translations. This translation must be 
done in carefully designed clinical trials, where not only the short-term benefit is tested, 
but also data on the long-term follow-up is collected. Therefore, the studies in this thesis 
serve both the pathophysiological understanding and the therapeutic innovation. All 
these improvements may guide clinicians to perform human studies with the idea in mind 
that it is more important to develop preventive strategies rather than treatment 
strategies for these morbidities. 
Valorization 
151 
References 
1. Aly, H., Elmahdy, H., El-Dib, M., Rowisha, M., Awny, M., El-Gohary, T., Elbatch, M., Hamisa, M., and El-
Mashad A.R. (2015) Melatonin use for neuroprotection in perinatal asphyxia: a randomized controlled pilot 
study. Journal of perinatology 35: 186-191. 
2. Barradas, D.T., Wasserman, M.P., Daniel-Robinson, L., Bruce, M.A., Disantis, K.I., Navarro, F.H., Jones, W.A., 
Manzi, N.M., Smith, M.W., and Goodness, M. B. (2016). Hospital utilization and costs among preterm
Infants by payer: nationwide inpatient sample, 2009. Maternal and child health journal 20: 808-828. 
3. Cilio, M.R., and Ferriero, D.M. (2010). Synergistic neuroprotective therapies with hypothermia. Seminars in 
fetal & neonatal medicine 15: 293-298. 
4. Costa, H.T.M.L., Costa, T.X., Martins, R.R., and Oliveira, A.G. (2018). Use of off-label and unlicensed
medicines in neonatal intensive care. PloSOne 13(9): e0204427. 
5. Douglas-Escobar, M., and Weiss, M.D. (2015). Hypoxic-ischemic encephalopathy: a review for the clinician. 
JAMA pediatrics 169: 397-403. 
6. El Frargy, M., El-Sharkawy, H.M., and Attia, G.F. (2015). Use of melatonin as an adjuvant therapy in neonatal 
sepsis. Journal of neonatal-perinatal medicine 8: 227-232. 
7. Filippi, L., Fiorini, P., Catarzi, S., Berti, E., Padrini, L., Landucci, E., Donzelli, G., Bartalena, L., Fiorentini, E.,
Boldrini, A., Giampietri, M., Scaramuzzo, R.T., la Marca, G., Della Bona, M.L., Fiori, S., Tinelli, F., Bancale, A., 
Guzzetta, A., Cioni, G., Pisano, T., Falchi, M., and Guerrini, R. (2018). Safety and efficacy of topiramate in
neonates with hypoxic ischemic encephalopathy treated with hypothermia (NeoNATI): a feasibility study.
The journal of maternal- fetal & neonatal medicine 31: 973-980. 
8. Fleischman, A.R. (2016). Ethical issues in neonatal research involving human subjects. Seminars in
perinatology 40: 247-253. 
9. Liu, L., Oza, S., Hogan, L., Chu,Y., Perin, J., Zhu, J., Lawn, J.E., Cousens, S., Mathers, C., and Black, R.E. (2016). 
Global, regional, and national causes of under-5 mortality in 2000–15: an updated systematic analysis with 
implications for the Sustainable Development Goals. Lancet 388: 3027-3035. 
10. Merritt, T.A., Gadzinowski, J., Mazela, J., and Adamczak, A.M. (2011). Epigenetic influences in the
development of bronchopulmonary dysplasia. Archieves of perinatal medicine 17: 17-22. 
11. Nair, J., and Kumar, V.H.S. (2018). Current and emerging therapies in the management of hypoxic ischemic 
encephalopathy in neonates. Children (Basel) 5: 99. 
12. Pace, C.C., Spittle, A.J., Molesworth, C.M., Lee, K.J., Northam, E.A., Cheong, J.L., Davis, P.G., Doyle, L.W.,
Treyvaud, K., and Anderson, P.J. (2016). Evolution of depression and anxiety symptoms in parents of very 
preterm infants during the newborn period. JAMA pediatrics 170: 863-870. 
13. Stoll, B.J., Hansen, N.I., Bell, E.F., Walsh, M.C., Carlo, W.A., Shankaran, S., Laptook, A.R.,Sánchez, P.J., Van
Meurs, K.P., Wyckoff, M., Das, A., Hale, E.C., Ball, M.B., Newman, N.S., Schibler, K., Poindexter, B.B.,
Kennedy, K.A., Cotton, C.M., Watterberg, K.L., D'Angio, C.T., DeMauro, S.B., Truog, W.E., Devaskar, U.,
Higgins, R.D. and Eunice Kennedy Shriver National Institute of Child Health and Human Development
Neonatal Research Network (2015). Trends in care practices, morbidity and mortality of extremely preterm 
neonates, 1993-2012. JAMA 314: 1039-1051. 
14. Ward, R.M., and Sherwin, R.C. (2015). Ethics of drug studies in the newborn. Paediatric drugs 17: 37-42. 

153 
Chapter 11
Curriculum vitae 

Curriculum vitae 
155 
Merih CETINKAYA, MD., PhD., 
Professor of Pediatrics and Neonatology 
Health Sciences University 
Kanuni Sultan Suleyman Training and Research Hospital,  
Department of Neonatology, Istanbul, TURKEY 
+90- 212-4955920, +90 532 3678867, drmerih@yahoo.com
Merih Cetinkaya graduated from Dokuz Eylul University, Faculty of Medicine in İzmir, 
Turkey. He completed his pediatric residency and neonatology fellowship in Uludag 
University, Faculty of Medicine. He also received his PhD from Physiology Department of 
Uludag University. He was in Vermont University, Fletcher Allen Health Care and Harvard 
University, Brigham and Women's Hospital as an observer in 2009.  
He became Associate Professor of Pediatrics in 2011. In 2017, he became Professor 
of Pediatrics in Health Sciences University in Turkey. He currently works as chief of the 
Neonatology Department of the Kanuni Sultan Suleyman Training and Research Hospital 
in Istanbul that serves as a referral center in Neonatology and Perinatology. His primary 
research areas involve new therapies for prevention and treatment of neonatal hypoxia-
ischemia, hyperoxic lung injury, and necrotizing enterocolitis. He also works on neonatal 
outcomes of preeclampsia and new biomarkers in the diagnosis of neonatal sepsis and 
necrotizing enterocolitis. His PhD in Maastricht University, Department of Experimental 
Perinatology is a continuation of these subjects. 
He published over 80 peer-reviewed manuscripts. He was the recipient of several 
national and international awards. He was awarded the ESPNIC Young Investigator Award 
at the 5th Congress of the European Academy of Pediatric Societies in October 2014. He 
also received the 1st SIN (Italian Neonatology Society) European Young Researcher 
Neonatology Award. He was the recipient of the Neonatology Investigator Award of the 
Turkish Neonatology Society in 2011 and 2016. He was also selected as a runner-up for 
the 4rd International Congress of the European Academy of Paediatric Societies 
Investigator Prize in 2012. He is a frequent speaker at both international and national 
congresses and meetings. 
Merih Cetinkaya is also a member of the Editorial Board and reviewer of several 
national and international medical journals. He works as a co-investigator in several 
international clinical studies. His primary aim is to develop new strategies against the 
most common morbidities in pediatrics, especially in neonatology. 
Chapter 11 
156 
INTERNATIONAL AWARDS 
Cetinkaya, M., Varturk, I., Korachi, M., Guven, S., Akın, I.M., Erener-Ercan, T., and 
Buyukkale, G. (2014). Association of E-NOS Gene Polymorphism in Development of 
Bronchopulmonary Dysplasia. The 5th Congress of the European Academy of 
Paediatric Societies EAPS, ESPNIC Paediatric and Neonatal Intensive Care Young 
Investigator Award 2014, October 17-21, Barcelona, Spain.  
Cetinkaya, M., Ozyener, F., Alkan, T., Kafa, I.M., Kurt, M.A., and Koksal, N. (2011). Possible 
neuroprotective effects of magnesium sulfate and melatonin as both pre- and post-
treatment in a neonatal hypoxic-ischemic rat model, 1st SIN (Italian Neonatology 
Society) European Young Researcher Neonatology Award, 11-14 October, Sorrento, 
Italy. 
PEER-REVIEWED PUBLICATIONS 
Acar, D.B., Kavuncuoglu, S., Cetinkaya, M., Petmezci, E., Dursun, M., Korkmaz, O., and 
Altuncu, E.K. (2015). Assesment of the place of tubular reabsorption of phosphorus in 
the diagnosis of osteopenia of prematurity. Turk pediatri arsivi 50: 45-50.  
Alan, S., Erdeve, O., Cakir, U., Akduman, H., Zenciroglu, A., Akcakus, M., Tunc, T., Gokmen, 
Z., Ates, C., Atasay, B., Arsan, S., and TurkNICU-RSV Trial Group. (2016). The journal of 
maternal-fetal & neonatal medicine 29: 2186-2193.  
Ali, R., Ozkalemkas, F., Kimya, Y., Koksal, N., Ozkan, H., Ozkocaman, V., Hoyrazlı, A., 
Cetinkaya, M., and Tunalı, A.  (2009). Acute leukemia and pregnancy. Leukemia 
research 33: e26-28. 
Babayigit, A., Cebeci, B., Buyukkale, G., Yilmaz, S.S., Bornaun, H., Oztarhan, K., Gokce, M., 
and Cetinkaya, M. (2015). Treatment of neonatal fungal infective endocarditis with 
recombinant tissue plasminogen activator in a low birth weight infant: case report 
and review of the literature. Mycoses 58: 578-581.   
Babayigit, A., Ozaydın, S., Cetinkaya, M., and Sander, S. (2018). Neonatal gastric 
perforations in very low birth weight infants: a single center experience and review of 
the literature. Pediatric surgery international 34: 79-84. 
Bas, A.Y., Koc, E., Dilmen, U., and ROP Neonatal Study Group. (2015).  Incidence and 
severity of retinopathy of prematurity. British journal of ophtalmology 99: 1311-1314. 
Bayram, F., Ozerkan, K., Cengiz, C., Develioglu, O., and Cetinkaya, M. (2010). Perinatal 
asphyxia is associated with the umblical cord nucleated red blood cell count in 
preeclamptic pregnancies. Journal of obstetrics and gynaecology 30: 383-386. 
Curriculum vitae 
157 
Bornaun, H., Oztarhan, K., Erener-Ercan, T., Dedeoglu, R., Tugcu, D., Aydogmus, C., 
Cetinkaya, M., and Kavuncuoglu, S. (2016). Regression of cardiac rhabdomyomas in a 
neonate after Everolismus therapy. Case reports in pediatrics 2016: 8712962. 
Bornaun, H., Yartası Tik, E., Keskindemirci, G., Ekiz, A., Oztarhan, K., Dedeoglu, R., and 
Cetinkaya, M. (2016). Right atrial appendage aneurysm in a newborn diagnosed with 
fetal echocardiography.  Case reports in pediatrics 2016: 8616918. 
Buyukkale, G., Cetinkaya, M., Akcay, A., Payaslı, M., Oztarhan, K., Ozbek, A.S., and 
Kavuncuoglu, S. (2012). Transient leukemia associated pericardial tamponade in a 
neonate with Down syndrome. Pediatric hematology and oncology 29: 386-388. 
Cakar, N., Kavuncuoglu, S., Aldemir, E., Cetinkaya, M., Guzeltas, A., and Arslan, G. (2014). 
The features of multiple pregnancies obtained by in vitro fertilization or 
spontaneously. Pediatrics international 56: 735-741.  
Cansev, M., Minbay, Z., Goren, B., Yaylagul, E.O., Cetinkaya, M., Koksal, N., and Alkan, T. 
(2013). Neuroprotective effects of uridine in a rat model of neonatal hypoxic-ischemic 
encephalopathy. Neuroscience letters 542:65-70.  
Cekmez, F., Canpolat, F.E., Cetinkaya, M., Aydınoz, S., Aydemir, G., Karademir, F., Ceylan, 
O.M., Ipcioglu, O.M., and Sarıcı, S.U. (2011). Diagnostic value of resistin and visfatin in
comparison with C-reactive protein, procalcitonin and IL-6 in neonatal sepsis.
European cytokine network 22: 113-117.
Cekmez, F., Canpolat, F.E., Cetinkaya, M., Pirgon, O., Aydınoz, S., Ceylan, O.M., Ipcioglu, 
O.M., and Sarıcı, S.U. (2012). IGF-1 and visfatin levels in retinopathy of prematurity.
Journal of pediatric ophthalmology and strabismus 49: 120-124.
Cekmez, F., Canpolat, F.E., Erdinc, K., Cetinkaya, M., Akın, O., Pamuk, U., and Sarıcı S.U. 
(2011). Response to hepatitis B vaccine differs birthweight among neonates. Vaccine 
29: 3096-3097. 
Cekmez, F., Canpolat, F.E., Pirgon, O., Cetinkaya, M., Aydınoz, S., Suleymanoglu, S., 
Ipcioglu, O.M., and Sarıcı, S.U. (2011). Apelin, vaspin, visfatin and adiponectin in large 
for gestational age infants with insulin resistance. Cytokine 56: 387-391. 
Cekmez, F., Cetinkaya, M., Tayman, C., Canpolat, F.E., Kafa, I.M., Uysal, S., Tunc, T., and 
Sarıcı, S.U. (2013). Evaluation of Melatonin and Prostaglandin E1 combination on 
necrotizing enterecolitis model in neonatal rats. Regulatory peptides 184: 121-125. 
Cekmez, F., Purtuloglu, T., Aydemir, G., Aydinoz, S., Fidancı, K., Karaoglu, A., Babacan, O., 
Canpolat, F.E., Cetinkaya, M., Tunc, T., and Suleymanoglu, S. (2012). Comparing 
beneficial effects of inhaled nitric oxide to L-arginine in necrotizing enterocolitis 
model in neonatal rats. Pediatric surgery international 28: 1219-1224. 
Chapter 11 
158 
Cekmez, F., Tayman, C., Saglam, C., Cetinkaya, M., Bedir, O., Gunal, A., Tunc, T., and Sarıcı 
S.U. (2012). Well-known but rare pathogen in neonates: Listeria monocytogenes. 
European review for medical and pharmacological sciences 16 Suppl 4: 58-61. 
Celebi, S., Hacımustafaoglu, M., Koksal, N., Ozkan, H., and Cetinkaya, M. (2010). 
Colistimethate sodium therapy for multidrug-resistant isolates in pediatric patients. 
Pediatrics international 52: 410-414. 
Celebi, S., Hacımustafaoglu, M., Koksal, N., Ozkan, H., Cetinkaya, M., and Ener, B. (2012). 
Neonatal candidiasis: results of a 8-year old study. Pediatrics international 54: 341-
349.  
Celik, H.G., Celik, E., Yıldırım, G., and Cetinkaya, M. (2017). Do triple test results predict 
risk of neonatal hyperbilirubinemia? Pakistan journal of medical sciences 33: 979-983. 
Celik, H.G., Semerci, S.Y., Yıldırım, G., and Cetinkaya M. (2017). Ininencephaly: a rare 
congenital anomaly reaching the term. Case reports in perinatal medicine 11 Apr. doi: 
10.1515/crpm-2016-0056. 
Cetinkaya, M., Alkan, T., Ozyener, F., Kafa, I.M., Kurt, M.A., and Koksal, N. (2010). Possible 
neuroprotective effects of magnesium sulfate and melatonin as both pre- and post-
treatment in a neonatal hypoxic-ischemic rat model. Neonatology 99: 302-310. 
Cetinkaya, M., Atasay, B., and Perk, Y. (2018). Turkish Neonatal Society guideline on the 
transfusion principles in newborn. Turk pediatri arsivi 53(Suppl 1): S101-S108. 
Cetinkaya, M., Bostan, O., Koksal, N., Semizel, E., Ozkan, H., and Çakır, S. (2011). Early left 
ventricular diastolic dysfunction in premature infants born to preeclamptic mothers. 
Journal of perinatal medicine 39: 89-95. 
Cetinkaya, M., Buyukkale, G., Payaslı, M., Ozbek, A.S., and Kavuncuoglu, S. (2013). An 
unusual cause of bilateral scrotal abscess in a preterm infant: Candida Albicans. 
Brazilian journal of infectious diseases 17: 260-262.  
Cetinkaya, M., Cansev, M., Cekmez, F., Tayman, C., Canpolat, F.E., Kafa, I.M., Uysal, S., 
Tunc, T., and Sarıcı, S.U. (2013). CDP-Choline reduces severity of intestinal injury in a 
neonatal rat model of necrotizing enterocolitis. Journal of surgical research 183:119-
128.  
Cetinkaya, M., Cansev, M., Cekmez, F., Tayman, C., Canpolat, F.E., Kafa, I.M., Yaylagul, 
E.O., Kramer, B.W., and Sarici S.U. (2015). Protective effects of valproic acid, a histone
deacetylase inhibitor, against hyperoxic lung injury in a neonatal rat model. PLoS One
10(5): e0126028.
Cetinkaya, M., Cansev, M., Kafa, I.M., Tayman, C., Cekmez, F., Canpolat, F.E., Tunc, T., and 
Sarıcı, S.U. (2013). Cytidine 5’-Diphosphocholine (CDP-Choline) ameliorates hyperoxic 
lung injury in a neonatal rat model. Pediatric research 74: 26-33. 
Curriculum vitae 
159 
Cetinkaya, M., Cekmez, F., Buyukkale, G., Erener-Ercan, T., Demir, F., Tunc, T., Aydın, F.N., 
and Aydemir, G. (2015). Lower vitamin D levels are associated with increased risk of 
early onset neonatal sepsis in term infants. Journal of perinatology 35: 39-45.   
Cetinkaya, M., Cekmez, F., Erener-Ercan, T., Buyukkale, G., Demirhan, A., Aydemir, G., and 
Aydin, F.N. (2015). Maternal/neonatal vitamin D deficiency: a risk factor for 
bronchopulmonary dysplasia in preterms? Journal of perinatology 35: 813-817. 
Cetinkaya, M., Cekmez, F., Canpolat, F.E., Akın, O., Atabek, C., Kozan, S., and Sarıcı S.U. 
(2012). Osephageal atresia in a neonate with translocation t (1;13). Genetic 
counseling 23: 73-75. 
Cetinkaya, M., Durmaz, O., Buyukkale, G., Ozbek, S., Acar, D., Kılıcaslan, I., and 
Kavuncuoglu S. (2013). Neonatal Bartter Syndrome and unilateral ectopic cyst as new 
renal causes of hydrops fetalis: two case reports and review of the literature. The 
journal of maternal-fetal & neonatal medicine 26: 1147-1150.  
Cetinkaya, M., Ercan, T.E., Saglam, O.K., Buyukkale, G., Kavuncuoglu, S., and Mete, F. 
(2014). Efficacy of prophylactic fluconazole therapy in decreasing the incidence of 
Candida infections in extremely low birth weight infants. American journal of 
perinatology 31: 1043-1048.  
Cetinkaya, M., Erener-Ercan, T., Cansev, M., Buyukkale, G., Cekmez, F., Aydemir, G., 
Pirhan, D., Genc, F.A., Acar, E., and Taskin, N. (2014). The utility of serial plasma sE-
selectin measurements in the prediction of retinopathy of prematurity in premature 
infants. Early human development 90: 517-521. 
Cetinkaya, M., Erener-Ercan, T., Kalayci-Oral, T., Babayigit, A., Cebeci, B., Semerci, S.Y., 
and Buyukkale, G. (2017). Maternal/neonatal vitamin D deficiency: a new risk factor 
for necrotizing enterocolitis in preterm infants? Journal of perinatology 37: 673-678. 
Cetinkaya, M., Koksal, N., Ozkan, H., Donmez, O., Saglam, H., and Kırıstıoglu, I. (2008). 
Hyperprostaglandin E syndrome: use of indomethacin and steroid, death due to 
necrotizing enterocolitis and sepsis. Turkish journal of pediatrics 50: 386-390. 
Cetinkaya, M., Oral, T.K., Karatekin, S., Cebeci, B., Babayigit, A., and Yesil, Y. (2017). 
Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower 
respiratory tract infections in preterm infants: determination of the ideal target 
population for prophylaxis. European journal of clinical microbiology & infectious 
diseases 36: 1629-1634. 
Cetinkaya, M., Ozen, S., Uslu, S., Gonc, N., Acunas, B., Akıncı, A., Satar, M., and Berberoglu, 
M. (2018). Diagnostic and therapeutic approach in newborns with ambiguous genitale
with disorder of sex development: consensus report of Turkish Neonatal and Pediatric
Endocrinology and Diabetes Societies. Turk pediatri arsivi 53 (Suppl 1): S198-S208.
Chapter 11 
160 
Cetinkaya, M., Ozkan, H., Celebi, S., Koksal, N., and Hacımustafaoglu, M. (2011). Human 
2009 influenza A (H1N1) virus infection in a premature infant born to a H1N1-infected 
mother: placental transmission? Turkish journal of pediatrics 53: 441-444. 
Cetinkaya, M., Ozkan, H., and Koksal N. (2008). Unilateral radius aplasia due to 
lamotrigine and oxcarbazepine use in pregnancy. The journal of maternal-fetal & 
neonatal medicine 21: 927-930.  
Cetinkaya, M., Ozkan, H., and Koksal, N. (2012). A new scoring system for evaluation of 
multiple organ dysfunction syndrome in premature infants: modified NEOMOD 
scoring system. American journal of critical care 21: 328-337. 
Cetinkaya, M., Ozkan, H., and Koksal, N. (2012). Maternal preeclampsia is associated with 
increased risk of necrotizing enterocolitis in preterm infants. Early human 
development 88: 893-898. 
Cetinkaya, M., Ozkan, H., Koksal, N., Akacı, O., and Ozgur, T. (2010). The efficacy of serial 
serum amyloid A measurements for diagnosis and follow-up of necrotizing 
enterocolitis in premature infants. Pediatric surgery international 26: 835-841. 
Cetinkaya, M., Ozkan, H., Koksal, N., Akacı, O., and Ozgur, T. (2011). Comparison of the 
efficacy of serial serum amyloid A, C-reactive protein and procalcitonin in the 
diagnosis and follow-up of necrotizing enterocolitis in premature infants. Journal of 
pediatric surgery 46: 1482-1489. 
Cetinkaya, M., Ozkan, H., Koksal, N., Celebi, S., and Hacımustafaoglu, M. (2009). 
Comparison of serum amyloid A concentrations with those of C-reactive protein and 
procalcitonin in diagnosis and follow-up of neonatal sepsis in premature infants. 
Journal of perinatology 29:  225-231. 
Cetinkaya, M., Ozkan, H., Koksal, N., Coskun, S.Z., Hacımustafaoglu, M., and Girisgin, O. 
(2008). Neonatal myiasis: a case report. Turkish journal of pediatrics 50: 581-584.  
Cetinkaya, M., Ozkan, H., Koksal, N., Karalı, Z., and Ozgur T. (2010). Neonatal outcomes 
of premature infants born to preeclamptic mothers. The journal of maternal-fetal & 
neonatal medicine 23: 425-430. 
Cetinkaya, M., Ozkan, H., Koksal, N., Sarısozen, B., and Yazıcı, Z. (2012). Osteofibrous 
dysplasia associated with pathological tibia fracture: a case report and review of the 
literature. Journal of pediatric orthopedics. Part B. 21: 183-186. 
Cetinkaya, M., Ozkan, H., Koksal, N., Yazıcı, Z., and Yalcınkaya U. (2008). Spondylocostal 
dysostosis associated with diaphragmatic hernia and neural tube defects. Clinical 
dysmorphology 17: 151-154. 
Curriculum vitae 
161 
Cetinkaya, M., Semizel, E., Bostan, O.M., and Cil, E. (2008). Risk of vasovagal syncope and 
cardiac arrhythmias in children with mitral valve prolapse. Acta cardiologica 63: 395-
398. 
Donmez, O., Cetinkaya, M., and Canbek, R. (2005). Hemoperfusion in a child with 
amitriptyline intoxication. Pediatric nephrology 20: 105-107. 
Erdeve, O., Okulu, E., Olukman, O., Ulubas, D., Buyukkale, G., Narter, F., Tunc, G., Atasay, 
B., Gultekin, N.D., Arsan, S., Koc. E., and Turkish Neonatal Jaundice Registry 
Collabolators. (2018). The Turkish Neonatal Jaundice Online Registry: A National Root 
Cause Analysis. PLoS One Feb 23;13(2): e0193108. 
Erdeve, O., Okulu, E., Tunc, G., Celik, Y., Kayacan, U., Cetinkaya, M., Buyukkale, G., Ozkan, 
H., Koksal, N., Satar, M., Akcali, M., Aygun, C., Ozkıraz, S., Zubarioglu, U., Unal, S., 
Turgut, H., Mert, K., Gokmen, T., Akcan, B., Atasay, B., Arsan, S., and Rescue HFOV 
Trial Group. (2019). An observational, prospective, multicenter study on rescue high-
frequency oscillatory ventilation in neonates failing with conventional ventilation. 
PLoS One June 10; 14(6): e0217768. 
Guven, S., Bozdag, S., Saner, H., Cetinkaya, M., Yazar, A.S., and Erguven, M. (2013). Early 
neonatal outcomes of volume guaranteed ventilation in preterm infants with 
respiratory distress syndrome. The journal of maternal-fetal & neonatal medicine 26: 
396-401.
Kalaycı, T., Ercan, T.E., Buyukkale, G., and Cetinkaya, M. (2015). Limb deformity in a 
newborn. Is rifampicin just an innocent bystander? European review for medical and 
pharmacological sciences 19: 517-519.  
Kaya, G., Saldir, M., Polat, A., Fidanci, M.K., Erdem, A., Erdem, G., Kurt, Y.G., Cetinkaya, 
M., Cekmez, F., Onguru, O., and Tunc, T. (2016). Evaluation of etanercept treatment 
in newborn rat model with hyperoxic lung injury. Fetal and pediatric pathology 35 (5): 
327-338.
Koksal, N., Akpınar, R., and Cetinkaya, M. (2009). Early Administration of the second 
surfactant dose in severe respiratory distress syndrome. Turkish journal of pediatrics 
51: 556-564. 
Koksal, N., Calıskan, B., Saglam, H., Yazıcı, Z., and Cetinkaya M. (2008). Reference values 
for neonatal thyroid volumes in a moderately iodine deficient area. Journal of 
endocrinological investigation 31: 642-646.   
Koksal, N., Harmancı, R., Cetinkaya, M., and Hacımustafaoglu, M. (2007). Role of 
procalcitonin and CRP in diagnosis and follow-up of neonatal sepsis. Turkish journal 
of pediatrics 49:21-29. 
Chapter 11 
162 
Koksal, N., Kavurt, A.V., Cetinkaya, M., Ozarda, Y., and Ozkan, H. (2011). Comparison of 
lipid emulsions on antioxidant capacity in preterms receiving parenteral nutrition. 
Pediatrics international 53: 562-566. 
Koksal, N., Kayık, B., Cetinkaya, M., Ozkan, H., Budak, F., Kılıc, S., Canıtez, Y., and Oral, B. 
(2012). Value of serum and bronchoalveolar fluid lavage pro- and anti-inflammatory 
cytokine levels in predicting bronchopulmonary dysplasia in premature infants. 
European cytokine network 23: 29-35. 
Koyuncuoglu, T., Turkyılmaz, M., Goren, B., Cetinkaya, M., Cansev, M., and Alkan, T. 
(2015). Uridine protects against hypoxic-ischemic brain injury by reducing histone 
deacetylase activity in neonatal rats. Restorative neurology and neuroscience 33: 777-
784. 
Kurnaz, D., Semerci, S.Y., Babayigit, A., Cebeci, B., Buyukkale, G., and Cetinkaya, M. (2018). 
Angioedema associated with nebulized recombinant human DNase in a preterm 
infant: case report. Journal of pediatric pharmacology and therapeutics 23: 219-222. 
Ozkan, H., Cetinkaya, M., and Koksal, N. (2012). Increased incidence of 
bronchopulmonary dysplasia in preterm infants exposed to preeclampsia. The journal 
of maternal-fetal & neonatal medicine 25: 2681-2685. 
Ozkan, H., Cetinkaya, M., Koksal, N., Ali, R., Gunes, A.M., Baytan, B., Ozkalemkas, F., 
Ozkocaman, V., Ozcelik, T., Gunay, U., Tunalı, A., Kimya, Y., and Cengiz, C. (2010). 
Neonatal outcomes of pregnancy complicated by idiopathic thrombocytopenic 
purpura. Journal of perinatology 30:  38-44. 
Ozkan, H., Cetinkaya, M., Koksal, N., Celebi, S., and Hacımustafaoglu, M. (2009). 
Pseudomonas aeroginasa pleural empyema in a preterm infant. Turkish journal of 
pediatrics 51: 395-398. 
Ozkan, H., Cetinkaya, M., Koksal, N., Celebi, S., and Hacımustafaoglu, M. (2014). Culture-
proven neonatal sepsis in preterm infants in a neonatal intensive care unit over a 7-
year period: Coagulase-negative Staphylococcus as the predominant pathogen. 
Pediatrics international 56: 60-66. 
Ozkan, H., Cetinkaya, M., Koksal, N., Ozmen, A., and Yıldız, M. (2011).  Maternal 
preeclampsia is associated with an increased risk of retinopathy of prematurity. 
Journal of perinatal medicine 39: 523-527. 
Ozkan, H., Cetinkaya, M., Koksal, N., and Yapıcı, S. (2011). Severe fetal valproate 
syndrome: combination of complex cardiac defect, multicystic dysplastic kidney, and 
trigonocephaly. The journal of maternal-fetal & neonatal medicine 24: 521-524. 
Curriculum vitae 
163 
Ozkan, H., Koksal, N., Cetinkaya, M., Kılıc, S., Celebi, S., Oral, B., and Budak, F. (2012). 
Serum mannan-binding lectin (MBL) gene polymorphism and low MBL levels are 
associated with neonatal sepsis and pneumonia. Journal of perinatology 32: 210-217. 
Ozyener, F., Cetinkaya, M., Alkan, T., Goren, B., Kafa, I.M., Kurt, M.A., and Koksal N. 
(2012). Neuroprotective effects of melatonin administered alone or in combination 
with topiramate in neonatal hypoxic-ischemic rat model. Restorative neurology and 
neuroscience 30: 435-444. 
Sahiner F, Cekmez F, Cetinkaya M, Kaya G, Kalaycı T, Gunes O, Sener K, Yapar M, Tunc T, 
Ecemis T, Cekmez Y, Kubar A. (2015) Congenital cytomegalovirus infections and 
glycoprotein genotypes in live-born infants: a prevalence study in Turkey. Infectious 
diseases (London, England) 47: 465-471. 
Saldir, M., Tunc, T., Cekmez, F., Cetinkaya, M., Kalayci, T., Fidanci, K., Babacan, O., Erdem, 
G., Kocak, N., Sari, E., Akgul, E.O., and Kul, M. (2015). Endocan and soluble triggering 
receptor expressed on myeloid cells as novel markers for neonatal sepsis. Pediatrics 
and neonatology 56: 415-421. 
Semerci, S.Y., Babayigit, A., Cebeci, B., Buyukkale, G., and Cetinkaya, M. (2016). Hepatic 
abscesses in preterm infants: report of three cases and review of the literature. 
Journal of tropical pediatrics 62: 255-260. 
Semerci, S.Y., Babayigit, A., Cebeci, B., Buyukkale, G., and Cetinkaya M. (2017) 
Cytomegalovirus as a seldom cause of non-immune hydrops fetalis: case report and 
review of the literature. Iranian red crescent medical journal 19(8): e55570.  
Semerci, S.Y., Bornaun, H., Kurnaz, D., Cebeci, B., Babayigit, A., Buyukkale, G., and 
Cetinkaya, M. (2018). Neonatal atrial flutter: Three cases and review of the literature. 
Turkish journal of pediatrics 60: 306-309. 
Semerci, S.Y., Kurnaz, D., Babayigit, A., Cebeci, B., Buyukkale, G., Cetinkaya, M., Guvenc, 
U., and Kucur, O. (2017). Neonatal appendicitis as a rare cause of intestinal 
perforation in a preterm neonate. Journal of the college of physicians and surgeans 
pakistan 27: S38-S40. 
Semerci, S.Y., Yucel, B., Erbas, I.M., Gunkaya, O.S., Talmac, M., and Cetinkaya, M. (2018). 
The utility of amniotic fluid pH and electrolytes for prediction of neonatal respiratory 
morbidities. Journal of maternal-fetal & neonatal medicine Jul 22: 1-5.  
Suleymanoglu, S., Cekmez, F., Cetinkaya, M., Tayman, C., Canpolat, F.E., Kafa, I.M., Tanju, 
A., Arzıman, I.K., Fidancı, M., Tunc, T., and Sarıcı, S.U. (2014). Protective effects of 
melatonin therapy in model for neonatal hyperoxic lung injury. Alternative therapies 
in health and medicine 20: 24-29. 
Chapter 11 
164 
Tayman, C., Cekmez, F., Kafa, I.M., Canpolat, F.E., Cetinkaya, M., Uysal, S., Tunc, T., and 
Sarıcı S.U. (2012). Beneficial effects of Nigella sativa oil on intestinal damage in 
necrotizing enterocolitis. Journal of investigative surgery 2012; 25: 286-294. 
Tayman, C., Cekmez, F., Kafa, I.M., Canpolat, F.E., Cetinkaya, M., Uysal, S., Tunc, T., and 
Sarıcı, S.U. (2013). Protective effects of Nigella sativa oil on hyperoxia-induced lung 
injury. Archivos de bronchoneumologia 49: 15-21.  
Tunc, T., Cekmez, F., Cetinkaya, M., Kalayci, T., Fidanci, K., Saldir, M., Babacan, O., Sari, E., 
Erdem, G., Cayci, T., Kul, M., and Kavuncuoglu S. (2015). Diagnostic value of elevated 
CXCR4 and CXCL12 in neonatal sepsis. Journal of maternal-fetal & neonatal medicine 
28: 356-361.  
Tuzun, F., Ozkan, H., Cetinkaya, M., Yucesoy, E., Kurum, O., Cebeci, B., Cakmak, E., 
Ozkutuk, A., Keskinoglu, P., Baysal, B., Kumral, A., and Duman, N. (2019). Is European 
Medicines Agency (EMA) sepsis criteria accurate for neonatal sepsis diagnosis or do 
we need new criteria? PLoS One Jun 6;14(6): e021800. 
165 
Acknowledgement 
It is a great honour for me to complete my PhD-thesis at Maastricht University, The 
Netherlands. I hope to continue my research line on the improvement of neonatal health 
in collaboration with Maastricht University. 
I owe my special thanks to my supervisor at Maastricht University, Prof. B. W. Kramer, for 
giving me the opportunity to pursue a PhD at Maastricht University. Because he always 
encouraged and supported me, I thank him for this kind support from past to future. 
I also want to thank my second supervisor, Professor T. Delhaas, for his valuable 
comments during the writing and editing stages of my thesis.  
A word of thank to my co-supervisor Dr. D. Gavilanes and to the members of the 
Assessment Committee. 
I also want to thank my colleagues Prof. M. Cansev, Prof. T. Alkan, Assoc. Prof. Dr. I.M. 
Kafa and all others from Uludag University, Faculty of Medicine, Departments of 
Physiology, Pharmacology and Anatomy for their collaboration during the experimental 
studies. I also want to thank to Prof. N. Koksal, Prof. E. Koc and Prof. E. Ozek for supporting 
me in all scientific activities.  
Lastly, I want to thank to my mother, sisters, dear friends who all supported me during 
all my scientific improvement stages. 

Translational approach for new therapeutic targets to prevent severe neonatal morbidities: From bench to bedside           Merih Cetinkaya
